Genetic Diversity and Molecular evolution of Hepatitis C Virus by Noppornpanth, S. (Suwanna)
  
 
 
 
 
Genetic Diversity and Molecular evolution of  
 
Hepatitis C Virus 
 
 
 
 
 
 
 
Suwanna Noppornpanth 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
The research described in this thesis was conducted at the Department of Virology of the 
Erasmus Medical Center in Rotterdam, The Netherlands. Parts of the studies were funded 
by the Commission of the European Community, HECSA Project (grant number ICA4-
CT-1999-10009).  
 
Printing of this thesis was financially supported by:  
Novartis Vaccine & Diagnostic SRL, Siena, Italy. 
 
 
 
Design of the cover : Salin & Suwanna 
 
ISBN : 978-90-9023431-1 
 
Printed by: PrintPartners Ipskamp, Rotterdam, The Netherlands 
 
© S. Noppornpanth, The Netherlands, 2008. All rights reserved. No part of this thesis 
may be reproduced or transmitted, in any form or by any means, without prior written 
permission of the author.  
   
 Genetic Diversity and Molecular Evolution of 
Hepatitis C Virus 
 
 
Genetische diversiteit en moleculaire evolutie van  
hepatitis C virus 
 
 
Thesis 
 
to obtain the degree of Doctor from the 
Erasmus University Rotterdam 
by command of the rector magnificus 
 
Prof. dr. S.W.J. Lamberts 
 
and in accordance with the decision of the Doctorate Board 
 
 
The public defense shall be held on 
Wednesday 24 September 2008 at 9:45 hrs 
 
by 
 
Suwanna Noppornpanth 
Born in Bangkok, Thailand 
  
  
 
   
 Doctoral Committee 
 
 
Promoter :  
Prof.dr. A.D.M.E Osterhaus 
 
Other members :  
Prof.dr. C.A.B. Boucher  
Prof.dr. S. Abrignani 
Prof.dr. R.A.M. Fouchier  
 
Copromoter :  
Dr. B.L. Haagmans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Table of Contents 
 
Chapter 1       General Introduction                                                                                10 
Chapter 2  Genotyping  hepatitis  C  viruses from Southeast Asia by a        36  
novel line probe assay that simultaneously detects core and  
5' untranslated regions.  
Journal Clinical Microbiology (2006)  
Chapter 3  Identification of a naturally occurring recombinant         54 
                        genotype 2/6 hepatitis C virus.        
      Journal of Virology (2006)  
Chapter 4  Characterization of hepatitis C virus deletion mutants        76 
circulating in chronically infected patients.         
      Journal Virology (2007)  
Chapter 5  Complete genome analysis of hepatitis C virus subtypes        96 
6t and 6u.     
      Journal General Virology (2008)  
Chapter 6  Molecular evolution of Hepatitis C Viruses : dating the      118 
origin of viruses using phylogenetic and relaxed molecular  
clock analysis.  
Manuscript in preparation 
Chapter 7 Detection of hepatitis C virus specific T cells using Epstein           140 
Barr virus based plasmids.  
Manuscript in  preparation 
Chapter 8 Summarizing discussion                    158 
 
Netherlandse samenvatting           182 
Acknowledgements            190 
Curriculum Vitae            193 
Publications             194 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Chapter 1 
 10 
                                        
                                                                                                              General Introduction 
 
 
 
 
CHAPTER 1 
 
 
 
 
  GENERAL INTRODUCTION 
 
 
 
 
 
 
                                                                     11 
Chapter 1 
 12 
                                                                                                              General Introduction 
Hepatitis C virus (HCV), an enveloped positive stranded RNA virus, is the 
causative agent of non-A, non-B (NANB) hepatitis (27). The virus was identified and 
characterized by molecular cloning techniques using serum from a NANB hepatitis virus 
infected chimpanzee (15) and based on the similarity of the genome organization and 
hydropathy profiles of several precursor proteins classified as a member of the 
Flaviviridae family. However, the low sequence homology compared to other 
flaviviruses eventually lead to its classification into a new genus hepacivirus, distinct 
from the other flavivirus members (33, 74). 
Initial studies demonstrated that blood transfusions were the main transmission 
route that caused the HCV epidemic, especially prior to the period of HCV-contaminated 
blood screening in 1992 (50). HCV high-risk groups include recipients of multiple blood 
transfusion, hemophiliacs, hemodialysis patients and intravenous drug users. Modes of 
transmission include contact with contaminated-blood products, sharing needles, mother-
to-child and sexual transmissions (69). Infection of the human liver is often clinically 
benign, with mild symptoms in the acute phase and fulminant hepatitis is very rare. The 
disease may even go unnoticed in cases of acute resolving HCV. In most cases (>70%) 
HCV infection leads to chronic persistent or active infection, often accompanied by 
complications of liver cirrhosis, or type II cryoglobulinaemia. The mechanisms of HCV 
persistence are not fully understood but the inability of the host innate and specific 
immune system to clear the virus is remarkable for a positive stranded RNA virus. HCV 
specific CD8+ T-cell responses are considered to play an important role in the 
containment and clearance of HCV infection but few of these cells are present in the liver 
and are unable to eradicate the infection. In addition, antibodies to HCV do not seem to 
play a major role in clearance of infection and re-infections are often observed with a 
different HCV strain, suggesting that immune responses to the initial strain did not 
protect against an infection with another strain of HCV (43).  
 HCV infection has reached epidemic proportions. Globally, an estimated 170 
million individuals are chronically infected and more than one million new infection 
cases are reported annually (19, 106). In the United States alone, nearly four million 
persons are infected and 30,000 acute new infections are estimated to occur each year 
(3). In Europe and Japan, the disease is already more important numerically than is either 
hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection and due to 
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the availability of the HBV vaccine the impact of hepatitis C infections will increase 
further. HCV infection causes a substantial portion of chronic liver disease mortality due 
to the induction of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) 
(52). About 4 to 20% of patients with chronic hepatitis C will develop liver cirrhosis 
within 20 years and HCC may develop after about 20 to 35 years. There is a significant 
rise in the incidence of HCC in many developed countries including Japan, Spain, 
France, and Italy, where the proportion of HCC attributable to HCV ranges from 50% to 
70% (56). In Japan, HCV-related HCC incidence has more than tripled over the past four 
decades and accounts in the 60–70 year age group for as much as 90% (38). Apart from 
HCC, co-infections with other viruses, especially HIV-1 and other hepatitis viruses, have 
gained more attention. These are of clinical importance, since the course of HCV 
infection is accelerated by co-infection with HIV-1 (75, 89), hepatitis A virus (HAV) or 
HBV (101, 108). 
 
HCV genome organization and viral replication 
The HCV genome consists of an RNA molecule of approximately 9,600 
nucleotides structured in a coding region that contains one large open reading frame, 
flanked by non-translated regions (UTR) at the 5’ and 3’ end. The polyprotein is cleaved 
into the structural (core, E1 and E2) and nonstructural proteins (NS2, NS3, NS4A, NS4B, 
NS5A and NS5B) with one additional small protein at the junction between the structural 
and non-structural elements (p7 protein) (Figure 1, (47)). The 5’untranslated region 
(5’UTR) consists of 341 nucleotides with highly conserved sequences among different 
HCV-isolates and contains an internal ribosome entry site (IRES). The IRES binds 
directly to the 40S ribosomal subunit controlling the viral protein translation, and is also 
important in viral pathogenesis (67, 99). The 3’untranslated region (3’UTR) contains the 
typical poly A or poly U, followed by a unique 98 nucleotide sequence to protect 
genomic RNA from degradation and aid in translation. This latter tail sequence was 
highly conserved among virus strains and can fold into a conserved stem-loop structure 
(39, 94). It suggests that the 3’UTR is a structure common to all HCV genomes and plays 
an important role in the initiation of viral replication.  
The polyprotein is translated as one open reading frame and subsequently post-
translationaly processed by both viral and cellular proteinases. Processing at the core/E1, 
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E1/E2, E2/p7, and p7/NS2 sites by host cell signal peptidase produces all structural 
proteins and p7. Two viral proteases are responsible for the maturation of the 
nonstructural proteins. NS2 contains an autoprotease, which cleaves the junction between 
NS2 and NS3 while NS3 protease cleaves the remaining non-structural proteins with 
NS4A as a cofactor for this activity (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 HCV genome organization. The 9.6-kb positive-strand RNA genome is schematically depicted at 
the top. Simplified RNA secondary structures in the 5'- and 3'-non-coding regions (NCRs) and the core 
gene, as well as the NS5B stem-loop 3 cis-acting replication element (5B-SL3) are shown. Internal 
ribosome entry site (IRES)-mediated translation yields a polyprotein precursor that is processed into the 
mature structural and non-structural proteins. Amino-acid numbers are shown above each protein (HCV H 
strain; genotype 1a; GenBank accession number AF009606). Solid diamonds denote cleavage sites of the 
HCV polyprotein precursor by the endoplasmic reticulum signal peptidase. The open diamond indicates 
further C-terminal processing of the core protein by signal peptide peptidase. Arrows indicate cleavages by 
the HCV NS2–3 and NS3–4A proteases. Dots in E1 and E2 indicate the glycosylation of the envelope 
proteins (4 and 11 N-linked glycans, respectively, in the HCV H strain) (57). 
 
The HCV CORE protein is a highly basic, RNA-binding protein that presumably 
forms the viral nucleocapsid. It has been reported that CORE protein interacts with 
numerous cellular proteins and affects host cell functions such as gene transcription, lipid 
metabolism, apoptosis and various signaling pathways (96). In addition, CORE has been 
associated with the induction of steatosis and HCC development (45). Several groups 
reported the existence of a protein encoded by an alternative reading frame within the 
core region (8). It comprises up to 160 aminoacids and is designated as ARFP 
(alternative reading frame protein) or F (frameshift) protein. The ARFP/F protein is 
dispensable for HCV RNA replication and whether it is expressed during natural HCV 
infection remains to be clarified. 
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The envelope glycoproteins, E1 and E2, are type I transmembrane proteins with 
C-terminal hydrophobic anchors, which mediate entry of the virus into the host cell. 
These E1 and E2 proteins form non-covalent heterodimers that represent the structure on 
the viral envelope confirmed by earlier electron microscopy observations and structural 
studies of the recombinant HCV particles, even though the particle assembly and release 
processes are poorly understood (102). 
p7 is a 63-amino acid polypeptide located at the junction between the structural 
and nonstructural region. It is composed of two transmembrane domains and forms 
hexamers with ion channel activity (65). It is believed that p7 could be important for viral 
assembly because the corresponding protein of the related bovine viral diarrhea virus 
(BVDV) is essential for the production of infectious progeny virus but not for RNA 
replication (32).  
Although NS2-3 protease activity is required for the replication in vivo, it is 
dispensable for replication of subgenomic replicons in vitro (68). Interestingly, the NS2-3 
region is the fusion site for the construction of efficient HCV chimeras (4) and  natural 
occurring recombinant viruses (36).  
NS3 is a multifunctional protein as it contains a serine protease located in the N-
terminal one-third that is responsible for the downstream cleavage in the nonstructural 
region and a NTPase/RNA helicase domain in the C-terminal two-thirds. Together with 
NS4A, a 54-amino acid polypeptide that is required as a cofactor, the NS3 serine 
protease enzyme is localized in intracellular membranes. The enzymatic activity of the 
NS3 NTPase/helicase is essential for RNA replication. Putative functions during 
replication could be to unravel replicative double strand RNA intermediates, to eliminate 
RNA secondary structures or to separate the genome from nucleic acid binding proteins. 
Recently, the NS3 serine protease turned out to influence the innate cellular host defense 
by inhibiting RIG-I and TLR3 signaling (29, 55). Therefore, the NS3 protease is 
particularly attractive target for the development of new antivirals (21, 76).  
 NS4B is a 27-kDa integral membrane protein that localizes to an ER-derived 
membranous compartment (35). Interestingly, the expression of NS4B induces a specificì 
membrane alteration,  designated  as  membranous web,  and  serves  as a scaffold for the  
formation of the viral replication complex (31). 
 16 
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NS5A is a phosphorylated zinc metalloprotein, that has attracted considerable 
interest because of its potential role in modulating the IFN response (93), even though 
these findings are still controversial. A striking observation was the concentration of cell 
culture adaptive replicon mutations within the central part of NS5A (7). These 
observations support the concept that NS5A plays an important role in the regulation of 
viral replication (48). The NS5B RNA dependent RNA polymerase (RdRp) is the key 
enzyme for HCV replication that promotes synthesis of new RNA genomes. Replication 
proceeds via synthesis of a complementary minus-strand RNA using the genome as a 
template and the subsequent synthesis of genomic plus strand RNA from this minus-
strand RNA intermediate. Due to its influence on HCV replication, NS5B has emerged as 
a major target for antivirals (21).  
Circulating HCV particles can be associated with low- and very-low-density 
lipoproteins (LP) and virus binding to the cell surface and entry may involve the low 
density lipoprotein receptor (LDLR). In addition several other membrane proteins, such 
as glycosaminoglycan (GAG), scavenger receptor class B type I (SR-B1), the tetraspanin 
protein CD81 and Claudin-1 (CLDN1), are thought to be involved in entry of virus. HCV 
entry likely involves transit through an endosomal, low pH compartment and fusion with 
the endosomal membrane (57). Subsequently, the positive-strand RNA genome serves as 
a template to make a negative-strand intermediate, which then serves as a template to 
produce multiple nascent genomes (Figure. 2). As in all positive-strand RNA viruses 
investigated so far (1), HCV forms a membrane associated replication complex, 
composed of viral proteins, replicating RNA, altered cellular membranes and additional 
host cell factors (24, 31). This specific membrane alteration, called the membranous web, 
was identified as the site of RNA replication in Huh-7 cells harboring subgenomic HCV 
replicons (31). In addition to coordinated protein-protein and protein-membrane 
interaction, essential cis-acting replication elements (CRE) of the RNA genome were 
recently discovered (107). Little is known about the late steps of the viral lifecycle, as 
these have only recently become available for systematic study. Virions presumably form 
by budding into the ER, or an ER-derived compartment, and exit the cell through the 
secretory pathway.   A possible link between lipoprotein  metabolism  and  viral  
assembly  and release has been proposed (34). 
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Figure 2. Life cycle of HCV. The steps of the viral life cycle are depicted schematically. The topology of 
HCV structural and nonstructural proteins at the endoplasmic reticulum (ER) membrane is shown. HCV 
RNA replication occurs in a specific membrane alteration, the membranous web (MW). IRES-mediated 
translation and polyprotein processing as well as membranous web formation and RNA replication, 
illustrated here as separate steps for simplicity, may occur in a tightly coupled manner (9).  
 
Although exciting progress has been made to determine the virion structure of the 
related alphaviruses and flaviviruses, HCV has not been definitively visualized and its 
structure remains to be elucidated. Based on filtration and electron microscopic studies, 
the HCV particle is a spherical lipid envelop with an approximate diameter of 
approximately 70 nm (102). The nucleocapsid of the particles, which were 50 nm in 
diameter, appeared to be icosahedral in structure and surrounded by an enveloped 
covered with surface projection (46).  
For many years, the extremely restricted host range and the inefficiency of in 
vitro models based on the incubation of cells in culture with HCV particles, hampered 
HCV research. A breakthrough came in 1999 when Lohmann et al. established the first 
functional subgenomic replicon system for HCV (49). In this system, the structural 
region was replaced by the sequence encoding the neomycin phosphotransferase gene 
resulting in G418 resistance and expression of the nonstructural proteins is directed by a 
heterologous encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) 
downstream of the neomycin phosphotransferase gene. After transfection into the human 
HCC cell line Huh-7, G418 resistant colonies contain self-replicating HCV RNA were 
selected. The replicon system made it possible to study efficient and genuine HCV RNA 
replication in vitro and structural aspects of the replication complex, virus-host cell 
interactions, and the efficacy of antiviral agents. A few years later, Wakita and 
 18 
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colleagues, generated a genotype 2a replicon (JFH-1), isolated from the serum of a 
patient with fulminant hepatitis C (102). This system turned out to replicate very 
efficiently in different cell types. Furthermore, the full-length JFH-1 sequence produced 
infectious viral particles that could be passaged in cell culture (102). Newly constructed 
chimeras with the structural region of the J6 genotype 2a clone improved this system 
significantly (47). The infectious HCV cell culture system represents the last major 
milestone in the field and renders the complete viral life cycle accessible to detailed 
analysis in vitro and may allow the identification of novel targets for antiviral therapy. 
 
Genomic heterogeneity and classification systems of HCV 
The HCV genome shows remarkable sequence variation generated by the lack of 
proofreading activity by the RNA polymerase and a high in vivo productive rate of an 
estimated 1012 virions per day (61).  To encompass this diversity, HCV has been 
classified in genotypes and subtypes (10, 97). Initially, genotypes were considered to 
differ more than 20% at the nucleotide level and more than 15% at the amino acid level 
(37). However, phylogenetic analyses indicated that genotype 10 is closely related to 
genotype 3 and genotype 7, 8, 9 and 11 to genotype 6 (82). Therefore, a new consensus 
nomenclature system was proposed to be used for HCV classification (81). According to 
this system, HCV is classified into genotypes on the basis of < 70% similarity of 
nucleotide sequence and phylogenetic relationship. The more closely related HCV strains 
(75-80% sequence similarity) within some genotypes are designated subtypes. Genotypes 
are numbered in order of discovery and subtypes are assigned lowercase letters (Table 1). 
Nowadays, HCV is classified into 6 major genotypes and more than 90 subtypes. 
Sequence variation between the HCV genomes was on average 0.9% (53), indicative of 
the presence of HCV quasispecies in hepatitis C patients. Furthermore, sequence 
heterogeneity was distributed throughout the genome except in the 5’UTR, while 
diversity was higher (1.6%) in the envelope genes than the others (95). A comparison of 
the complete HCV genome reveals that non-synonymous substitutions are less frequent 
compared to synonymous ones, except in hypervariable region 1 (HVR1). Moreover, 
translations are more common than transversions, particularly at the third position of the 
codon (86). Currently, intensive sequencing of HCV genomes is being conducted and 
nearly 50,000 HCV sequences, including 507 full-length genomes, have been deposited 
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in generic data banks so far (41). To perform sequence classification, annotation, and 
analysis of such a large collection, several sequence databases are dedicated specifically 
to HCV, such as Los Alamos HCV database     (http://hcv.lanl.gov/content/hcv-index), 
the hepatitis C virus database   (http://s2as02.genes.nig.ac.jp/)  and   HCVDB  
(http://euhcvdb.ibcp.fr/euHCVdb/jsp/index.jsp). 
 
Table 1  Genotypes/subtypes that are presently defined in the database  
 
     Genotype                                Assigned subtypes  
 
1   a, b, c, d, e, f, g, h, i, j, k, l, m  
2   a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r  
3   a, b, c, d, e, f, g, h, i, k, l  
4   a, b, c, d, e, f, g, h, k, l, m, n, o, p, q, r, s, t  
5   a  
6   a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s,t 
 
 
HCV genotyping  
HCV genotype identification is clinically important for prediction of response to, 
and in determining the duration of antiviral therapy (109). Nowadays, most treatment 
protocols require preceding genotype information for HCV infected patients. This is 
illustrated by the fact that genotype 1 and 4 are more resistant to treatment with pegylated 
alpha interferon and ribavirin than genotype 2 and 3 (54, 110). Moreover, it has been 
suggested that patients with chronic HCV genotype 1b infection show more severe liver 
disease than patients infected with other genotypes (78).  
HCV genotyping based on the detection of genotype-specific HCV antibodies is 
relatively easy to perform providing a tool for large epidemiological studies. One of the 
serologic genotyping assays contains five different specific peptide sequences of the NS4 
region and two specific peptide of the core region taken from the HCV genomes of 
genotypes 1, 2, and 3 (22). The second serologic genotyping assay is based on the 
detection of genotype-specific antibodies directed to epitopes encoded by the NS4 region 
of the genomes for genotypes 1 through 6. Results from both assays showed a 
concordance rate of more than 96% for genotypes 1, 2, and 3 (30), but low sensitivity of  
 20 
                                                                                                              General Introduction 
genotyping has been observed in other studies using sera from HCV genotype 6 or HIV 
coinfected patients (5, 88).   
Molecular genotyping techniques to detect HCV RNA rely on the amplification 
of short HCV RNA regions from clinical specimens, followed by a HCV genotype-
specific assay. The gold standard and most definitive method for HCV genotyping is 
sequencing of a specific PCR-amplified portion of the HCV genome obtained from the 
patient, followed by phylogenetic analysis. Determination of HCV genotype has been 
focused on sequence analysis of the HCV complete genome, NS5b, Core, E1, and 
5’UTRs (83). Other methods that have been reported lately depend on the short 
amplification of HCV RNA, followed by re-amplification with type-specific primers 
(64), hybridization with type-specific probes (91) or by digestion of PCR products with 
restriction endonucleases that recognize genotype-specific cleavage site (11). The 
VERSANT® HCV genotype assay, (INNO-LiPA) is based on the amplification of the 
5’UTR with biotinylated primers, after which the PCR product is hybridized to a 
membrane impregnated with genotype-specific probes and detected with streptavidin 
linked to a colorimetric detector (90). However, it has been noted that this test directed 
towards the 5’UTR falsely identifies some genotype 6 variants (6c-6l) from South East 
Asia (SEA) as genotype 1 (13, 91) and it is unable to distinguish subtypes 1a from 1b in 
5-10% of the cases (12, 84). In general, all molecular HCV genotyping methods have a 
high sensitivity and specificity. Sequencing of amplified DNA, however, does not 
usually identify mixed infections with two different HCV genotypes. Even though all 
these methods are suitable to identify precisely the major HCV genotypes, only the direct 
nucleotide sequencing followed by phylogenetic analysis is efficient in discriminating 
among subtypes. However, these techniques are costly, time-consuming and require 
specialized facilities to ensure accurate results.  
 
Epidemiology and geographic distribution of HCV 
HCV shows a large degree of geographic variability in its distribution. Countries 
with the highest reported prevalence rates are located in Africa and Asia; areas with 
lower prevalence include the developed nations in North America, Northern and Western 
Europe, and Australia (Fig.3) (77). The seroprevalence rate is about 1% in Western 
Europe and North America, 3-4% in some Mediterranean and Asian countries and up to 
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10-20% in parts of Central Africa and Egypt (103). Populous nations in the developed 
countries with relatively low rates of HCV seroprevalence include Germany (0.6%), 
Canada (0.8%), France (1.1%), and Australia (1.1%). Low, but slightly higher 
seroprevalence rates have been reported in the USA (1.8%), Japan (1.5–2.3%), and Italy 
(2.2%) (for a review see (77)). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Prevalence of HCV in the world (Source, WHO 2007) 
(http://www.nathnac.org/pro/factsheets/images/hep_c_epi.jpg) 
 
There is a wide range of prevalence estimates from developing countries, and 
generally less data are available to validate assumptions about the burden of disease 
compared with the developed world. China, whose citizens account for one fifth of the 
world’s population, has a reported seroprevalence of 2.5-4.9% (105).  In other countries 
like India, Indonesia and Pakistan, this may range from 0.9 % to 6.5% (16, 58, 92).  
Egypt, with an estimated population of 73 million, has the highest reported 
seroprevalence rate at 22% due to the use of parenteral antischistosomal therapy 
contaminated with HCV (28). 
HCV genotypes have a geographic distribution with genotype 1 being more 
common in the Americas and Europe, followed by genotypes 2, 3 and 4. Subtype 1b 
accounts for most infections in China and Japan, genotype 4 is more prevalent in the 
Middle East and North Africa, genotype 5a is seen almost exclusively in South Africa, 
and genotype 6 is common in Hong Kong and South-East Asia (23, 79). Variants of 
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genotype 6, originally termed genotypes 7, 8 and 9, have been reported primarily in 
South-East Asia and genotypes 10 and 11 in Indonesia (97, 98).  
Through a phylogenetic analysis of nucleotide sequences of the HCV genome, 
such as the NS5B region, it is possible to demonstrate clustering of HCV isolates that are 
more or less closely related, even within a single subtype. Using these techniques spread 
of HCV genotype 1b through infected blood products and subtype 1a and 3a in 
intravenous drug users, was demonstrated (6, 66). Together with the coalescent theory of 
population genetics, phylogenetic analysis has been used to estimate the historical age 
and distribution rate of different HCV genotypes (59, 70). As a result, these models 
indicate that genotype 1 originated within the last 100 years, whereas types 4 and 6 are 
several times older. Subtype diversity within genotypes 1, 2 and 4 from Western Africa 
and genotypes 3 and 6 in South-East Asia implicates long-term presence of HCV in these 
populations (59, 70). Based on the genotype distributions, it was suggested that HCV has 
been endemic in sub-Saharan Africa and South-East Asia for a considerable time, and 
that the occurrence of infection in Western and other non-tropical countries represents a 
relatively recent emergence in new risk groups (60, 80). In the 20th century, widespread 
use of blood transfusion, unsterilized needles for injections and vaccinations caused HCV 
to spread. These new transmission routes account for the epidemic spread of HCV over 
the past 50 years in Europe, Egypt and elsewhere (17, 60, 70, 71).  
 
HCV molecular evolution  
 Dating the origin of HCV and estimate when HCV was introduced into human 
population remains difficult due to the inability to identify HCV or HCV-like variants in 
ape or monkey species (51). In theory, it may be possible to calculate the divergence 
times of the main clades and splitting of subtypes by using the constant nucleotide 
substitution rate over time. By comparing HCV sequences from sequential samples from 
chronically infected individuals or from those infected by a common source, rates of 
sequence change were measured to be 1.44 x 10-3 nucleotide changes per site per year 
over the whole genome (63). Smith et al. calculated an evolutionary rate of 7.4 x 10-4 
nucleotide substitutions per site per year for the E1 gene and 4.1 x 10-4 for the NS5B 
gene and suggested that the subtypes diverged around 300 years ago, and the divergence 
of the different genotypes should have occurred more than 500-2000 years ago (85). 
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However, it is known that HCV is a fast evolving virus and does not contain a constant 
rate of nucleotide substitution sites along the genome. Therefore, the evolutionary 
dynamics of highly diverse genetic groups, such as HCV genotype 6, still remain elusive.  
 The forces that drive the early divergence of the six major genotypes of HCV and 
the underlying basis of the current geographical distribution of genotypes also remain 
unclear. Hypothetically, HCV evolution may be driven by sequence variation caused by 
the lack of proofreading activity of the viral RNA polymerase RdRP creating a 
quasispecies and further amplified by immune selection. Because genome changes occur 
frequently at synonymous sites in the coding regions of the genome (86), it is unlikely 
that viruses would accumulate phenotypically neutral changes. The expectation from this 
neutral theory would be that such diversification should occur at a constant rate over 
time, allowing to estimate spread of HCV in specific transmission networks, such as 
IDUs (17, 70, 71). The prediction of the time of introduction of specific genotypes, such 
as 1a, 1b, 3a and 4a, into new risk groups for infection in Western countries was 
estimated in the same way (87). The phylogenetic tree structure of genotype 4a in Egypt 
demonstrated that it is compatible with the time of introduction of HCV into that 
population through potential treatment for schistosomiasis (Bilharzia) in the 1950s and 
1960s (28, 71, 72). The increasing sequence diversity within genotypes 3a, 1a, 1b, 2a and 
2b, respectively, suggests time points of introducing these viruses at earlier times in the 
20th century, associated with other risk factors for infection, such as injecting drug use, 
blood transfusion and large-scale immunizations. 
Recombination was reported in many families  of  RNA  viruses,  including  other 
members of the family Flaviviridae (44, 100). It’s role in HCV evolution became evident 
only a decade after HCV was discovered, through the identification of a naturally 
occurring inter-genotypic recombinant form of HCV (1R_1b/2k) in St. Petersburg (36). 
More recently, an intragenotypic recombinant HCV (1a/1b) has identified in Peru (18). 
The true frequency of HCV recombination may be underestimated, especially in areas of 
endemic with a high prevalence of different HCV genotypes, due to currently used 
methods that are not suited for identification of recombinant strains  (18, 79). 
Viral escape from cytotoxic T-cells lymphocytes (CTLs) and antibodies has been 
identified as a major driving force for the evolution of human and simian 
immunodeficiency virus but also HCV (2, 62). In HCV infection, two recent studies 
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support a role for CD8 T-cell responses and reversions in driving HCV evolution (20, 
73). Both studies identified dominant viral escape mutants in HCV patients with 
persistent viremia. Amino acid substitutions occurred 13-fold more often within than 
outside T cell epitopes, and every chronic HCV patient carried amino acid substitution in 
at least one epitope while there was no substitution in T cell epitopes for a year after 
infection in a person who cleared viremia. Similarly, studies in HCV infected 
chimpanzees demonstrated that over a period of several years a new strain of the virus 
emerged with a mutation in the CTL epitope that was no longer recognized by the CTLs 
isolated earlier (40). Apart from escaping CTL responses, several studies have shown B-
cell epitope shifts, apparently the result of the presence of anti-hypervariable region 
(HVR) antibodies, which support the hypothesis that antibody neutralization allows 
selection of variants (26, 42, 104). Neutralization of HCV in chimpanzees with 
homologous plasma obtained from the same chronically infected patient showed that 
neutralization was achieved with plasma obtained 2 years after the initial exposure but 
not with plasma obtained 11 years later (25). Analysis of viral isolates of the same patient 
showed significant genetic divergence of HCV over time.  
 
Aim and the outline of the thesis 
The goal of this thesis was to characterize and study genetic diversity and 
molecular evolution of HCV in South East Asia (SEA). The enormous HCV sequence 
diversity represents a significant hurdle to develop effective vaccines and novel 
therapeutic interventions. The current standard treatment of hepatitis C is combination of 
pegylated interferon-α and ribavirin that can induce a sustained response in 42–82% of 
patients, although therapy must be discontinued in some patients due to side effects 
associated with treatment. Clinical studies have shown that HCV genotype is an 
independent prognostic factor in predicting response to antiviral therapy (78). In addition, 
vaccine development has been slowed by the extreme antigenic variability of the virus, 
although recombinant E1 and E2 protein vaccines can elicit protective immunity when 
tested in chimpanzees (14). 
To study prevalence and incidence of different HCV genotype infections in Thai 
and Vietnamese urban settings, serum samples were collected from selected populations, 
with different risks of being infected within the setting of the EU funded project HECSA 
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(Hepatitis C vaccine efficacy against South East Asian genotypes). Careful monitoring of 
the epidemic situation in a given population is one of the important issues in vaccine 
development and in preparing for clinical trials. In both countries, samples were collected 
retrospectively and prospectively from regular blood donors with a track record of 
regular blood donation and hepatitis C patients. All samples were screened by 
commercial ELISA for antibodies against HCV and used for molecular characterization 
of the virus present. The Thai laboratories, in close collaboration with the European 
laboratories, subjected positive samples to detailed genotype analysis using standard RT-
PCR sequencing protocols. Special attention was paid to the identification of genoype 6 
positive samples and the occurrence of subtypes within this genotype. HCV genotype 6 
circulate specifically in Asia and SEA, but rare in other part of the world. Information 
about epidemiology, the effect of diversity on clinical aspects and the molecular 
evolution of HCV genotype 6 are limited. In this thesis, several studies were designed to 
increase our knowledge regarding the HCV molecular evolution in SEA by identification 
of blood donors’ HCV-positive sera collected from Bangkok, Thailand and Ho Chi Minh 
City, Vietnam.  
Because molecular diagnosis based on the conserved region (5’UTR) could not 
distinguish HCV genotype 1 and 6, a new developed diagnostic test to separate genotype 
6 from 1 based on 5’UTR-Core genes was examined (Chapter 2). In addition, through 
analysis of two distinct regions in the HCV genome, a natural recombination of different 
HCV genomes (genotype 2i/6p) was found in one sample collected from Vietnam 
(chapter 3). Additionally, HCV defective interfering (DI) viruses with a large fragment 
deletion of E1-E1-NS2 regions were found to be present in the plasma of chronic 
infected patients (Chapter 4). Both mechanisms may further support the idea that 
variation of HCV is caused through different molecular mechanisms. Next the molecular 
evolution of HCV genotypes 1-6 was studied using whole genomes available from the 
HCV database and those characterized in this study (Chapter 5 and 6). Because host CTL 
responses play an important role in the molecular evolution of HCV, tools were 
developed to detect CTL activity in chronically infected patients using a plasmid system 
enabling the expression of diverse HCV genome fragments (Chapter 7). The findings 
presented in this thesis are evaluated in a summarizing discussion (Chapter 8). 
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ABSTRACT 
 
Hepatitis C viruses (HCVs) display a high level of sequence diversity and are currently 
divided into six genotypes. A line probe assay (LiPA), which targets the 5’untranslated 
region (5’UTR) of the HCV genome, is widely used for genotyping.  However, this assay 
cannot distinguish many genotype 6 subtypes from genotype 1 due to high sequence 
similarity in the 5’UTR.  We investigated the accuracy of a new generation LiPA 
(VERSANT HCV Genotype 2.0 assay), in which genotyping is based on 5’UTR and core 
sequences, by testing 75 selected HCV RNA positive sera from South East Asia 
(Vietnam and Thailand). For comparison, sera were tested on the 5’UTR based 
VERSANT HCV Genotype assay (LiPA) and processed for sequence analysis of the 
5’UTR-to-core and NS5b regions as well. Phylogenetic analysis of both regions revealed 
the presence of genotype 1, 2, 3 and 6 viruses. Using the new LiPA assay, genotype 6c-6l 
and 1a/b samples were more accurately genotyped than with the previous test only 
targeting the 5’UTR (96% versus 71% respectively). These results indicate that the 
VERSANT HCV Genotype 2.0 assay is able to discriminate genotype 6c-6l from 
genotype 1, and allows a more accurate identification of genotype 1a from 1b by using 
the genotype-specific core information.  
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INTRODUCTION 
 
Hepatitis C virus (HCV), an enveloped positive-stranded RNA virus of the family 
Flaviviridae, is recognized as a major cause of chronic liver disease. Because of its high 
genetic heterogeneity, HCV has been classified into 6 genotypes and a huge number of 
subtypes (18, 20). Genotypes 1, 2, and 3 are widely distributed around the world while 
genotypes 4 and 5 have been identified mainly in Africa (22). Genotype 6 was found 
locally in South East Asia (SEA) (11, 26, 27, 28). 
Genotype identification is clinically important for prediction of responses to, and 
in determining the duration of, antiviral therapy (30). This is illustrated by the fact that 
genotypes 1 and 4 are more resistant to treatment with pegylated interferon-α and 
ribavirin than genotypes 2 and 3 (9, 31). Moreover, it has been suggested that patients 
with chronic HCV genotype 1b infection show more severe liver disease than patients 
infected with other genotypes (17). Nowadays, most treatment protocols require 
preceding genotype information of HCV infected patients.  
A variety of technologies has been developed for HCV genotype determination. 
Most of these assays rely on the amplification of short HCV RNA regions from clinical 
specimens, followed by a type-specific assay, such as line probe reverse hybridization 
(23, 25), restriction fragment length polymorphism analysis (1), or sequence analysis (20, 
29). Almost all available commercial assays target the 5’UTR, because the highly 
conserved sequences of this region are most suitable for RT-PCR amplification.  
The VERSANT HCV Genotype assay (LiPA) is one of the most widely used 
methods for HCV genotyping. In this assay the 5’UTR of HCV is amplified with 
biotinylated primers, after which the PCR product is hybridized to a membrane 
impregnated with genotype-specific probes and detected with streptavidine linked to a 
colorimetric detector (24). Despite the high conservation of the 5’UTR, genotype 
determination of HCV based on the 5’UTR is accurate for most genotypes (8, 21, 29). 
However, it has been noted that methods which are based on the use of the 5’UTR falsely 
identify genotypes 6c-6l from SEA as genotype 1, which is also the case in the 
VERSANT HCV Genotype assay (3, 24). Moreover, this assay is unable to distinguish 
genotype 1a from 1b in 5-10% of the cases (2, 21). Therefore, it has been recommended 
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to use other coding regions of the HCV genome (e.g. core, E1, and/or NS5b) for 
genotype identification (18). 
A new generation of the line probe assay (VERSANT HCV Genotype 2.0 assay) 
was recently developed, which uses core sequence information, in addition to 5’UTR, to 
improve the accuracy of HCV genotyping. After amplification of the 5’UTR-to-core 
region and hybridization to type-specific probes of the 5’UTR and core, it is possible to 
distinguish between genotypes 1a, 1b and 6c-6l. In the present study, we selected 75 sera 
of HCV RNA-positive blood donors collected from Bangkok, Thailand and Ho Chi Minh 
City, Vietnam in order to test the accuracy of the new VERSANT HCV Genotype 2.0 
assay. The data were compared to results obtained with the previous VERSANT HCV 
Genotype method and sequence analysis. We show that the VERSANT HCV Genotype 
2.0 assay is able to discriminate genotypes 6c-6l from genotype 1, and allows a more 
accurate identification of genotype 1a from 1b by using the genotype-specific core 
information.  
 
MATERIALS AND METHODS 
 
Samples.  A total of 152 HCV-positive plasma samples of blood donors from Ho 
Chi Minh City, Vietnam and Bangkok, Thailand were obtained during 2000-2002. From 
this collection of samples, 75 were selected based on an initial characterization to include 
preferentially genotype 6 viruses (12, 26). Samples were kept at –80 oC until further 
analysis.  
RNA isolation and RT-PCR. Viral RNA was isolated from 200 µl serum or 
EDTA-plasma by the High Pure RNA isolation Kit (Roche, Diagnostics GmbH) and 
eluted with 50 µl water. cDNA was synthesized using 10 µl extracted RNA, 2 µl random 
hexamer primers (150 µg/ml; Boehringer Mannheim) and MMLV Reverse transcriptase 
(Invitrogen) according to the instructions of the manufacturers.  The 5’UTR-core 
sequences (nucleotides 47 to 695, according to the numbering system for reference strain 
HCV-H Genbank accession number M67463) were amplified by nested PCR with 
primers 16 (5’-GRGGCGACACTCCACCAT-3’), 410 and primers s17 and 951, as 
described previously (10). NS5b sequences (nucleotides 8283 to 8624, according to the 
numbering system for HCV-H strain) were amplified by nested PCR with primers Pr3, 
 40 
                                                  Novel HCV LiPA assay based on 5’UTR and core regions 
 
Pr4, Pr1, and Pr2 using conditions described in previous reports (16) with modifications. 
Briefly, in the first PCR, performed with Pr3 and Pr4, 1.5 mM MgCl2 was used in the 
reaction mixture, and the following thermal profile: initial denaturation at 94oC for 90 s; 
5 cycles of denaturation at 94oC for 30s, annealing at 64oC for 45 s and elongation at 
72oC for 1 min, followed immediately by 30 cycles at 94oC for 30 s, 64oC with a drop of 
–0.5oC between each cycle for 45s and elongation at 72oC for 1 min. The last 5 cycles 
were performed at 94oC for 30 s, 48oC for 45 s and 72oC for 1 min. A final elongation at 
72oC for 10 min was also included. The nested PCR, performed with primer Pr1 and Pr2, 
was carried out on 2 μl of the first PCR product with the following thermal profile: 95oC 
for 7 min; 50 cycles at 95oC for 30 s, 63oC for 30 s and 72oC for 30 s, with a final 
elongation step at 72oC for 10 min. The amplified products were gel-purified and 
sequenced. 
DNA sequencing and phylogenetic analysis.  Sequence reactions on PCR 
products were performed using BigDye Terminator Cycle sequencing Ready Reaction kit 
(Applied Biosystems) and an ABI prism 3100 Autosequencer (Applied Biosystems). 
Multiple sequence alignments were generated with BioEdit version 7.0.1.  Phylogenetic 
analyses were conducted using the Tajima-Nei model with rate heterogeneity parameter 
and Neighbor-joining method. Confidence values were calculated by bootstrap analysis 
(1000 replicates) and consensus trees were produced by MEGA version 3.0 (7).  
 Reference strains used in this study were obtained from Genbank: genotype 1a 
(M67463), 1b (AB016785), 1c (AY051292), 2a (AB047639), 2b (AB030907), 2c 
(D50409), 2k (AB031663), 3a (AF046866), 3b (D49374), 3k (10a, D63821), 4a 
(D45193, Y11604), 5a (D50466, Y13184), 6a (D88469, AY859526), 6b (D84262), 6c 
(7d, D37843, D37885), 6d (7b, D84263), 6e (7a, D31971, D30397), 6f (7c, D38078, 
D38078), 6g (11a, D63822), 6h (9a, D84265), 6i (9b, D37850, D37864), 6j (9c, D37848, 
D37862), 6k (8b, D84264), 6l (8a, D88470, D87357), 6n (DQ278894).  
INNO-LiPA line probe assay.  Sera samples were extracted with the Viral DSP 
kit (Qiagen) according to the manufacturer’s instructions, with elution volume of 60 µl. 
The cDNA synthesis and amplifications for VERSANT HCV Genotype assay (Bayer 
HealthCare, manufactured by Innogenetics, Ghent, Belgium) were performed according 
to the manufactures instructions. For the VERSANT HCV Genotype 2.0 assay (Bayer 
HealthCare, manufactured by Innogenetics, Ghent, Belgium) a multiplex RT-PCR was 
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performed according to the manufactures instructions on the extracts to amplify the 
5'UTR and core regions of the HCV genome, utilizing primers HCVPr95 AT&AC, 
HCVPr96b, HCVPr769b, HCVPr822b, generating two distinct PCR products from 
5'UTR and core regions, respectively. Briefly, master mixes were prepared using these 
primers, buffer, enzymes, and deoxynucloside triphosphates (dNTPs), including 
deoxyuridine triphosphate (dUTP), from the VERSANT HCV Amplification 2.0 assay. 
Twenty microliters of RNA extract was added to the master mix and treated with uracil-
N-glycosylase to prevent contamination by amplification product from previous PCRs. 
Subsequently, the mix was incubated for 30 minutes at 50°C and 15 minutes at 95°C for 
RT and PCR activation respectively, immediately followed by 40 cycles of 95°C for 30 s, 
50°C for 30 s, 72°C for 15 s. After amplification, the PCR products were immediately 
stored at -20°C, to prevent residual uracil-N-glycosylase activity. Hybridization and color 
development steps were performed in the Auto-LiPA48 instrument (Innogenetics, Ghent, 
Belgium), according to the manufacturer’s instructions and were not different for the two 
assays. Strip patterns obtained from both assays were interpreted following the 
manufacturer’s interpretation chart. HCV genotyping results from the LiPA assays were 
compared to the gold standard phylogenetic analysis of core and NS5b sequences. The 
sensitivity of the assay was determined by probit analysis to 2106 IU/ml. 
Nucleotide sequence accession numbers.  New sequences reported in this study have 
been submitted to Genbank database and assigned accession numbers DQ155445, 
DQ155447-455, DQ155457, DQ15460-463, DQ15465-474, DQ155477-493, DQ155495-
500, DQ640336-361 for 5’UTR-to-core phylogenetic analysis. Sequences accession 
numbers DQ155503, DQ155505-513, DQ155515, DQ155518-521, DQ155523-532, 
DQ155535-551, DQ155553-558, DQ640362-386 were used for NS5b sequences 
analysis.  
 
RESULTS 
 
Determination of HCV genotype by sequence analysis.  To investigate the accuracy of 
the newly developed VERSANT HCV Genotype 2.0 assay for genotype 6 identification, 
we selected a set of samples from SEA HCV positive blood donors to encompass mainly 
genotype 1 and 6 viruses. A total of 75 samples, 50 from Vietnam and 25 from Thailand, 
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were included in this study. Viral RNA served as template for RT-PCR amplification of 
5’UTR-core (nucleotides 47-695) and NS5b (nucleotides 8283-8624) sequences. 
Amplicons were sequenced twice in both orientations. Degenerate sequences were 
preserved in order to determine the specificity of the line probe hybridization assays (see 
below). To determine the HCV genotype, phylograms were constructed with reference 
strains for 5’UTR-core and NS5b regions (Fig.1 and data not shown). Only samples 
which showed genotype consistency of both regions were selected (n = 73) and 2 
discordant samples (D3 and D54) which turned out to be a recombinant virus and a 
mixed infection were characterized by full-length genome analysis as described 
elsewhere (12). As evident from the 5’UTR-core phylogenetic analysis (Fig. 1, Table 1), 
our sample collection contained genotype 1 (n = 29), 2  (n = 4), 3 (n = 7) and 6 (n = 33) 
viruses. 
 Determination of HCV genotype by the VERSANT HCV Genotype (5’UTR) assay.  
To examine the accuracy of HCV genotyping by the line probe hybridization assay based 
on the 5’UTR sequence, we tested all selected samples using the VERSANT HCV 
Genotype assay (Fig. 2A; Table 1). This assay correctly determined the genotype of 71% 
(52/73) of the samples as compared to sequence analysis. From these identified 
genotypes, 15% (8/52) were subtype indeterminate of which 4 were of subtype 1a, 2 of 
subtype 1b, 1 of subtype 2a and 1 of subtype 3b. Only one sample (2%) of genotype 1a 
was incorrectly subtyped as genotype 1b (Table 1). All 21 samples that could not be 
genotyped correctly are genotypes 6c-6l that were typed to genotype 1. The 5’UTR 
sequences of the 6c-6l samples are very similar to the genotype 1 5’UTR sequences, 
especially in the regions where probes 3, 4, and 6 are located (24, Fig. 3), which explains 
the mistyping of the genotypes 6c-6l in this assay.  
Determination of HCV genotype by the VERSANT HCV Genotype 2.0 (5’UTR-
core) assay.  The new HCV LiPA assay consists of 25 lines in total (Fig. 2B). Lines 1 to 
21 are identical to the strip configuration of the VERSANT HCV Genotype assay (Fig. 
2A), which is based on the 5’UTR sequences. Another four lines specific for the core 
region are used for control core amplification, genotype 6c-6l, 1a, and 1b, respectively. 
These core specific lines are only to be considered when 5’UTR line patterns refer to 
genotype 1. 
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Figure 1 The midpoint rooted neighbor-joining tree of the 5’UTR-to-core region among selected 
HCV field viruses from SEA and prototype strains. The tree was constructed for nucleotides 47 
to 695 of the HCV genome (numbering according to reference strain HCV-H Genbank accession 
number M67463) by using the Tajima-Nei model with rate heterogeneity parameter. Confidence 
values (>70%) calculated by bootstrap analysis (1,000 replicates) are indicated at the major 
branching points. Branch lengths are drawn to scale. The prototype HCV strains obtained from 
Genbank are indicated in bold.  
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TABLE 1. Comparison of HCV genotyping results obtained by phylogenetic analysis, 
the VERSANT HCV Genotype assay (5’UTR), and the VERSANT HCV Genotype 2.0 
assay (5’UTR-core) for 73 specimens obtained from SEA. 
  
                                                No. of HCV genotyped samples (type or subtype) 
                                         as determined by a
   Genotype  
                                     Phylogenetic analysis     VERSANT HCV    VERSANT HCV2.0 
               5’UTR/core    NS5B   (5’UTR)          (5’UTR/Core) 
 
 Genotype 1         
  Subtype1a                   13     13  6 (1a)            11 (1a) 
       2 (1a or 1b)  2 (1)* 
1 (1b)   
       4 (1) 
        
  Subtype 1b            16     16           14 (1b)            14 (1b) 
       2 (1)              2 (NT)* 
  
Genotype 2 
  Subtype 2a                       4       4  3 (2a or 2c)  4 (2a or 2c) 
       1 (2) 
 
Genotype 3   
  Subtype 3a                     3          3  3 (3a)    3 (3a) 
  Subtype 3b                     4       4  3 (3b)    3 (3b) 
       1 (3)    1 (3)* 
 
Genotype 6 
  Subtype 6a                  12     12           12 (6a)            12 (6a or 6b) 
  Subtype 6c to 6n          21     21           19 (1b)            20 (6c to 6l) 
                              2 (1)              1 (NT)* 
 
a NT, Nontypeable.  *, INNO-LiPA line patterns shown in Fig. 2C 
 
 
 
 
Figure 2 (A and B) Comparison of INNO-LiPA strip patterns obtained from VERSANT HCV 
Genotype assay (5’UTR lines) (A) and the new VERSANT HCV Genotype 2.0 assay 
(5’UTR/core lines) (B). Both assays were tested with HCV genotype 1a, 1b, 2a, 3a, 6a and 6c-6l 
samples. Type-specific line numbers and interpreted genotypes of 5’UTR and core regions are 
indicated on the left side of each panel. (C) Patterns of the VERSANT HCV Genotype 2.0 assay 
obtained from subtype-indeterminate samples(from Th41, D89 [genotype 1a], Th48 [genotype 
3b] and nontypeable samples (from Th6, Th44 [genotype 1b], Th52 [genotype 6f]. Sample codes 
and specific probe numbers are indicated. MKR, marker line; CONJ CTRL, conjugate control; 
AMPL CTRL, amplification control; AC NCR, amplification control of noncoding region; AC 
CORE, amplification control of core.   
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Upon analysis of the same sample set as described above, the new VERSANT 
HCV Genotype 2.0 assay correctly classified the HCV genotype in 96% (70/73) of the 
samples. All genotype 6 samples could be distinguished from genotype 1 viruses. This 
result is in agreement with sequence comparisons of HCV core region obtained from 
these samples, showing differences between genotype 1 and 6 viruses (Fig. 3). 
Incorporation of core probes in the assay therefore explains the more accurate HCV 
genotype 6 classification results with the new VERSANT HCV Genotype 2.0 assay 
(Table 1). Only three samples could not be subtyped; the subtype 1a samples Th41 and 
D89, showed strong binding of core specific line 25 (subtype 1a), but also a faint band at 
the position of line 26 (subtype 1b), while the subtype 3b sample Th 48 showed only 
UTR specific line 13 (Fig. 2C).  
Three samples (4%) could not be genotyped; sample Th52 (genotype 6 by 
sequence analysis) showed binding to line 24 indicating a subtype 6 virus, whereas there 
was no binding to the 5’UTR lines 3 and 4 (Fig. 2C). As shown in figure 3, this result can 
be explained by a single nucleotide substitution in the Th52 core sequence at a position 
where probes 3 and 4 bind (nucleotide 183, CÆ T and nucleotide 215, AÆ G, 
respectively). On the other hand, samples Th6 and Th44 (subtype 1b by sequence 
analysis) bound to core lines 24 and 26 (genotype 6 and 1b, Fig. 2C). To test the 
possibility of double infection in these samples, RT-PCR products of UTR-core regions 
of Th6 and Th44 samples were cloned and at least 25 clones per sample were sequenced. 
No evidence of a mixed genotype infection could be obtained in the samples tested, 
although the presence of a co-infecting strain as a minor population cannot entirely be 
ruled out. 
 
DISCUSSION 
 
Clinical studies have shown that the HCV genotype is an important predictor for 
efficiency of antiviral treatment. Therefore, many efforts have been made to develop 
assays for HCV genotyping and several commercial tests are available (13). The gold 
standard for determination of HCV genotype is sequence analysis of phylogenetically 
informative coding regions of the HCV genome and comparison to consensus sequences 
of known genotypes. However, sequence analysis of amplicons is laborious and is not 
accurate in identifying mixed infections.    Moreover, as the informative sequences on the 
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Figure 3 Alignment of the 5’UTR and core sequences of a subset of samples obtained from SEA. 
Sample codes and genotypes are indicated in the left-hand column. Residues identical to the 
major sequence are indicated by dots. The positions of specific probes of the VERSANT HCV 
Genotype assay (5’UTR) are boxed. The first nucleotide position of each box is indicated at the 
bottom left corner. The LiPA line number outside the box indicates the predicted reactivity of 
each isolate in the sequence alignment. The core sequence alignment starts with the ATG 
initiation codon (positions 342 to 345 of the HCV genome; the numbering system is as described 
for Fig.1). Slashes indicated discontinuous sequences within the 5’UTR. 
 
 
genome are also regions with a relatively high heterogeneity, primers may fail to anneal, 
resulting in assay failures.  
Hybridization of HCV 5’UTR sequences to genotype-specific probes with the 
VERSANT HCV Genotype assay has so far been the keystone for HCV genotyping, 
because the high degree of sequence conservation makes this region ideal for RT-PCR 
amplification. However, this region contains lower phylogenetic information than other 
genomic sequences such as core and NS5b (15). Not surprisingly, its ability to 
discriminate between HCV genotypes was challenged by the high diversity of HCV 
sequences, especially by the genotypes 6c-6l from SEA (19, 21, 24, this study). Because 
of the high homology of the 5’UTR between genotype 1 and genotype 6c-6l, the latter 
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are claimed to be genotype 1 by the assay (24, Fig. 2, Table 1). Moreover, it has been 
reported that the VERSANT HCV Genotype assay could not accurately distinguish 
between genotypes 1a and 1b in 5-10% of cases, because specific probes for both 
subtypes are lacking (2). Mistyping of genotype 6 as genotype 1 may influence the 
clinical management of patients, since genotype 6 viruses show a higher response to 
therapy than genotype 1 (4).  
The new VERSANT HCV Genotype 2.0 assay is designed to increase the 
accuracy of HCV genotype/subtype identification by including core specific probes that 
discriminate between genotypes 1a, 1b and 6c-6l. Because of the retained phylogenetic 
information in this region, the core gene is one of the recommended regions for HCV 
genotyping (18). Although attempts have been made previously to design specific 
5’UTR/core probes for genotype identification, these were not tested for genotype 6 
viruses (25). In this study, we have tested the new VERSANT HCV Genotype 2.0 line 
probe assay with 73 samples obtained from SEA, of which 45% were of genotype 6 
(33/73). A marked improvement in accurate genotyping is seen with the new assay as 
compared to the old assay that only targeted the 5’UTR (~96% versus 71%). As 
expected, the increase in precision is largely due to correct genotyping and subtyping of 
6c-6l and 1a/b viruses, respectively. Our sample set not only contains genotype 6a, but 
also the new variants of genotypes 6d, 6e, 6f, 6i, 6l and 6n (Fig. 1). All of these were 
correctly identified by the VERSANT HCV Genotype 2.0 assay. With regard to the 
heterogeneity of genotype 6 sequences, 5’UTR/core line probe assay proved its ability to 
recognize a broad variety of genotype 6 viruses.  
Only 4% (3/73) of the samples could not be genotyped. One of these showed a 
new pattern of genotype 6c-6l (Th52). Two other samples (Th6 and Th44) showed 
specific hybridization with probes of genotype 1b and 6c-6l. Although sequence variation 
between HCV strains offers an explanation as only few nucleotide changes could cause 
cross-reactivity with probes thought to be subtype-specific, this seems not very likely. 
Alternatively, these results could indicate the presence of genotypically different viruses 
in the samples. Attempts to confirm this by sequence analysis were not successful, 
possibly because the detection of mixed infections by sequence analysis of amplified 
fragments is not sensitive enough (6, 14). The hybridization patterns, indicating a 
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possible mixed infection of genotype 1 and 6 viruses, are not evident from the line 
patterns observed with the old version of the LiPA test. 
One of the other commercial assays that is frequently used for genotyping HCV is 
the Trugene HCV 5’NC genotyping kit. In comparative studies between this assay and 
the previous VERSANT HCV Genotype test, the accuracy of genotyping was similar, 
although Trugene showed a slightly higher percentage of correct subtype identifications 
(5). The efficiency of Trugene in discriminating genotype 6 subtypes is currently not 
known.  However, its exclusive use of the 5’UTR region for genotype identification 
points towards a reduced efficiency in the correct assignment of genotype 6c-6l viruses.  
Therefore, the new VERSANT HCV Genotype 2.0 assay, which also takes into account 
HCV core sequences, may actually be the most suitable current tool for routine HCV 
genotyping. This assay may not only be crucial for clinical evaluation of patients, but 
also for future epidemiological, evolutionary and pathogenesis studies. 
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ABSTRACT  
 
Hepatitis C viruses (HCVs) display a high level of sequence diversity and are currently 
classified into six genotypes and an increasing number of subtypes. Most likely, this 
heterogeneity is caused by genetic drift; evidence for recombination is scarce. To study 
the molecular heterogeneity of HCV in Vietnam, we analyzed 58 HCV RNA positive 
sera from Vietnamese blood donors by sequence analysis of the CORE and NS5B 
regions. Phylogenetic analyses revealed the presence of genotype 1 (38%), genotype 2 
(10.3%) and genotype 6 viruses (51.7%). All samples showed concordant results except 
for two (D3 and D54). Sample D54 was a mixed infection of genotype 2i and 6h viruses. 
Whole genome analysis and bootscan analysis of sample D3 on the other hand, revealed 
a recombinant virus with genotype 2i and genotype 6p sequences at the 5’ and 3’ ends, 
respectively. The crossover point was located between nucleotide position 3405-3464 
(numbering according to prototype strain HCV-H, M67463), at the NS2/NS3 junction. 
The identification of this naturally occurring recombinant virus strengthens the concept 
that recombination may play a role in HCV epidemiology and evolution. Furthermore, 
the location of the recombination breakpoint may be relevant for constructing infectious 
chimeric viruses.   
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INTRODUCTION 
 
Hepatitis C virus (HCV), an important causative agent of acute and chronic 
hepatitis, is an enveloped plus-strand RNA virus that belongs to the family Flaviviridae 
(33). Its genome, approximately 9.4 kb in length, encodes both structural (Core, E1, E2) 
and nonstructural (p7, NS2, NS3, NS4a/b and NS5a/b) proteins in a single open reading 
frame (6). Short conserved untranslated regions (UTRs) located at the 5’ and 3’ ends of 
the genome are required for viral replication (9, 10). An internal ribosomal entry site in 
the 5’UTR is involved in protein translation (46).  
Because of its heterogeneity, HCV is classified into six major genotypes and a 
large number of subtypes (36-38). Different genotypes display up to 30% sequence 
diversity, whereas subtypes vary more than 20% (37, 38).The variability is distributed 
unequally across the genome, with regions such as E1 and E2 displaying most sequence 
diversity, whereas 5’UTR and CORE  sequences are more conserved (39). Several 
methods were developed to determine the HCV genotype such as serological genotyping, 
RT-PCR amplification with genotype specific primers, restriction fragment length 
polymorphism (RFLP) analysis, reverse hybridization assay and sequence analysis (28). 
Of these methods, sequence analysis of phylogenetically informative regions is more 
reliable for genotype and subtype identification. Genotyping of HCV is important for 
prediction of responses to, and in determining the duration of antiviral therapy (23, 28). 
Moreover, assessment of the distribution of genotypes in different parts of the world may 
help to understand the epidemiology and evolution of HCV.  
The geographic distribution of HCV relates to different epidemic histories and 
routes of transmission. Some genotypes, such as 1a/b, 2 and 3a, are widely distributed to 
Western countries, United States and Japan as a result of transmission via blood 
transfusion and contaminated needles between intravenous drug users (IDUs) (2). These 
strains typically have limited sequence diversity, resulting from the recent introduction of 
a few strains from endemic areas (36). On the other hand, a more complex viral 
heterogeneity is observed in parts of Africa and South-East Asia. In Western Africa, 
HCV infection is caused predominantly by genotype 2, while genotype 1 and 4 are most 
prevalent in Central Africa (4, 24).  In both areas, a notable divergence of subtypes, 
especially broad genotype 2 variety in Ghana, was reported (5). Similar observations 
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were made in Asia, where genotype 1, 3 and 6 dominate (33), and a large variety of 
genotype 6 was demonstrated in Vietnam, Thailand, Myanmar, China and Hong Kong (8, 
25, 34). This large sequence divergence points to a long-term presence of HCV infection 
among local populations through variety of routes, including vertical, sexual and 
household contact transmission (35, 41) The sequence diversity of HCV is supposedly 
caused by a high mutation rate of the RNA-dependent RNA-polymerase during 
replication (41). Interestingly, recombination, commonly seen among RNA viruses, 
including other members of the family Flaviviridae (14, 20, 47, 51) is not thought to play 
a major role (39, 40, 49). The fact that recombinant forms of HCV have been observed in 
nature, such as the St. Petersburg strains containing sequences of both genotype 2k and 
1b (18) and a possible 1a/1b recombinant virus in Peru (7), would suggest that all 
requirements for genetic exchanges could be met. However, only few chimeric HCV 
genomes were described, which may be due to detection limits of currently employed 
methods that are not suited for discovering recombinant strains. It is therefore possible 
that the true frequency of HCV recombination is underestimated (7, 18, 35), especially in 
endemic areas with a high prevalence of different HCV genotypes.  
In the present study, we analyzed sera from 58 HCV RNA-positive blood donors 
from Ho Chi Minh City, Vietnam, in order to survey the molecular heterogeneity of HCV 
in this area. The CORE and NS5B genes of each sample were sequenced and 
phylogenetic analysis was performed. Two samples gave discordant results and were 
analyzed by full-length genome sequencing. Our results revealed one mixed genotype 
infection, whereas the other sample contained an intergenotypic recombinant virus. 
 
MATERIALS AND METHODS 
 
Serum samples.  Fifty-eight previously identified HCV-positive sera from the 
Pasteur Institute Ho Chi Minh City were collected. All samples were obtained from 
blood donors between 2000-2002. Samples were kept at – 80 oC until further analysis. 
Amplification of HCV CORE and NS5B regions.  Viral RNA was extracted 
from 100 μl serum by the High Pure RNA isolation kit (Roche Diagnostics GmbH) and 
eluted with 30 μl water. cDNA was synthesized from 10 μl extracted RNA with Moloney 
murine leukemia virus reverse transcriptase  (Invitrogen) and random hexamer primers, 
according to the instructions of the manufacturers. Core sequences (Fig.1A, nucleotides 
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339 to 695, according to the numbering system for reference strain HCV-H Genbank 
accession number M67463) were amplified by nested PCR with oligonucleotides s17, 
410, 953, and 951 (Table 1), as described previously (24). NS5b sequences (Fig.1A, 
nucleotides 8283 to 8624) were amplified by nested PCR with primers Pr3, Pr4, Pr1, and 
Pr2 (Table 1) using conditions described in previous reports (32) with modifications. 
Briefly, in the first PCR, performed with Pr3 and Pr4, 1.5 mM MgCl2 was used in the 
reaction mixture, and the following thermal profile: initial denaturation at 94oC for 90 s; 
5 cycles of denaturation at 94oC for 30s, annealing at 64oC for 45 s and elongation at 
72oC for 1 min, followed immediately by 30 cycles at 94oC for 30 s, 64oC with a drop of 
–0.5oC between each cycle and elongation at 72oC for 1 min. The last 5 cycles were 
performed at 94oC for 30 s, 48oC for 45 s and 72oC for 1 min. A final elongation at 72oC 
for 10 min was also included. The nested PCR, performed with primer Pr1 and Pr2, was 
carried out on 2 μl of first PCR product with the following thermal profile: 95oC for 7 
min; 50 cycles at 95oC for 30 s, 63oC for 30 s and 72oC for 30 s, with a final elongation 
step at 72oC for 10 min. The amplified product were gel-purified and sequenced. 
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C    E1     E2    p7 NS2        NS3      NS4A/B   NS5A   NS5B   
 
 
 
 
 
 
 
 
Figure 1 Hepatitis C virus genome organization and a schematic outline of the strategies used for 
RT-PCR amplification of (A) CORE and NS5B regions and (B) overlapping fragments covering 
the entire genome. Boxes represent the coding regions for the Core protein (C), envelope 1 and 2 
(E1 and E2) proteins, p7, and nonstructural proteins 1-5 (NS1-NS5). Also indicated are the 5’- 
and 3’untranslated regions (5’UTR and 3’UTR). Black lines and dotted lines indicate the first- 
and second-round PCR products, respectively. Forward and reverse primers are presented at the 
5’ and 3’ end of PCR products. The nucleotide positions and genetic organization are according 
to the numbering system for the prototype strain HCV-H (accession number M67463). 
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Table 1.   Primers used for amplification and sequencing of HCV. 
 
Primer                  Sequence 5’ – 3’                       Position          Polarity      References 
 
16†  grggcgacactccaccat               16-33       Forward      this paper 
s17†  accatagatcactcccctgt           29-48               Forward           31 
953  aggtctcgtagaccgtgcatcatg          321-344       Forward        24 
951  caygtragggtatcgatgac         697-716         Reverse        24 
410       atgtaccccatgaggtcggc        731-750         Reverse        24 
693  aayttgggtaargtcatcg         693-711       Forward      this paper 
845  ccyggttgctcyttytctat         849-868       Forward      this paper 
1298   ctgggayatgatgatgaa        1298-1315       Forward      this paper 
1992†   ggntgyacvtggatgaa          1992-2008       Forward      this paper  
2085  ttsckgaarcartcvgtrgg        2085-2104       Reverse       this paper 
3277F‡  atggagaagaarvtyatcac           3277-3296       Forward      this paper 
3277R† ctratrabyttvdtctccat                 3277-3296       Reverse       this paper 
3636   tggtcyacattggtrtacatytg       3636-3658       Reverse       this paper 
4039‡¶  ggcagyggbaaragyac         4039-4955       Forward      this paper 
4662†  crccygtrtasccrgtcat          4662-4680       Reverse       this paper 
4863  ccstcngghatgttyga        4863-4879       Forward      this paper 
A5310  cccaggtgctagtgacgac        5304-5322       Reverse             31 
5460†   tagmrcaytcytccatctc          5460-5478       Reverse       this paper 
5930‡  agtsgcyttyaarrtcatg          5930-5948       Forward      this paper 
6085  gctatbagyckgttcatcca        6084-6103       Reverse       this paper 
6800  tcccbtgygarccbgag        6820-6836       Forward      this paper 
7039  tggmggcargaratggg        7038-7054       Forward      this paper 
7100‡   aagmggvtcraargagt         7102-7118       Reverse       this paper 
7600  tgvcgratkagrgagttgc        7681-7699       Reverse       this paper 
8170  atgggrttctcctaygayac        8244-8263       Forward      this paper 
Pr1       tggggatcccgtatgatacccgctgctttga   8245-8275       Forward         32 
Pr3¶  tatgayacccgctgytttgactc       8256-8278       Forward         32 
Pr2‡       ggcggaattcctggtcatagcctccgtgaa   8616-8645       Reverse          32 
Pr4  gcngartayctvgtcatagcctc       8622-8644      Reverse           32 
8625‡              gartacctrgtcatagc          8625-8641       Reverse       this paper 
9325¶   ctacrgtaagtaggagtaggc         9325-9345       Reverse       this paper 
3’UTR¶  aaaaaaaaaaaaaaaaaa           9418-9435       Reverse       this paper 
   
 
† Primer used for amplification of cDNA fragment nt 17-5460 
‡ Primer used for amplification of cDNA fragment nt 3227-8625 
¶ Primer used for amplification of cDNA fragment nt 4039-9435 
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HCV full-length genome amplification. Total RNA was isolated from 100 μl 
serum by proteinase K digestion and phenol-chloroform extraction as previously 
described (31) and dissolved in 20 μl sterile water. To generate a long fragment of 
cDNA, reverse transcription was performed on 10 μl RNA with Expand Reverse 
Transcriptase (Roche Diagnostics GmbH) and primers 5460, 8625 or 3’UTR (Table 1, 
Fig.1B), according to the manufacturer’s instructions, in a total volume of 30 μl at 42 oC 
for 2h. Ten-μl volumes of cDNA were amplified with 2.5 units of Expand High Fidelity 
Enzyme mixture (Roche Diagnostics GmbH), 1x Expand PCR buffer, 0.4 mM of each 
dideoxynucleotide and 0.4 μM outer primer pairs (Table 1) with a thermal profile that 
was described previously (31). First-round amplification from each cDNA reaction 
resulted in three overlapping PCR fragments (nucleotides 16 to 5460, 3227 to 8625 and 
4039 to 9416, Fig.1B). Two-μl volumes of amplified product were subjected to nested 
PCR with inner primers to generate overlapping genome fragments (nucleotides 17 to 
3277, 1992 to 4662, 4039 to 7100, 5930 to 8645 and 8256 to 9325, Fig. 1B) under 
similar conditions as employed for the first PCR. Amplified products were gel-purified 
with the Qiaquick gel extraction kit (Qiagen) and ligated directly into plasmid pCR2.1 
(TA cloning kit, Invitrogen). For each amplicon, five positive clones were selected and 
sequenced. 
DNA sequencing and sequence analysis.  Sequence reactions on PCR products 
and plasmids were performed using BigDye Terminator Cycle sequencing Ready 
Reaction kit (Applied Biosystems) and an ABI prism 3100 Autosequencer (Applied 
Biosystems). Sequencing primers were shown in Table 1. Multiple sequence alignments 
were generated with the BioEdit program (version 7.0.1). Phylogenetic analyses were 
conducted using the Kimura-2 parameter model and Neighbor-joining methods.  
Bootstrapping (1000 replicates) was tested and consensus trees were produced by 
program of MEGA version 3.0 (19).  
Reference strains used in this study were obtained from Genbank: genotype 1a 
(M67463), 1b (D90208), 2a (AF169005, AB047644), 2b (AF238486), 2c (D50409), 2f 
(D49754), 2k (AB031663), 2i (L48499, X76411), 3a (D28917), 3b (D49374), 3k (10a, 
D63821), 4a (Y11604), 5a (Y13184), 6a (Y12083), 6b (D84262), 6c (7d, D37857, 
D37843), 6d (7b, D84263), 6e (7a, D87365, D88478), 6f (7c, D38078, D38079), 6g (11a, 
D63822), 6h (9a, D84265), 6i (9b, D37864, D37850), 6j (9c, D37862, D37848), 6k (8b, 
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D84264), 6l (8a, D87359, D88472), 6p (L38340, L38380). The sequence of hepatitis G-
B virus (U22304) was used as an outgroup. 
Similarity and bootscanning analyses of whole genome sequences were 
performed with the Simplot program (version 2.5 for Window 95/NT; available from the 
author, Stuart C. Ray, online (http://sray.med.som.jhmi.edu/RaySoft/SimPlot/).  
Nucleotide sequence accession numbers. New sequences reported in this study have 
been submitted to Genbank and have been assigned accession numbers DQ155444-
DQ155501 (CORE sequences), DQ155502-DQ155559 (NS5B sequences), DQ155560 
(D3 complete genome sequence), DQ155561 (D54 genotype 2i complete genome 
sequence), DQ155562 and DQ155566 (D54 5’UTR-to-CORE sequences). 
 
RESULTS 
Genotyping of HCV isolates from Ho Chi Minh City, Vietnam.   
 We obtained 58 serum samples from Vietnamese blood donors, which were 
previously found to be HCV antibody positive. Viral RNA served as template for RT-
PCR amplification of the Core and NS5B sequences (Fig.1). To study HCV diversity, a 
phylogram, based on 333 nucleotides of the NS5B isolated from these 58 samples and 26 
prototype strains, was constructed (Fig. 2A). This analysis revealed the presence of 
genotype 1 (38%), genotype 2 (10.3%) and genotype 6 (51.7%) viruses. All Vietnamese 
1b isolates sub-clustered together with a bootstrap value of 80%, while most of the 
subtype 1a strains were grouped with the 1a reference sequence (Fig. 2A). Five samples 
were characterized as subtype 2a, and one strain (D54) was identified as subtype 2i. High 
levels of sequence divergence were observed among the genotype 6 viruses; 4 HCV’s 
(D41, D53, D83, and D88) exhibited separate branches from prototype strains, supported 
by bootstrap values. These data are a showpiece example of why it is so difficult to 
subtype genotype 6 variants based on reference sequences.  
To confirm the consistency of genotyping, we constructed a phylogram based on 
the 357 nucleotides of the CORE sequence (Fig. 2B). Although the HCV CORE 
sequences of Vietnamese genotype 1 and 2 strains showed less divergence compared to 
prototypes than in the NS5B sequence, the genotype 6 strains showed considerable 
variety. Overall, 56/58 samples showed concordant genotyping results. Interestingly, 
sample D3  was  characterized as genotype 2i  based on the CORE  region but typed as a  
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Figure 2 Rooted neighbor-joining trees depicting the phylogenetic relationships among HCV 
field variants and prototype strains. Trees were constructed for (A) a 333-nucleotide segment of 
the NS5B gene and (B) a 357 nucleotides of the Core gene, with the Kimura-2 parameter model. 
Confidence values (>70%) calculated by bootstrap analysis (1,000 replicates) are indicated at the 
major branching points. Branch lengths are drawn to scale. The prototype HCV strains obtained 
from Genbank are indicated by bold letters and Hepatitis G-B virus (U22304) was used as an 
outgroup sequence. Samples that gave discordant results in the phylogenetic trees are specified 
by asterisks and grouped to the related strain with circular mark. 
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genotype 6p after phylogenetic analysis of the NS5B sequence. Sample D54 on the other 
hand was classified as genotype 6h by analysis of the CORE sequence but grouped with 
genotype 2i after NS5B analysis.   
Characterization of sample D54: mixed infection with HCV genotypes 2 and 6.  
Conflicting phylogenetic data, such as obtained for the CORE and NS5B 
sequences in samples D3 and D54, are indicative for the presence of either a mixed 
infection with two different genotypes or an intergenotypic recombinant virus. Upon 
analysis with the 5’UTR reverse-hybridization line probe assay (INNO-LiPA HCV II), 
HCV from sample D3 was identified as genotype 2 and patient D54 was shown to have a 
mixed infection with HCVs of genotype 2 and genotype 1 or 6 variant (data not shown). 
To further characterize sample D54, the 5’-UTR-to-CORE region (nucleotides 
29-752) was amplified, cloned and sequenced. The alignment of CORE sequences 
obtained from sample D54 with prototype strains indicated that this patient had been 
double-infected with HCV genotype 2i (clone 20) and 6h (clone1) viruses (Fig.3). 
Complete genome sequences of both genotypes from sample D54 were determined 
following the strategy indicated in figure 1. No evidence for recombination was found. 
Phylogenetic analysis of CORE, E1 and NS5B sequences of HCV from sample D54 
confirmed that one of the full-length sequences was of genotype 2i, whereas the other 
was of genotype 6h (data not shown).  
Characterization of sample D3: HCV genotype 2/6 recombinant.  
Sequence analysis of 10 individual clones of 5’UTR-CORE sequences from 
sample D3, confirmed the data from the INNO-LiPA HCV II line probe assay, 
suggesting the presence of a viral strain belonging to genotype 2i (data not shown). 
Because the data depicted in Fig. 2 strongly indicate the presence of both genotype 2i and 
6p sequences, we suspected the presence of a recombinant virus. The full-length genome 
sequence of sample D3 was determined. In order to identify recombination breakpoints, 
we employed similarity plot and bootscanning analysis (Fig. 4). Since complete 
sequences of genotype 2i and genotype 6p were not found in sequence databases, we 
used genotype 6d (VN235, D84236) and the genotype 2i strain from sample D54 as 
reference sequences.   Genotype 1a  (HCV-H , M67463 )  was   included  as  an outgroup  
sequence.  Fig. 4 A  shows the  genetic  distances  between the  reference  strains and the 
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                   1 0         2 0         3 0         4 0         5 0         6 0         7 0   
          - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - |  
 
  NDM59 G2a   A T G A G C A C A A A T C C T A A A C C T C A A A G A A A A A C C A A A A G A A A C A C C A G C C G T C G C C C A C A A G A C G T T A A G T   
  VAT96 G2k   - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A - A - - - C - - - - - - - - G - - - - - C - - - -   
 
  HN4 G2i     - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T - A - - - C - - - - - - - - G - - - A - - - - - -   
  D54-C20 G2  - - - - - - - - - - - - - - - - - - - - - - - - - - - - T - - - - - - - - - - - - - - - T - A - - - C - - - - - - - - G - - - - - - - - - -   
  D54-C1 G6   - - - - - - - - - C T - - - A - - - - - C - - - - - - - - - - - - - - - - - - - - - - - T - A - - - - - - - - - T A T G - - - - - C - - - -   
 
  VN004 G6h   - - - - - - - - - C T - - - A - - - - - C - - - - - - - - - - - - - - - - - - - - - - - T - A - - - - - - - - - T A T G - - - - - C - - - -   
  VN235 G6d   - - - - - - - - - C T - - - A - - - - - C - - - - A - - G - - A - C - - - - - - - - - - A - A - - - - - - - - - - - - G - - - - - C - - - -   
 
  VN538 G6a   - - - - - - - - - C T - - - A - - - - - C - - - - - - - - - - - - - - - - - - - - - - - - - A - - - - - - - - - - A T G - - - - - C - - - -   
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  VAT96 G2k   - C - - - - - C - - T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   
  HN4 G2i     - C - - - - - C - - - - - - - - - - - - - - C - - - - - - - - G - - - - - - - - - - - - - - - - - - - -
 
- - - - - - - - - - - - - - - - - -   
  D54-C20 G2  - C - - - - - C - - T - - - - G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   
 
 
  D54-C1 G6   - C - - - - - C - - - - - - - - - - - - - - C - - T - - - - - T - - - - - - - - - - - - - - - - - - - - - - - T C - T - - - - - - - - - - -   
  VN004 G6h   - C - - - - - C - - - - - - - - - - - - - - - - - T - - - - - T - - - - - - - - - - - - - - - - - - - - - - - T C - T - - - - - - - - - - -   
  VN235 G6d   - C - - - - - - - - - - - T - - - - - - - - - - - T - - - - - C - - - - - - C - - - - - - - - - - - - - - - - - C - - - - - - - - - - - - -   
  VN538 G6a   - C - - - - - - - - - - - T - - - - - - - - - - - - - - - - - T - - - - - - - - - - - - - - - - - - - - - - - - C - - - - - - - - - - - - -   
 
 
 
 
                 1 5 0        1 6 0        1 7 0        1 8 0        1 9 0        2 0 0        2 1 0  
          - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - |  
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  VAT96 G2k   - - - - - - - - - - - - - - - - - - C - - A - - - - - - - - - - - - - - C - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T   
  HN4 G2i     - - - - - - - - - - - - A - - - - - C - - A - - - - - - - - - - - - - - - - - G - - G - - - - - - - - - - - - - - G - - - - - - - - - - - G   
  D54-C20 G2  - - - - - - - - - - - - A - - - - - T - - A - - - - - - - - - - - - - - - - - G - - G - - - - - - - - - - - - - - A - - - - - - - - - - - -   
  D54-C1 G6   - - - - - - - - - - - - - - - - - - T - - A - - - - - - - - - - - T A - A - - C - - G - - - - - - - - - - - A - - A - - G - T G - - C - A G   
  VN004 G6h   - - - - - - - - - - - - - - - - - - C - - A - - - - - - - - - - - T A - A - - C - - G - - - - - - - - - - - A - - A - - G - C G - - C - A G   
  VN235 G6d   - - - - - - - - - - - - - - - - - - T - - A - - - - - - - - - - - C A - A - - T - - G - - - - - - - - - - - A - - A - - G - C G - - C - - -   
  VN538 G6a   - - - - - - - - - A - - - - - - - - C - - - - - A - - - - - - - - C A - A - - C - - G - - - - - A - - T - - A - - A - - G - C G - - C - A G   
 
 
 
 
 
                  2 2 0        2 3 0        2 4 0        2 5 0        2 6 0        2 7 0        2 8 0  
              - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - | - - - - |  
  NDM59 G2a   T C C A C T G G C A A G T C C T G G G G A A A A C C A G G A T A C C C C T G G C C C C T G T A T G G G A A T G A G G G A C T C G G C T G G G   
  VAT96 G2k   - - - G - - - - - - - - - - - - - - - - - C G T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - C - - - - - G - - - -   
  HN4 G2i     A - - - - - - - - - - - - - - - - - - - - C G T - - - - - - - - T - - - - - - - - - - - - - - C - - A - - C - - - - - C - - - - - T - - - -   
  D54-C20 G2  A - - - - - - - - - - - - - - - - - - - - C G T - - - - - - - - - - - T - - - - - - - - - - - - - - - - - - - - - - - C - - - - - T - - - -   
  D54-C1 G6   C - G - - A - - - C G T A G - - - - - - T C - - - - C - - C - - - - - T - - - - - - - - C - - - - - C - - C - - - - - C T G - - - A - - - -   
  VN004 G6h   C - G - T A - - - C G T A G - - - - - - T C - - - - C - - C - - - - - T - - - - - - - - T - - - - - C - - C - - - - - C T G - - - A - - - -   
  VN235 G6d   C A G - - G - - - C G T A - - - - - - C - C - G - - T - - G - - T - - - - - - - - - - - C - - C - - - - - - - - - - - C T G - - - - - - - A   
  VN538 G6a   - - - C A G - - - - G - C A - - - - - C T C - G - - C - - - - - T - - T - - - - - T - - T - - - - - A - - C - - - - - C T G - - - G - - - -   
Fig. 3 Alignment of CORE sequences obtained from sample D54. Two representative clones, 
clone 1 (C1) and clone 20 (C20), were aligned with genotype 2a, 2k, 2i, 6a, 6d and 6h prototype 
strains. The D54 sequences are indicated in bold. Accession numbers of references strains are 
indicated in Materials and Methods. Residues identical to the major sequence are indicated by 
dashed and numbering of the nucleotides starts at the first codon of CORE gene.   
 
 
potential recombinant HCV strain of sample D3. The 5’UTR-to-NS2 region of the HCV 
strain of sample D3 is more related to subtype 2i sequences, whereas the NS3-to-NS5B 
region is more closely related to subtype 6d. Thus, the Simplot analysis (Fig. 4) 
corroborates the results from the phylogenetic trees (Fig. 2), providing evidence that the 
HCV strain in sample D3 is a recombinant virus. It is of note that the recombinant virus 
of sample D3 shows ~25% sequence divergence when compared with genotype 6d 
viruses in its C-terminal part of the genome.  
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4  (A) Similarity plots of the intergenotypic recombinant D3 strain and HCV genotype 1a 
(HCV-H), 2i (D54) and 6d (VN235) based on the entire genome using a window size of 600 bp, a 
step size of 20 bp and the maximum-likelihood parameter. Gaps were ignored and 1000 bootstrap 
replicates were used. (B) Bootscan plots showing the likelihood of clustering of the putative 
intergenotypic recombinant of sample D3 with reference strains, with 1000 bootstrap replicates 
and neighbour-joining tree analysis. As a reference, the genomic organization of HCV, drawn to 
scale, is depicted on top. Arrows indicate the recombination breakpoints. The nucleotide 
positions are numbered as described in the legend of Fig.1.  
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Bootscan analysis of the D3 HCV genome revealed the existence of only one 
recombination breakpoint, located within the NS2-NS3 region (Fig. 4B), between 
nucleotides 3405 - 3464 (Fig. 5A) and amino acids 1022 – 1042 (Fig. 5B). Interestingly, 
the recombination site is a conserved region at the amino acid level (Fig. 5B), which is 
cleaved by the NS2-NS3 protease (15, 43). Almost all cases of genetic exchanges in 
RNA viruses are thought to occur via copy-choice RNA recombination (26, 51).  
Template switching is supposedly aided by homology between the donor and acceptor 
strand and secondary RNA structures (1, 26). According to the proposed mechanism of 
HCV recombinant formation described by Kalinina et al. (17), the secondary RNA 
structure around the recombination site may enhance genetic exchanges in vivo. We 
could identify a stable hairpin structure (nucleotides 3423 to 3464) in the positive strand 
of genotype 6d strain VN235, that is not present in genotype 2i, which may have played a 
role in the creation of our recombinant genotype 2i/6 virus (data not shown).  
 To rule out the possibility of reverse transcription and PCR artifacts, we used a 
different reverse primer (4662, Table 1) to generate a cDNA fragment of HCV from 
sample D3 and amplified a short PCR product covering the NS2/NS3 region with primer 
3277F and 4662 (position 3277 to 4662) (Fig.1). The results confirmed the 
recombination breakpoint. 
 
DISCUSSION 
 
         
       
   
Until recently, there was no evidence for recombination in hepatitis C viruses. 
Therefore, it has been implicitly assumed that HCV diversity was generated through 
genetic drift. Recently, however, both intergenotypic and intragenotypic recombinant 
HCVs have been identified (7, 18). In this paper, we have identified a second 
intergenotypic recombinant form of HCV.  
Molecular heterogeneity of HCV in 58 HCV-positive serum samples from blood 
donors in Ho Chi Minh City were analysed. Phylogenetic analyses revealed the presence 
of genotype 1 (38%), genotype 2 (10.3%) and genotype 6 (51.7%) viruses. The 
Vietnamese genotype 1a and 1b viruses in our study, formed separate clusters and 
showed lower diversity compared to the genotype 6 strains. This may suggest that 
genotype 1  viruses  were  relatively  recently  introduced in Vietnam and were spread by  
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            940        950        960        970        980         
            |----|---- |----|---- |----|---- |----|---- |----|----  
HCV-H G1a      KLGALTGTCV YNHLAPLRDW AHNGLRDLAV AVEPVVFSRM ETKLITWGAD  
D54 G2i        A--RWL-IYI -D--T-MS-- -AR------- ----I---P- -K-V-----E  
D3_RF_2 2i/6p  A--RWF--YI -D--T-MS-- -AS------- -----I--P- -KRV-----E  
VN235 G6d      ----W---YI -D-----ST- -SD------- -----T--P- -K-I------  
                                                         1022             
                                                             NS2        NS3 
           990        1000       1010       1020       1030 
            |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H G1a      TAACGDIING LPVSARRGQE ILLGPADGMV SKGWRLLAPI TAYAQQTRGL   
D54 G2i        --------H- ------L-R- V-------YT ---------- ----------   
D3_RF_2 2i/6p  --------H- ------L-R- V-------YT ----K----- ---H------   
VN235 G6d      -------LA- ------L-HL LF-----D-K -M-------- ---C------  
            1042 
             
            1040       1050       1060       1070       1080 
            |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H G1a      LGCIITSLTG RDKNQVEGEV QIVSTATQTF LATCINGVCW TVYHGAGTRT   
D54 G2i        --A-VV---- ---TEQA--- -VL--I--S- -G-T-S--L- --F----NK-   
D3_RF_2 2i/6p  --T-V----- ----E----I -V-------- ---AV---L- -------SK-   
VN235 G6d      --T-V----- --R-V----I -VL-----S- -G-A----M- -------SK-  
  
           1090       1100       1110       1120       1130 
            |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H G1a      IASPKGPVIQ TYTNVDQDLV GWPAPQGSRS LTPCTCGSSD LYLVTRHADV   
D54 G2i        L-GSR---T- M--SAEG--- ---S-P-TK- -E-----AV- ------N---  
D3_RF_2 2i/6p  L-G-----C- M-------M- -----P-A-- ---------- V-----N---   
VN235 G6d      L-G-----C- M-------M- -----P-T-- -------A-- ------N---   
 
  
           3300       3310       3320       3330       3340       3350  
              |----|---- |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H_G1a     GGGGCAGATA CCGCCGCGTG CGGTGACATC ATCAACGGCT TGCCCGTCTC TGCCCGTAGG 
D54_G2i       --------G- -G--G--A-- ---------- --AC-T--A- ----T----- A-----GTT- 
D3_RF2_2i/6p  --------G- -A--A----- ---A-----T --AC-T--A- ----T--T-- A--T--GCT- 
VN235 G6d     --T-----C- -T--A----- T--C--T--- C-GGCT--GC -T--G----- ---A--CTT- 
                                                           
                                                         3405      NS2         
           3360       3370       3380       3390       3400       3410   
           |----|---- |-----|--- |----|---- |----|---- |----|---- |----|---- 
HCV-H_G1a     GGCCAGGAGA TACTGCTTGG GCCAGCCGAC GGAATGGTCT CCAAGGGGTG GAGGTTGCTG 
D54_G2i       ----G---AG -CT----A-- T--C--T--- --CTACAC-- ----A----- ---AC-C--C 
D3_RF2_2i/6p  ----GC---G -C-----G-- T--C--T--- --CTACAC-- ----A----- --A-C-T--C 
VN235 G6d     --T--TTT-C -CT-C----- ---G-----T -AT---AAGA G--T---C-- ---AC-A--T 
  
                NS3                                                                      3464  
              3420       3430       3440       3450       3460       3470       
              |----|---- |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H_G1a     GCGCCCATCA CGGCGTACGC CCAGCAGACG AGAGGCCTCC TAGGGTGTAT AATCACCAGC 
D54_G2i       --T-----T- -C--T----- ---------A C-T-----G- -G--CGCC-- -G-GGTA--T 
D3_RF2_2i/6p  --T------- ----C--TCA ---A-----T C-C-----A- -T---ACA-- TG-------T 
VN235 G6d     --T-----T- -C------TG ---A-----T C-T--AT-A- -G--AACA-- TG-T------ 
 
 
              3480       3490       3500       3510       3520       3530  
              |----|---- |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H_G1a     CTGACTGGCC GGGACAAAAA CCAAGTGGAG GGTGAGGTCC AGATCGTGTC AACTGCTACC 
D54_G2i       --A-----G- -C-----G-C GG-GCAA-CT --C--A---- --G-TT---- C--CATC--- 
D3_RF2_2i/6p  --C--A--T- -C-------- TG-G--C--- --C---A-A- -AG-G--C-- C--G--C--T 
VN235 G6d     --C--C---- ----T-GG-- TGTG--T--A --A---A-A- -AG-GC-C-- C--A--G--- 
 
 
              3540       3550       3560       3570       3580       3590 
              |----|---- |----|---- |----|---- |----|---- |----|---- |----|---- 
HCV-H_G1a     CAGACCTTCC TGGCAACGTG CATCAATGGG GTATGCTGGA CTGTCTACCA CGGGGCCGGA 
D54_G2i       ---T------ -T-GC--CAC A---TCG--- --TCT----- -C--G-T--- ---C-----C 
D3_RF2_2i/6p  -----T---- ----T--AGC TG-A------ --CCT----- -A-----T-- ---------C 
VN235 G6d     ---T-T---- ---GT--CGC ------C--- --GATG---- -G-------- T--T--T--- 
 
               
  
5B 
5A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Alignment of nucleotide (A) and amino acid (B) sequences of the NS2/NS3 region of the 
intergenotypic HCV recombinant of sample D3 and reference strains. Recombinant sequence is shown in 
bold. Boxes with solid lines indicate the cleavage site for the NS2/NS3 protease. The dotted box indicates 
the sequence forming the postulated hairpin proposed to promote recombination. The broken lines indicate 
the protease cleavage site of the NS2-NS3 protein. Vertical arrows overlap nucleotides 3405-3464, or 
amino acid 1022-1042, represented the recombination breakpoint. The nucleotide and amino acid positions 
are according to the numbering system described in the legend of Fig.1. 
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intravenous drug users and through use of contaminated blood products (35, 41). The 
higher heterogeneity of genotype 6 viruses would indicate, on the other hand, that these 
strains have circulated in Vietnam for a longer period of time (29, 41). The Vietnamese 
genotype 2a viruses clustered together and are related to subtype 2a from Japan. 
Interestingly, one of the strains that infected patient D54 was identified as a relatively 
rare subtype 2i, based on comparison with CORE, E1, and NS5B sequences of prototype 
2i strain HN4. Subtype 2i was first identified in France in 1994 (30); the origin of the 
Vietnamese 2i virus is unknown. It is not unlikely that it was introduced in Vietnam by 
French citizens. 
The most striking observation in our study is the identification of a HCV 
recombinant in Vietnam; the second intergenotypic recombinant that is described thus 
far. This virus contains sequences from subtype 2i and genotype 6. The genotype 6 
region in this virus is probably most closely related to a new subtype 6p, of which 
recently a short NS5B sequence was reported (42). The new HCV recombinant thus can 
be classified as a candidate RF2_2i/6p strain. The recombination breakpoint is located 
between nucleotides 3405 and 3464. In the HCV polyprotein, this region is cleaved by 
the NS2-NS3 protease, and is reasonably conserved among different HCV genotypes 
(43). The copy-choice model, originally proposed in case of poliovirus recombination 
(20, 45), supports almost all possible mechanisms of RNA viruses described thus far. In 
this case, hybrid RNAs might be formed when the viral RNA-dependent RNA 
polymerase (RdRp) complex switches during replication. Our data suggest that both the 
high level of homology between donor and acceptor strand, and the presence of a hairpin 
structure in the region where the genetic exchange occurred, facilitated the generation of 
this recombinant.  
It is worth noting that the recombination breakpoints in both identified 
intergenotypic HCV recombinants are located in the NS2/NS3 region of the genome (18). 
This may suggest that this region of the genome is especially suitable for creating viable 
intergenotypic recombinants in vivo. Moreover, this observation may aid researchers in 
designing chimeric HCV genomes for in vitro experiments, using the recently 
constructed infectious clone of HCV (21, 50, 54). 
The frequency of successful recombination events is determined among others by 
(i) the properties inherent to the viral replicase, (ii) the odds of double infection of single 
   69 
Chapter 3 
cells, and (iii) the viability of the recombinant progeny and the increase in fitness of the 
recombinant virus compared to its non-recombinant parents. Overall there is ample 
evidence that the generation of HCV recombinants is a rare event (35, 40, 49). On the 
one hand most recombinants generated may not be stable which is illustrated by the fact 
that chimeric HCV replicons, even constructed from closely related HCV subtypes 1a 
and 1b, often fail to replicate in cell culture (11, 13). Recent studies indicated that 
optimal HCV replication complexes composed of the various NS proteins, cis-acting 
RNA elements and cellular factors, are required for HCV replication (12, 22, 52). 
Possibly, recombinants that maintain successful replication complexes are scarce and 
they may not be able to compete with parental viruses. But even if new replication 
competent recombinant viruses are generated, they may be hampered in infectious virus 
particle formation as suggested by recent experiments with infectious full length 
genotype 1a/2a chimeras (21). 
However, the fact that recombinant HCV viruses have been found (7, 18) would 
suggest that in principal the viral replicase is allowing the generation of chimeric 
genomes. The overlap in genotype distributions in many parts of the world would in 
theory increase the chance of double infections and thus the likelihood of recombination, 
especially in cases of frequent repeated needle-sharing over short time-intervals by 
infected drug users and the use of contaminated blood products. Although most of HCV 
recombinant strains might be selected out by natural selection (35, 49), the fact that 
recombinant viruses have been identified would suggest that at least some recombinants 
are viable.  
Based on these findings we may currently underestimate the true frequency of 
HCV recombination. Recombination events in HCV are difficult to detect if they 
occurred between variants of the same subtype or between highly diverse subtypes. Even 
though there are some reports describing different genotype/subtype sequences of 
different regions obtained from single sample (27, 53), there are always doubts of mixed 
infection or contaminated samples (27).  Moreover, most studies into HCV variability are 
based on analysis of single, short genomic regions making detection of potential 
recombinants unlikely. Therefore, the current methodology of sequencing short genomic 
regions as markers for entire viral genomes is challenged now, since it may not produce 
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accurate results of all genetic characteristics. Sequence analysis of whole HCV genomes 
would possibly increase the detection of natural HCV recombinants.   
Recombination has been well documented for many RNA viruses (51), including 
other members of the family Flaviviridae (3, 16, 44, 47, 48, 51), of which evolution was 
for long supposed to be clonal, with diversity generated by the accumulation of 
mutations. The mere fact that recombinant HCV viruses have been identified (7, 18); this 
study), suggests that the assumption that HCV diversity is caused only via genetic drift is 
no longer tenable and that the role recombination plays in HCV evolution and biology 
demands serious consideration. Clearly, the fact that recombination occurs between 
subtypes and genotypes of HCV not only presents a serious impediment on vaccine 
development, but also on prediction of response to antiviral therapy.  
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ABSTRACT 
 
Hepatitis C virus (HCV) has a linear positive-stranded RNA genome of ~9600 
nucleotides in length and displays a high level of sequence diversity caused by high 
mutation rates and recombination. However, when we performed long distance reverse 
transcription PCRs on HCV RNA isolated from serum of chronic HCV patients not only 
full-length HCV genomes but also HCV RNAs which varied in size from 7600 to 8346 
nucleotides and contained large in frame deletions between E1 and NS2 were amplified. 
Carefully designed control experiments indicated that these deletion mutants are a bona 
fide natural RNA species, most likely packaged in virions. Moreover, deletion mutants 
were detected in sera of patients infected with different HCV genotypes. We observed 
that 7/37 (18.9%) of genotype 1, 5/43 (11.6%) of genotype 3 and 4/13 (30.7 %) of 
genotype 6 samples contained HCV deletion mutant genomes. These observations 
further exemplify HCV’s huge genetic diversity and warrant studies to explore their 
biological relevance.  
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INTRODUCTION 
 
 Hepatitis C virus (HCV) is an enveloped virus that belongs to the Family 
Flaviviridae. Its linear positive-stranded RNA genome of approximately 9.6 kb in length 
encodes both structural (Core, E1, E2) and nonstructural (p7, N2, NS3, NS4a/b and 
NS5a/b) proteins in a single open reading frame, flanked by short conserved untranslated 
regions (UTRs) located at the 5’ and 3’ ends of the genome required for viral replication 
and protein translation (5, 7, 8). One of the most striking characteristics of HCV is its 
capacity to cause a chronic liver disease in a high percentage of individuals (24). To do 
so, HCV encodes proteins which promote persistence and sequence variation, especially 
in the envelope genes (E1 and E2), results in escape from adaptive immune responses (9, 
27).  
Lack of proof reading ability of the viral RNA-dependent RNA polymerase is the 
driving force behind HCV’s genetic diversity. As a result of the large amounts (1012) of 
virions  produced each day in chronic hepatitis C patients and the rate of incorrect 
nucleotide insertions which reaches the order of 10-3 to 10-4 base substitutions per site 
per year, HCV quasispecies are generated (22, 26). Recombination may be one other 
mechanism by which genetic diversity is driven, given the recent identification of natural 
occurring intergenotypic recombinant viruses (13, 21). Because of the huge genetic 
diversity, HCVs are currently categorized into six major genotypes and more than 80 
subtypes (25). 
HCV genetic variation has been studied in relation to epidemiology, response to 
antiviral therapy and clinical parameters, using different techniques that have focused on 
short genomic regions. However, analysis of full-length viral genomes may be necessary 
to better understand the characteristics of HCV. Previously, we analyzed sera from HCV 
RNA-positive blood donors from Ho Chi Minh City, Vietnam in order to analyze the 
molecular heterogeneity of HCV in South East Asia (21). Based on sequence analysis of 
Core and NS5b regions in a set of sera, two samples were identified which contained 
viruses of different genotypes. Whole genome analysis and bootscan analysis of one 
particular sample revealed a recombinant virus with genotype 2i and genotype 6p 
sequences at the 5’ and 3’ ends, respectively. Partial characterization of the other sample 
revealed the presence of a full-length genotype 2i virus and another genotype 6 virus, 
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which could be characterized only partially. In the present study, we further 
characterized this virus by a large fragment amplification method. Surprisingly, we 
identified a naturally occurring HCV deletion mutant genotype 6h virus that contained a 
large in-frame deletion of E1 and E2 genes. Further studies confirmed the existence of 
circulating HCV E1-E2 deletion mutants in a substantial percentage of chronic hepatitis 
C patients. 
 
MATERIALS AND METHODS 
 
Samples. HCV-positive sera of blood donors from Ho Chi Minh City, Vietnam 
and Bangkok, Thailand were obtained during the period from 2000 to 2002. Samples 
were genotyped based on sequence analysis as described previously (21). Thirteen 
samples of HCV genotype 6 were selected and characterized in this study. Other sera 
from chronic hepatitis C were obtained from the Erasmus MC, Rotterdam; thirty-seven 
plasmas of HCV genotype 1 and forty-three samples of genotype 3 were randomly 
selected for this study. All samples were kept at –80oC until further analysis. 
RNA extraction and large fragment PCR amplification.  Total RNA was 
isolated from 100 μl serum by proteinase K digestion and phenol-chloroform extraction 
as previously described (23) and dissolved in 20 μl sterile water. To generate a long 
fragment of cDNA, reverse transcription (RT) was performed on 10 μl RNA with 
Expand Reverse Transcriptase (Roche Diagnostics GmbH) and primers 5460, 8625 or 
3’UTR, according to the manufacturer’s instructions, in a total volume of 30 μl at 42oC 
for 2h as described previously (21). Ten-μl volumes of cDNA were amplified with 2.5 
units of Expand High Fidelity Enzyme mixture (Roche Diagnostics GmbH), 1x Expand 
PCR buffer, 0.4 mM of each dideoxynucleotide and 0.4 μM outer primer pairs with a 
thermal profile that was described previously (21). First-round amplification from each 
cDNA reaction resulted in three overlapping PCR fragments (primers 16 and 5460, 
3227F and 8625, 4039 and 3’UTR). Next, 2-μl volumes of amplified product were 
subjected to nested PCR with inner primers to generate overlapping genome fragments 
(primers s17 and 3277R, 66 (5’-tcccgcgagagccatagt-3’) and 3636, 1992 and 4662, 4039 
and 7100, 5930 and Pr2, Pr3 and 9325) under similar conditions as employed for the first 
PCR. Amplified products were gel-purified with the Qiaquick gel extraction kit (Qiagen) 
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and ligated directly into plasmid pCR2.1 (TA cloning kit, Invitrogen). For each 
amplicon, five positive clones were selected and sequenced.  
To determine the sensitivity of HCV deletion mutants to RNase, we performed an 
assay as previously described (14). HCV plasma samples were treated with or without 
0.1% Triton X-100 in PBS at 37oC for 1 hr, subsequently 5 Units of RNase A (Qiagen) 
was added and incubation continued for 1 hr. In order to degrade RNase A before RNA 
extraction, Proteinase K was added to each reaction and incubated at 37 oC for 15 min 
prior to adding lysis buffer. RNA was extracted as previously described (23) and was 
analyzed by RT-PCR. 
Large fragment PCR and deletion mutant amplification using specific 
primers.  In order to avoid mismatch of degeneracy primers, specific primers were 
designed for large fragment PCR of specific samples. Moreover, primers overlapping the 
deletion region of specific samples were designed and used for deletion mutant 
amplification described in this study (Table 1). Conditions for RT-PCR were identical to 
the protocol described above.  
 
TABLE 1 Primers used for amplification HCV of specific samples 
 
 
  Primera  Sequence (5’ to 3’)  Positionb          Polarity      Sample 
 
 
3277R           CTRATRABYTTVDTCTCCAT 3277-3296 Reverse All 
3277RP21    GTGATGATCTTGGTCTCCAT 3277-3296 Reverse P21 
3277RR30       GTGATGACCTTAATTTCCAT 3277-3296 Reverse R30 
3277RD33 GTCATGAGCTTGGTCTCCAT 3277-3296 Reverse D33 
3277RD88 GTGATAACCTTCTTCTCCAT 3277-3296 Reverse D88  
DelFP21 TGCGGATCTGTTTTCTGTG 1182//2538 Forward P21 
DelFR30 GCTGATGACGTTATGATGG  987//2253 Forward R30 
DelFD33 CTATGAGGCGGATATACC  980//2389 Forward D33 
DelFD88 CCCTGCACTATCCCCAAC  913//2757 Forward D88 
DelFD54† GCAGCATCGGTTATGAGG  970//3003 Forward D54 
 
 
a † , Specific primer used for amplification of sample D54 genotype 6h.  
b //, Nucleotide position of specific primer designed over the cross-junction site of 
deletion region. The nucleotide position is according to the numbering system for the 
prototype strain HCV-H (accession number M67463). 
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cDNA synthesis using high thermal Reverse Transcriptase. To prevent HCV 
RNA secondary structure formation during RT, we performed cDNA synthesis using 
high thermostability reverse transcriptase enzyme. Transcriptor Reverse Transcriptase 
(Roche) and Superscript TM III  Reverse Transcriptase (Invitrogen) were used for cDNA 
sysnthesis, according to the manufacturer’s instructions. Protector RNase Inhibitor 
(Roche) was used in this experiment because of its heat resistant property. Conditions of 
RT-PCR are identical to the protocol described above, except for the incubation times; 
transcriptor RT was incubated at 50oC for 5 min and 55oC for 50 min while Superscript 
III was used at 55oC for 50 min. 
Southern blot hybridization. Ten µl of PCR amplification products were loaded 
on 0.8% agarose-Tris-boric-EDTA (TBE) buffer gel. DNA samples were denatured in 
0.5 N NaOH and 1.5 M NaCl for 45 min, neutralized in 1M Tris-HCl (pH 7.4) and 1.5 M 
NaCl for 45 min before transfer to Hybond N+ membranes (Amersham) by 
electroblotting (Amersham) in 1x TBE buffer according to the manufacturer. The blots 
were air dried for 30 min and UV-irradiated for 10 min. Hybridization procedure was 
conducted as described (6) with biotin-labeled probe specific for 5’UTR (5’-
attccggtgtactcaccggttccg-3’, nucleotides 149-174) at 50 oC for 3 hrs. Membranes were 
washed and incubated with Streptavidin-POD conjugated (Roche) at 42oC for 45 min. 
After several washes the blots were visualized with enhanced chemiluminescence 
detection reagents (Roche) according to the protocol of the manufacturer, and by 
exposure to hyperfilm (Amersham) for 1 to 5 min. 
Preparation of synthetic complete and deletion mutant HCV RNA.  HCV 
large fragment amplicons were cloned into plasmid pCR 2.1 (TA cloning kit, Invitrogen) 
under control of the T7 promoter. Plasmids were linearized with BamHI and purified 
using Qiaquick PCR purification (Qiagen) and in vitro transcription was performed as 
described elsewhere (2). Reaction mixtures contained ~ 1µg of linearized DNA template, 
5.0 mM rNTP-mix, 40 U RNaseOut (Invitrogen), 1x reaction buffer, and 50 U T7 RNA 
polymerase (Invitrogen) in a total volume of 20 µl. After 2 hrs at 37 oC, 5 U DNase I 
(Qiagen) was added and incubation prolonged for 1 hr. DNase-treated synthetic RNA 
was purified by phenol-chloroform extraction and used as a template for RT-PCR 
reaction.  
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DNA sequencing and sequence analysis.  Sequence reactions on PCR products 
and plasmids were performed using BigDye Terminator Cycle sequencing Ready 
Reaction kit (Applied Biosystems) and an ABI prism 3100 Autosequencer (Applied 
Biosystems). Multiple sequence alignments were generated with the BioEdit program 
(version 7.0.1).  
 Nucleotide sequence accession numbers. New sequences reported in this 
study have been submitted to Genbank and have been assigned accession numbers: 
RP21.complete (EF420126), RP21.deletion  (EF420127), RP30.complete (EF420128), 
RP30.deletion  (EF420129), D88.complete (EF420130), D88.deletion (EF420131), 
D33.complete (EF420132), D33.deletion (EF420133) and D54 (EF420134). 
 
RESULTS 
 
Identification of a HCV genotype 6 deletion mutant. In order to study the genetic 
diversity of HCV in South East Asia, we analyzed serum samples obtained from 
Vietnamese blood donors. Previously, we reported that cloning of 5’UTR-to-Core region 
of one specific sample (D54) revealed the presence of genotype 2i and 6h strains and the 
whole genome of the genotype 2i virus was published previously (21). However, short 
fragment amplification of nucleotides 17 to 2085 (according to numbering system of 
prototype strain, M62321, genotype 1b) and 1992 to 3277 only amplified genotype 2i 
sequences; genotype 6h sequences were never obtained (21). Remarkably, large 
fragment amplification of nucleotides 17 to 3277 always amplified a smaller product of 
approximately 1200 bps. A subsequent effort to amplify a fragment from nucleotides 66 
to 3636 again revealed the amplification of a small PCR product (approximately 1500 
bps). In contrast, some other samples such as D42 showed the expected amplicon of 
3600 bps (Fig. 1A). Southern blot hybridization using a HCV specific probe, revealed 
the specificity of the PCR products. Subsequent nucleotide sequence analysis of the 
obtained amplicons revealed a 2022 nucleotide (674 amino acid) in-frame deletion in 
E1/E2/p7 and part of the NS2 region (Fig. 1B) in the genotype 6h strain. Because of the 
nature of the PCR-method, the smaller genotype 6h fragment is amplified preferentially 
over the larger strain 2i fragment. Thus, both a full-length 2i strain and a deletion mutant 
of the 6h strain seem to be present in sample D54. 
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Nucleotides     1      342       915    1491      2580 2769   3420      5313          6258            7602           9378    9416 
B 
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 5’UTR 
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Figure 1. Identification of a HCV genotype 6h virus with a deletion in the E1-NS2 region in a 
patient (D54) double infected with genotypes 2i and 6h. (a) RT-PCR analysis (nucleotides 66-
3636) of HCV RNA from sample D54 (lane 1) and sample D42 (lane 2) and subsequent southern 
blot analysis are shown in the left and right panel, respectively. Amplicons were separated in 
0.8% agarose gels along with a marker (M) for which the molecular weights are given on the left 
side in kilobasepairs (Kb). The deletion mutant and wild-type HCV genome are indicated on the 
right side. (b) The upper panel depicts the genome organization of HCV with boxes indicating the 
coding regions for the Core protein (C), envelope 1 and 2 (E1 and E2) proteins, p7, and 
nonstructural proteins 1 to 5 (NS1 to NS5). Also indicated are the 5’- and 3’untranslated regions 
(5’UTR and 3’UTR) and the nucleotide and amino acid numbers, according to the numbering 
system for the prototype strain HCV-H (accession number M67463). In the lower panel, black 
lines indicate the D54 full-length (genotype 2i) and deletion (genotype 6h) sequences, 
respectively. The shaded box displays the position of the in-frame deletion region (Δ674).  
 
 
Detection of HCV deletion mutants in chronically infected hepatitis C patients. To 
determine whether HCV deletion genomes can be detected in other hepatitis C patients, 
we randomly selected plasma samples obtained from HCV genotype 1, 3 and 6 infected 
blood donors or chronic hepatitis C patients and performed a long fragment amplification 
of the HCV genome (nucleotides 66 to 3636). We observed that 7/37 (18.9%) of 
genotype 1, 5/43 (11.6%) of genotype 3 and 4/13 (30.7 %) of genotype 6 samples 
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contained HCV deletion mutant genomes. RT-PCR analysis performed on at least two 
independent RNA isolations from the same patient sample resulted in the same deletion 
products.  Four samples (genotype 1, 3 and genotype 6) were selected and found to 
contain deletion mutants of varying size (Fig. 2A). In contrast, amplicons generated by 
primer 1992 (located in the deleted region) and 3636, showed bands of the expected size 
(1644 bps) for all samples, indicating that non-deleted genomes were present in plasma 
as well (Fig. 2B). HCV specificity of the amplified bands was confirmed by southern 
blot analysis (data not shown). Sequencing of the fragments confirmed the presence of 
in-frame deletions in the E1-p7 region (Fig. 2C).  Sequence analysis of 3-5 clones per 
sample revealed that the sequence of the deletion junction was identical in all clones for 
a given sample. Moreover, there were minor differences in the sequence of regions 
flanking the deletion junctions, implying independent quasispecies diversification of the 
deletion variants relative to their wild-type parent (Fig.3). 
 
Experimental confirmation of HCV E1-E2 deletion mutants. To confirm that the 
deletion genomes were not RT-PCR artifacts, we performed a wide array of experiments 
to prove that the deletion mutant genomes are bona fide RNA species present in the 
serum of chronically infected patients. First of all, the initial large fragment PCR 
analysis utilized degenerate primers for amplification (21). To avoid the possibility of 
primer mismatch during amplification, reverse primers 3277R (nucleotides 3277-3296) 
specific for sample P21 (genotype 1), R30 (genotype 3), D33, and D88 (genotype 6) 
were used (Table 1). Subsequent analysis using these specific primers revealed similar 
results as observed in the previous experiment (Fig. 4A). In some but not all experiments 
the full-length genome could be detected, but at a lower level given the preferential 
amplification of the deletion mutant genomes. Moreover, amplification of the 5’UTR-to-
Core (nucleotides 17 to 750) and NS3-to-NS5 (nucleotides 4039-8625) regions showed 
no evidence for the presence of deletions in these parts of the HCV genome (Fig. 4B-C). 
Next, we designed isolate specific primers overlapping the deleted region (Table 1). As 
presented in Fig. 4D, these primers amplified HCV specific products with appropriate 
lengths in the samples they were designed for, but not in others (not shown).  
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 5’UTR 
Amino acid               1              192            384              747  810           1027                 1658   
 
Nucleotides       1        342           915            1491           2580  2769        3420                  5313     
C           E1           E2        p7     NS2          NS3 
    D88 genotype 6 
G  TCA  GCC  CTG  CAC  TAT  CC C CAA CGG  GCG  CTC  GCG  
     190    191     192     193    194                 805     806     807     808    809 
Δ 611
    D33 genotype 6 
G  GTC  TAT  GAG  GCG  GAT  A TA CCG  GCT  TTG  TCC  ACT 
     213     214    215     216     217               683     684    685    686    687 
Δ 466
    R30 genotype 3 
G  GAG  GCT  GAT   GAC  GTT  AT G  ATG  GTT  GTG  GGA  GGT 
     215     216     217     218     219                 637     638    639    640      641
Δ 418
    P21 genotype 1 
G  CTC  TGC  GGA  TCT  GTT  TT C  TGT  GCC  TGC  TTG  TGG 
     280     281    282      283    284              732    733     734     735   736 
Δ 448
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HCV deletion mutants occur in the serum of chronically HCV–infected genotype 1, 3, 
and 6 patients. RT-PCR products obtained from HCV genotype 1 (G1; P21), genotype 3 (G3; 
R30) and genotype 6 (G6; D33, D88) serum samples, using degenerate primers for amplification 
of HCV nucleotides 66 to 3636 (a) and 1992 to 3636 (b), were separated in 0.8% agarose gels. 
The molecular weight marker (M) is indicated on the left side in kilobasepairs (Kb). (c) A 
schematic representation of complete and deletion genomes determined for the different HCV 
genotypes. The upper panel depicts the genome organization of HCV as in Fig. 1. Forward and 
reverse primers to detect complete and deletion HCV genomes are presented. In the lower panel, 
black lines indicate the full-length and deletion sequences, respectively. The shaded boxes 
display the position of the in-frame deletion region.  
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Figure 3.  Consensus sequence alignments of different HCV ull length complete genomes (com) 
and deletion mutants (del). Nucleotide differences between complete and deletion mutant 
sequences are shown in bold. Residues identical to the major sequence are indicated by a dash, 
the deletion region is indicated by dots and slashes indicate discontinuous sequences of the 
deletion regions. The nucleotide position is presented above the sequences (numbering system for 
the prototype strain HCV-H) and sample names are indicated in the left-hand column. 
Complement nucleotide codes; R =T or C, Y=G or A.  
            1170       1180      1190       1200       2540       2550       2560       2570 
            ---------| ---------| ---------| ---------| ---------| ---------| ---------| ---------| 
1(com)    CGCTATGTAC GTGGGGGATC TCTGCGGATC TGTTTTCCTC/GCGTCTGTGC CTGYTTGTGG ATGATGCTGC TGGTAGCTCA 
1(del)    C----C---- ---------- ---------- ------..../....------ ---C------ ----R----R ---------- 
            980        990       1000       1010       2250       2260       2270       2280 
          ---------| ---------| ---------| ---------| ---------| ---------| ---------| ---------| 
0(com)    GCAGTATTGT GTATGAGGCC GATGACGTTA TTTTGCACAC/CAAGGTGAGG ATGTTTGTAG GCGGTTTTGA ACACCGGTTT 
0(del)    -----G---- ---------T ---------- -........./.........- ---G----G- -A-------- ------R--- 
     970        980        990       1000       2400       2410       2420       2430 
          ---------| ---------| ---------| ---------| ---------| ---------| ---------| ---------| 
3(com)    TGCCCAAATT CAAGTATTGT CTATGAGGCG GATACCATCA/TATGCCGGCT TTGTCCACTG GCCTGATCCA TCTTCACCAG 
3(del)    ----A----- ---------- ---------- ----....../..-A------ ---------- ---------- ---------- 
     900    910  920         930       2770      2780       2790       2800 
          ---------| ---------| ---------| ---------| ---------| ---------| ---------| ---------| 
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Figure 4. Experimental confirmation of HCV E1-E2 deletion mutants. RT-PCR (left panel) and 
southern blot analysis (right panel) of HCV genotype 1 (P21), genotype 3 (R30) and genotype 6 
(D33 and D88), using sequence specific primers to amplify (a) 5’UTR to NS3 (nucleotides 17 to 
3277), (b) 5’UTR to Core (nucleotides 17 to 750), and (c) NS3 to NS5 (nucleotides 4039 to 
8625) regions. Amplicons were separated in 0.8% agarose gels along with a marker (M) for 
which the molecular weights are given on the left side in kilobasepairs (Kb). (d) Gel-
electrophoresis of RT-PCR products amplified from RNA of samples P21, R30, D33, and D88 
with primer 3636 and a junction site primer overlapping the deleted region that was specifically 
designed for each sample (Table 1). Molecular weight marker (M) is indicated on the left side. 
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To minimize the frequency of template switching during cDNA synthesis (18), 
we used (RNAse H-deficient) high thermostability reverse transcriptase (RT) enzymes to 
perform cDNA synthesis. Using these enzymes, small sized non-specific bands 
disappeared, but deletion genome fragments were detected using both Transciptor RT 
(Fig. 5) and Superscript III RT (not shown). Southern blot analysis confirmed the 
specificity of the amplified products (Fig. 5A). In addition, we designed a simulation 
experiment in which we performed an RT-PCR assay with in vitro transcribed RNA 
obtained from cloned DNA templates derived from the full-length or deletion genome of 
sample P21. Amplification of the full-length RNA template revealed only bands for full- 
length template (no deletion form) (Fig. 5B), whereas the template for deletion genome 
only showed bands for the deletion form (Fig. 5C) Based on all control experiments 
above, we conclude that the observed deletion mutants of HCV are bona fide natural 
RNA species and that the deletions are found only in the region encoding the E1, E2, p7 
and NS2 proteins. 
 
Circulating HCV deletion mutants are protected from RNase. In case that HCV 
deletion mutants in plasma originate from replicating viruses in the liver, viral RNAs 
should be packaged in viral particles and resist degradation by RNase A. Plasma was 
treated with Triton X-100 to disintegrate membranes and the sample was treated with 
RNase A. As shown in Fig. 6, similar to HCV full length genomes, HCV deletion 
mutants were detected in samples treated with RNase A, but not when Triton X-100 was 
added concomitantly. These results were confirmed using deletion specific primers (Fig. 
6) Thus, circulating HCV deletion mutant genomes are most likely located within viral 
particles. 
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Figure 5. HCV deletion mutants are bona fide RNA species. (a) Comparison of RT-PCR 
amplification of HCV nucleotides 66 to 3636 (left panel) and southern blot analysis (right panel) 
of HCV genotype 1 (P21), genotype 3 (R30) and genotype 6 (D33 and D88) serum samples, 
using Expand reverse transcriptase (lanes 1, 3, 5, and 7) and Transcriptor reverse transcriptase 
(lanes 2, 4, 6, and 8). (b) RT-PCR analysis of in vitro transcribed full-length HCV RNA (left 
panel) and deletion mutant RNA (right panel) of sample P21 (genotype 1), using primer 3636 and 
either primer 66 or a junction site primer overlapping the deleted region (DelFP). Reactions were 
performed in the presence (+) or absence (-) of T7 RNA polymerase. As controls, a cDNA clone 
containing either full-length or deletion mutant HCV (C) or RNA isolated from P21 serum 
sample (P) were taken along. Molecular weight marker (M) is shown in kilobasepairs (Kb) on the 
left side. The amplicons representing deletion forms (Del) are indicated with an arrow.  
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Figure 6. HCV RNA genotype 1 (P21) deletion mutant circulating in plasma is protected from 
RNAse A digestion. The P21 serum sample was treated with or without 0.1% Triton X-100 and 1 
µg RNAse A before RNA extraction. RT-PCR amplifications of nucleotides 66 to 3636 (deletion 
mutant, left panel), 1992 to 3636 (full length, middle panel) and of the deletion mutant with a 
junction site primer overlapping the deleted region (DelFP) and primer 3636 (deletion mutant, 
right panel) are shown. Molecular weight marker (M) is indicated on the left side. 
 
 
DISCUSSION 
 
In this study, we identified and characterized circulating HCV deletion mutants 
in plasma of chronically infected HCV patients. These HCV RNAs always co-existed 
with full-length genomes, contained a large in frame deletion that varied in size from 
1254 to 2022 nucleotides located in the E1-NS2 region of the genome. We concluded 
that these deletion mutants are natural occurring RNA species on the basis of carefully 
designed control experiments using deletion-specific primers for amplification, elevated 
temperatures for cDNA synthesis, and in vitro transcribed RNA as template. Moreover, 
samples have their own unique deletion mutant that contains nucleotide substitutions as 
compared to the full-length genome , suggesting independent evolution of the full-length 
genome and deletion mutant. Efforts to detect the full length and deletion mutants by 
northern blot techniques were unsuccessful. Therefore accurate estimations on the ratio 
of both forms present in the plasma are difficult to make. The fact that only one 
dominant deletion form is detected per sample, suggests that the “fittest” defective virus 
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is selected. Last but not least, deletion mutants likely occur in all HCV genotypes as we 
identified deletion mutants in ~20% of chronic HCV patients infected with genotype 1, 3 
and 6. It is of note that our discovery seems to validate the claims of subgenomic HCV 
in liver biopsy specimens of chronic HCV patients and liver transplant recipients (12, 
29). The region where the deletion occurs is similar in all studies but in contrast to our 
findings, these authors reported also the presence of out-frame deletion genomes. 
Moreover, our findings generalize the detection of HCV deletion mutants to a significant 
portion of the chronic hepatitis C patients infected with different genotypes. 
The deletion genomes contain essential parts for autonomous HCV replication 
(5’UTR, core and NS2-NS5-3’UTR), regions similar to what has been described for the 
artificially constructed subgenomic replicons (17, 28), and may therefore represent 
naturally occurring replicons. Interestingly, both full-length genome and mutant genome 
were resistant to degradation by RNAseA, suggesting that both RNA forms are packaged 
in virions. Assuming that HCV particle assembly requires functional E1/E2 
glycoproteins, the deletion mutants can only be packaged and secreted from cells when 
cells are co-infected with a wildtype virus with a full-length genome. 
 The HCV deletion mutants are highly reminiscent of DI particles described for 
many viruses (10), including members of the Flaviviridae family, such as tick-borne 
encephalitis virus, Murray Valley encephalitis virus, Dengue virus, West Nile virus and 
Japanese encephalitis virus (1, 3, 15, 19, 30). DI viruses are mutants that arise 
spontaneously when the standard wildtype virus is passaged in tissue culture at high 
multiplicities of infection. The DI genomes contain cis-acting signals required for 
replication, but lack part or most of the region encoding viral proteins (4). These smaller 
viruses can be complemented by co-infection with a helper (wild-type) virus, and might 
interfere with the replication of helper virus by competition for limiting factors from the 
host cell (16). To our knowledge, most, if not all, DI particles have been discovered in 
laboratory settings and HCV is the first positive-stranded RNA virus for which defective 
genomes have been described in a natural human  infection in vivo. 
Methods to quantify and determine the heterogeneity of HCV genomes are 
currently used routinely to guide antiviral therapy and to study evolution and 
epidemiology of this virus. The existence of deletion mutants in chronic hepatitis C 
patients further exemplifies the huge diversity of HCV and has some major implications. 
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First, viral load quantification methods based on amplification of the 5’UTR (20) detect 
both defective and complete genomes. Considering a high amount of circulating HCV 
deletion mutant, it may be of interest to differentiate between these genomic HCV forms 
in order to further unravel the pathogenesis of HCV and response to antiviral therapy. 
However, given the fact that only a fraction of the patients harbour deletion mutants a 
large panel of samples from well characterized patients needs to be screened. Last, but 
not least, it has been proposed that defective viruses may play a significant role in the 
establishment and maintenance of chronic infection in vivo (11), despite the fact that 
most if not all data comes from in vitro experiments (15, 30). Whether HCV deletion 
genomes play a role in the persistence of HCV remains to be delineated.  
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ABSTRACT 
 
Hepatitis C virus (HCV) genomes exhibit high nucleotide sequence diversity. In this 
study, we performed complete genome sequence analysis of eleven HCV genotype 6 
samples from Vietnam and Thailand. We identified nine HCV complete genomes 
belonging to subtypes 6a (D9), 6e (D42, D88), 6f (TH52), 6i (TH24), 6l (D33), 6n 
(TH22, TH31) and 6o (D85). Phylogenetic analysis of the Core/E1 and NS5B regions 
from unclassified genotype 6 isolates from Asian immigrants in Canada revealed that two 
other viruses (D49 and D83) could be classified as novel candidates of HCV subtypes 6t 
and 6u. 
 
 
 
 
 98 
                                                       Complete genome analysis of HCV subtypes 6t and 6u 
 
INTRODUCTION 
 
Hepatitis C virus (HCV) is an enveloped positive-stranded RNA virus which 
belongs to the Family Flaviviridae and is the leading cause of acute and chronic hepatitis 
in about 3% of the human population (23). The entire viral genome contains about 9,600 
nucleotides encoding structural (Core, E1, E2) and nonstructural (P7 and NS2-NS5B) 
proteins flanked by untranslated regions (5). The virus shows extreme genetic diversity 
and currently six major groups (genotypes 1-6) and a large number of subtypes have been 
identified (25). Viral genomes of different genotypes may vary by 30-35%, while 
nucleotide sequences of subtypes may differ by 15-20%  (26). 
HCV genotype 6 viruses mainly circulate in South East Asia (SEA), including 
Vietnam (32), Indonesia (30), Thailand (4, 29), Cambodia (3) and Myanmar (24). 
Currently, genotype 6 viruses are classified into 17 subtypes (6a-6q) based on complete 
genome analysis (9, 10, 12, 30, 31). Recently, the existence of subtype 6r and 6s viruses 
was proposed based on sequence analysis of core/E1 and NS5B from HCV strains 
isolated from Cambodian immigrants in Canada (14). In addition, a subtype of some 
viruses could not be assigned and these were classified as novel candidate HCV genotype 
6 (8, 24).  
High nucleotide sequence heterogeneity hampers complete genome 
characterization of new subtypes due to inefficient primer annealing. We developed 
techniques to obtain large RT-PCR fragments amplified from HCV positive sera using 
degenerate primers sets and obtained entire HCV genome sequences from 100 μl HCV 
positive sera (15). This led to the complete genome characterization of a Vietnamese 
HCV recombinant genotype 2i/6p strain (15). In this report, we selected several sera from 
HCV positive blood donors from Vietnam and Thailand based on a preliminary screen to 
include rare or unclassified HCV subtypes 6 (15) and performed full-genome sequencing 
to characterize further HCV subtypes 6.  
 
MATERIALS AND METHODS 
 
Total RNA was isolated from 100 μl serum by proteinase K/phenol chloroform 
extraction as described previously (18). The entire HCV genome was amplified from 
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three different cDNA reverse transcriptions from position 5460, 8625 and 9325 
(numbering system according to prototype strain H77, Genbank accession no. 
AF009606). Three overlapping large PCR fragments were first-round amplified by 
degenerate primers, followed by nested PCR as described (15). Amplified products were 
gel-purified with the Qiaquick gel extraction kit (Qiagen) and ligated directly into 
plasmid pCR2.1 (TA cloning kit, Invitrogen). For each amplicon, five positive clones 
were selected and sequenced. Multiple sequence alignment was performed with the 
BioEdit program (version 7.0.1) according to amino acid alignment. Phylogenetic trees 
were constructed from Tree Puzzle 5.2 (22) and MrBayes version 3.0b4 (20) programs 
using genetic distance calculated with the maximum-likelihood with rate heterogeneity 
method and Bayesian method, respectively. Transition/translation ratio, proportion of 
invariant sites and gamma distribution factors were estimated based on the real sequence 
datasets. Nucleotide and amino acid substitution were estimated by using HKY and 
WAG models respectively. Bootstrapping was calculated from 10,000 treepuzzle steps or 
5000 trees generated from the MrBayes program. Pairwise nucleotide comparison was 
estimated based upon p distances with MEGA3 software (7). Phylogenetic analysis and 
sequence similarity test were performed using reference sequences of HCV subtype 6a-
6q, published in the Los Alamos HCV database (http://hcv.lanl.gov/content/hcv-index).  
Genetic recombination events were examined by similarity plot and bootscanning 
analysis, using the SimPlot program (version 3.5.1 for windows98/NT/2000/XP; 
available from the author, Stuart C. Ray, http://sray.med.som.jhmi.edu/SCRoftware).   
 
RESULTS  
 
We characterized 11 complete HCV genotype 6 genomes, including seven 
isolates from Vietnam (D9, D33, D42, D49, D83, D85, D88) and four isolates from 
Thailand (TH22, TH24, TH31, TH52). These genomes varied in length from 9373 to 
9423 nucleotides, encoding 3016 to 3023 amino acids (Table 1).  
The whole genome of TH52 shared the main branch with samples C-0044 and C-
0046, representative of HCV subtype 6f (Fig. 1a). There is a high sequence similarity 
(94.7%) compared to the prototype strain and results from the short fragment analysis 
confirmed that TH52 is a member of HCV subtype 6f (Table 2 and Fig. 2). Interestingly,  
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Table 1  Genome organization of the new eleven HCV isolates in this study. 
 
 
 
Genotype      Genome    Length of different regions (nts) 
 
Strain        Nts AAs    5’UTR  Core  E1      E2      p7    NS2   NS3 NS4A  NS4B NS5A NS5B 3’UTR 
 
6a/D9    9388 3020       328    573    576    1104    189    651    1893    162    783    1353    1776     - 
6e/D42    9382 3019       325    573    576    1101    189    651    1893    162    783    1353    1776     - 
6e/D88     9394  3023 325    573    576   1101    189    651    1893    162    783    1365    1776     - 
6f/TH52   9382 3019 325    573    576   1089    189    651    1893    162    783    1365    1776     - 
6i/TH24   9376 3017 325    573    576   1095    189    651    1893    162    783    1353    1776      - 
6l/D33   9376 3017 325    573    576   1095    189    651    1893    162    783    1353    1776     - 
6n/TH22  9373 3016 325    573    576     1092    189    651    1893    162    783    1353    1776     - 
6n/TH31  9373 3016 325    573    576   1092 189    651    1893    162    783    1353    1776     -    
6o/D85   9423 3017 325    573    576   1092    189    651    1893    162    783     1356    1776   47 
6t/D49   9376 3017 325    573    576     1092 189    651    1893    162    783    1356    1776     - 
6u/D83   9379 3018 325    573    576     1098    189    651    1893    162    783     1356    1776    - 
 
 
Nucleotide numbering is according to reference strain H77 (GenBank accession number AF009606) 
Nts= nucleotide numbers , AAs=amino acid numbers. 
 
52/53 samples of subtype 6f classified in the Los Alamos database were obtained from 
Thailand (6). Full-length genomes of HCV subtype 6i (Th602 and C-0159), a subtype 
found in Thailand only, have been sequenced recently (10). TH24 complete genome and 
Core, E1 and NS5B phylogenetic trees showed 99-100% bootstrap support related to the 
C-0159 sequence (Fig. 1a). We identified TH22 and TH31 strains as HCV subtype 6n 
based on phylogenetic analysis of full-length nucleotide and amino acid sequences (Fig. 
1a and 1b), while whole genome sequence similarity was 93.9 and 95.8% respectively, 
when compared to subtype 6n reference strain D86/93 isolated from Thailand (10). Both 
strains clustered with KM42 isolated from China (11) and D86/93 with high bootstrap 
support. HCV subtype 6n was first isolated from Thailand (2), and then later reported to 
be isolated from India, China and Myanmar (24).   
D9 showed 92.6 % sequence similarity with subtype 6a (strain 6a33, GenBank 
accession no. AY859526) and 100% bootstrapping phylogeny support using complete, 
short fragment nucleotide and full-length amino acid sequences (Table 2, Fig. 1a, 1b and 
Fig. 2). HCV subtype 6a was first discovered in 1993 in Hong Kong (27) and has been 
distributed throughout Asia, including China (11), Vietnam (16), Taiwan and Singapore 
(Los Alamos HCV database).  
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Figure 1. Phylogenetic tree based on complete nucleotide (a) and amino acid (b) sequences. In 
bold, the six genotypes are indicated, subtypes are designated 1a-6q and 6 (unassigned subtype). 
The HCV prototype sequences are indicated by isolate name followed by the Genbank accession 
number in parenthesis. Confidence values (>70%) calculated from 10,000 treepuzzle steps are 
indicated at the major branching points. Branch lengths are drawn to scale. The eleven HCV 
strains determined in this study are shown in boldface and asterisks. Unassigned samples are 
specified with circular marks. Nucleotide sequences presented in this study were submitted to 
Genbank accession number EU246930- EU246940. 
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Phylogenetic analysis of short regions (core, E1 and NS5B) indicated that D33 
clustered to the subtype 6l prototype strain 537796 (Fig. 2). Complete genome phylogeny 
and pairwise similarity (95.1%) confirmed classification of D33 as subtype 6l (Fig. 1a 
and Table 2). Remarkably, subtype 6l and 6k were isolated from Vietnamese individuals 
(8, 9). D85 on the other hand had 92.5% sequence similarity to subtype 6o prototype 
strain QC227 isolated from an Asian immigrant in Canada (14), confirmed by phylogeny 
of whole genome and short fragment analysis (Fig. 1a and Fig. 2). Subtype 6o is a rare 
subtype in SEA and we detected only one subtype 6o virus out of 95 HCV-positive 
samples collected from Vietnam (data not shown). 
Based on full-length nucleotide and amino acid sequences D42, D88 and D83 are 
closely related to subtype 6e strain GX004, recently reported from China (8) (Fig. 1a and 
1b). Sequence similarities compared with GX004 were 87.0, 90.8 and 83.6 % for D42, 
D88 and D83, respectively (Table 2). However, phylogenetic analysis of complete 
genome, core and NS5B sequences revealed that D83 branched separately from other 
subtypes (Fig. 1a and Fig. 2). D83 was about 18% different from D42 and D88 at 
nucleotide and about 10% different at amino acid level (data not shown).  
Based on nucleotide and amino acid sequences of the whole genome, D49 
branched closely to subtype 6q (Fig. 1a and 1b). However, short genome fragment 
analysis using core and NS5B revealed branching with subtype 6q and 6d respectively 
while E1 analysis showed a separate branch linked to subtype 6p (Fig. 2). Sequence 
similarities compared to subtypes 6a-6q prototype sequences were 72.6-79.2% (Table 2). 
Although complete genome sequences of HCV subtypes 6a-6q were used as 
reference strains, some genomes such as GZ52557 and KM41 isolated from China (11), 
and at least 23 strains (provided in the Los Alamos HCV database) based on short 
fragment sequences of core/E1 and NS5B (Table 3) could not be classified. Because we 
could not subtype D49 and D83, we re-analysed the phylogenetic tree including all 
subtypes (6a-6s) and unassigned subtype samples reported thus far. Now the core-E1 
region of D49 showed close relation with subtype 6p and clustered with QC240, QC131 
and QC145, while NS5B clustered to the same viruses but separated more clearly from 
other subtypes (Fig. 3a and b). Unexpectedly, both core/E1 and NS5B from D83 grouped 
with QC191 and QC323 viruses and clearly clustered separately from subtype 6e (Fig. 3a 
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and b). Thus, viruses D49, QC240, QC131 and QC145 were assigned to the novel HCV 
subtype 6t, while D83, QC191 and QC323 are candidate subtype 6u viruses. 
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Figure. 2.  Rooted Neighbor-joining trees constructed from sequences of (a) CORE (377 bps, 
position 342-718), (b) E1 (402 bps, position 921-1316) and (c) NS5B (324 bps, position 
8282-8605) among HCV genotype 6 and outgroup sequences (H77). The HCV prototype 
sequences are indicated by an isolate name and subtype classification as 6a-6q and 6 
(unassigned subtype). Confidence values (>70%) calculated by bootstrap analysis (1000 
replicates) are indicated. Branch lengths are drawn to scale. The eleven HCV strains 
determined in this study are shown in bold and asterisks. Unassigned samples are specified 
with circular marks.  
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Table 3 Unassigned HCV genotype 6 strains. 
 
 
Strain name    Country           Year          Regions 
     CORE              E1         Core/E1       NS5B 
 
KM41  China  2002  DQ278893   DQ278893   DQ278893   DQ278893 
GZ52557 China  2005  DQ278892   DQ278892   DQ278892   DQ278892 
IG57272 United States 2004  AY734479  AY734480 AY734479-80 AY734481 
MYAN-3E-3 Myanmar 2004          -        AB254861         -              AB103143 
CMBD-14 Cambodia 2005       -       DQ179116     DQ179116  DQ179117 
CMBD-86 Cambodia 2005       -       DQ179143     DQ179143       -  
QC56  Canada 2004       -  -      EF115927  EF116150 
QC81  Canada 2004       -  -      EF115928  EF116151 
QC112  Canada 2004       -  -      EF115929  EF116152 
QC131      Canada 2004       -  -      EF115932  EF116155 
QC145  Canada 2004       -  -      EF115934  EF116157 
QC148  Canada 2004       -  -      EF115935  EF116158 
QC150  Canada 2004       -  -      AY754611  AY754612 
QC191  Canada 2004       -      -      EF115943   EF116166 
QC197  Canada 2004       -  -      AY754629  AY754630 
QC226  Canada 2004       -  -      EF115947  EF116170 
QC240  Canada 2004       -  -      EF115948  EF116171 
QC251  Canada 2004       -  -      EF115952  EF116175 
QC255  Canada 2004       -  -      EF115953  EF116176 
QC266  Canada 2004       -  -      EF115954  EF116177 
QC269  Canada 2004       -  -      EF115955  EF116178 
QC271  Canada 2004       -  -      EF115956  EF116179 
QC273  Canada 2004       -  -      EF115957  EF116180 
QC323  Canada 2004       -  -      EF115974  EF116197 
QC327  Canada 2004       -  -      EF115975   EF116198
  
 
  
 
 
 
 
 
Figure. 3. Rooted neighbor-joining trees depicting the phylogenetic relationship among HCV 
genotype 6 unassigned sequences and prototype strains. Trees were constructed for (a) a 424-
nucloetides segment of the CORE/E1 genes (position 869-1292) and (b) a 324-nucleotides 
segment of the NS5B gene (position 8282-8605). Bootstrap values (5000 replicates) are shown 
along each main branch. Branch lengths are drawn to scale. The prototype HCV genotype 6 
strains, indicated by an isolated name, are designated 6a-6s and 6 (unassigned subtype). Genbank 
Accession numbers of subtype 6s and 6r were indicated in parenthesis after the isolate name. 
HCV genotype 1a (H77, accession number AF009606) was used as an outgroup sequence. The 
eleven HCV strains obtained in this study are shown in bold and asterisks. The new assigned 
subtypes 6t and 6u are specified with parenthesis marks.  
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DISCUSSION 
 
Using full-length genome sequences is considered the gold standard of HCV 
genotype/subtype identification. Due to the heterogeneity, whole genome amplification 
using specific primers is troublesome and 25-30 amplicons are required (12). We used 
degenerate primers to amplify a large PCR fragment and generated three to five 
amplicons, resulting in cost and time efficient characterization of the HCV genomes. 
Based on the pairwise sequence similarity and phylogenetic analysis of full-length and 
short fragment sequences, we identified complete genomes of HCV subtype 6a (D9), 6e 
(D42, D88), 6f (TH52), 6i (TH24), 6l (D33), 6n (TH22 and TH31) and 6o (D85). 
Moreover, two new subtypes 6t (D49) and 6u (D83) were assigned. Recombination 
between the two newly described genomes and other HCV sequences was not observed 
(data not shown). 
Although phylogenetic analysis based on the full-length genome is the most 
accurate method for HCV classification, most HCVs have been classified based on short 
sequences analysis of core, E1 and NS5B regions (19, 21, 26). Historically, HCV 
classification based on short sequence phylogenetic analysis using a simple nucleotide 
substitution model has led to incorrect branching between closely related subtypes. HCV 
genotype 7, 8 and 9 from SEA have been identified using the unweighted pair-group 
method with arithmetic mean (UPGMA) for phylogenetic tree construction (32). 
However, combining the complex nucleotide substitution model with neighbor-joining 
results in grouping of these sequences to HCV genotype 6 subtypes (13, 28). In our 
study, we performed the classification based on the HKY nucleotide substitution model 
and maximum- likelihood method to increase the accuracy of nucleotide phylogenetic 
analysis. Moreover, we generated protein phylogenetic trees based on amino acid 
sequences to confirm our results.  
 Even though a range of HCV subtype 6a-6q whole genomes has been 
characterized, a number of viruses cannot be classified (14). These unassigned samples 
may represent candidate new HCV subtypes. Assignment of subtype 6t and 6u in our 
study is in line with the HCV genotyping consensus proposal (26).  NS5B and core/E1 
sequences of at least three examples are required for a provisional designation of HCV 
new subtype and at least 15% difference at the nucleotide level to other HCV subtypes 
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should be present (26). We have defined two full-length genome sequences that represent 
new subtypes of HCV genotype 6. Subtype 6t comprises D49, QC240, QC131 and 
QC145, all isolated from Vietnamese individuals and subtype 6u includes D83, which 
grouped to QC191 and QC323 and shows a separate branch from subtype 6e. Sample 
QC191 and QC323 originated from Asian immigrants in Canada but remained 
unassigned with respect to subtype classification (14). Grouping of D83 sequence 
obtained from our study with these strains suggests that subtype 6u circulates in SEA. 
High sequence similarity of HCV subtypes 6e and 6u indicates that both may share the 
same origin but have shown genetic drift as a result of long-term circulation. 
 Molecular evolution of HCV genotype 6 based on phylogenetic relationship 
separates all subtypes into three groups. Subtypes 6a and 6b are related to each other, 
subtypes 6c, 6d, 6e, 6f, 6g, 6p, 6q and 6o share the same phylogenetic branch and the last 
group contains subtypes 6h, 6i, 6j, 6k, 6l, 6m and 6n. Epidemiologic studies of HCV 
genotype 6 have revealed that certain subtypes, such as 6d, 6h and 6l are found in 
Vietnam while 6c, 6f, 6i and 6j are found in Thailand, whereas subtype 6m and 6n were 
isolated mainly from Thailand and Myanmar. Although there may be some sampling bias 
and information about subtype distribution is lacking from some countries such as Laos, 
Cambodia and Myanmar, these results suggest that spread of HCV occurs in closed 
populations. These data are consistent with the idea that HCV genome diversity is related 
to geographic distribution and routes of viral transmission in certain areas. Whereas 
genotype 1, 2 and 3 have spread worldwide mainly through contaminated blood and 
intravenous drug users (1), the genotype 4, 5 and 6 viruses are more restricted to African 
and Asian countries (26) and vary genetically as a result of long endemicity in certain 
areas (17).   
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ABSTRACT 
 
Estimating the evolutionary rate and time of Hepatitis C virus (HCV) divergence in 
humans has been proven daunting. In this study, we investigated the evolutionary pattern 
of HCV including analysis of phylogenetic informative regions, best-fitting nucleotide 
substitution model, phylogeny reconstruction and molecular clock hypothesis testing by 
analysing the entire genome sequences of HCV genotype 1-7 as well as individual 
genomic regions. Our results show that phylogenetic trees of complete genome and NS3 
sequences, created under the GTR+I+Γ model can be used for accurate HCV 
classification. Evolutionary rate and molecular clock hypothesis testing have been 
addressed by a Bayesian Markov Chain Monte Carlo (MCMC) method, accounting for 
lineage-specific rate variation and using a relaxed molecular clock. Our analysis revealed 
a relative high average rate of evolution based on the full-length genome (5.71x10-4 
substitution/site/year), which was 2.5 and 3.3 times higher in the NS3 and NS5A gene 
respectively. The approximated age of the entire tree was about 4600 years, based on the 
whole genome sequences. The estimated time to the most recent common ancestor 
(tMRCA) of the different genotypes suggest the emergence of genotype 2 and 7 about 
4400 years ago, of genotype 3 and 5 around 4000 years ago, and of genotype 1 and 4 
about 3000 years ago. Genotype 6 represents the youngest clade, which evolved about 
2600 years ago.  
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INTRODUCTION 
 
 Hepatitis C Virus (HCV) is a positive strand RNA virus classified as member of 
the genus Hepacivirus, family Flaviviridae (27). Its complete genome organization, 
resembles that of the pestiviruses and flaviviruses and encodes untranslated regions 
(5’UTR and 3’UTR), structural (Core, E1, E2) and nonstructural (p7, NS2-NS5) proteins 
(5, 8, 9). HCV is an important pathogen that causes chronic hepatitis, cirrhosis and 
hepatocellular carcinoma. WHO estimates that 3% of the world’s population has been 
infected with HCV and there are more than 170 million chronic carriers who are at risk 
of developing liver cirrhosis and/or liver cancer (40).  
HCV evolution is believed to be mediated by several processes such as genetic 
drift caused by lack of proof-reading activity in the viral RNA-dependent RNA-
polymerase during replication (36), immune pressure (2) and recombination (12). Based 
on the genetic distance among isolates, HCV is classified into six major genotypes 
(genotype 1-6) with a huge number of subtypes. Genotypes may vary by 30-35% of their 
viral genomes, while subtypes may differ by 15-20% of their nucleotide sequences (31). 
Genotyping of HCV is clinically important in determining potential response to 
interferon therapy and the required duration of such therapy. For instance, genotypes 1 
and 4 are less responsive to interferon-based treatment and require prolonged therapeutic 
intervention compared to genotypes 2, 3, 5 and 6 (15).  In general, HCV genotypes are 
associated with a particular geographical region (1, 27, 3, 4, 16, 6, 17, 28). Dating the 
origin of the HCV is difficult because of the lack of HCV or HCV-like variants occurring 
in ape or monkey species (14). In theory, it may be possible to calculate the times of 
divergence of the six main clades and also the time of splitting of HCV subtypes by using 
constant nucleotide substitution rate over time. Based on this strategy, Smith et al. 
calculated the origin of HCV based on analysis of the E1 and NS5B genes, suggesting 
that the subtypes diverged around 300 years ago, and the divergence of the different 
genotypes should have occurred between 500 and 2000 years ago (33).  
 The aim of this study was to use statistical testing in order to establish the best-fit 
model of evolution using different data sets. We evaluated phylogenies derived from 
whole genome HCV sequences and several genomic regions of HCV, and employed a 
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Bayesian Markov Chain Monte Carlo (MCMC) approach to address phylogenetic 
relationships and dating the origin of genotypes. 
 
MATERIALS AND METHODS 
 
Compilation of sequence data. 
Data sets of full-length genomes, representing all HCV genotypes, were 
downloaded  from  Los  Alamos Hepatitis  C  Virus Database  (13),    http://hcv.lanl.gov/ 
content/hcv-index). Only sequences were used for which the exact year and place of 
isolation were available. Recombinant sequences were excluded. A data set of 96 
complete genomes belonging to genotype 1-7 was complied (Table 1). The coding 
nucleotide sequences were aligned in-frame, using the ClustalW algorithm implemented 
in Bioedit Program (version 7.0.9). All sequence alignments are available from the 
authors on request. 
Analysis of the phylogenetic signal/noise. 
The presence of phylogenetic signal across the genome was examined by 
performing a likelihood mapping analysis on groups of four sequences (quartets) 
randomly chosen (35). Likelihood mapping analyses were performed with the program 
TREE-PUZZLE (26) on the HCV full-length genome and different genomic regions 
(including UTRs). For each analysis all 10,000 possible quartets for the 96 sequences of 
all genotypes were evaluated. 
Models of nucleotide substitution and likelihood ratio test. 
The best-fit substitution model was determined by MODELTEST 3.06 
(http://darwin.uvigo.es/software/modeltest_server.html) (22), and likelihood scores were 
compared using the hierarchical likelihood ratio tests (hLRT) and the Akaike Information 
Criterion (AIC) implemented in PAUP version 4.0b10 (38).  
Best phylogenetic tree search using likelihood Ratchets and PAUP strategies.  
PAUP 4.0b10 was used to infer maximum likelihood (ML) phylogenetic trees 
generated with the best-fitting nucleotide substitution model. Accelerated likelihood 
explorations were performed using likelihood ratchets (39) in conjunction with PAUPRat 
(29) for more efficient searching of the likelihood surface. Likelihood ratchet uses 
multiple sequential truncated searches on different starting trees created by fast 
 122
                                                                                                 Molecular evolution of HCV 
 
algorithmic searches on reweighed data, analogous to the parsimony ratchet (20), which 
has been shown to increase search efficiency (39). Best trees of HCV full-length genome 
and regions that contain high phylogenetic signal were constructed from at least 10 
iterations of the likelihood ratchets by using Heuristic ML tree search parameter with 
Branch-swapping subtree-pruning-regrafting (SPR) algorithm. Best trees generated from 
each iterations was compared and consensus tree was performed by PAUP program. 
Evolutionary analysis. 
Overall rates of evolutionary change (nucleotide substitutions per site per year) 
and the age to the most recent common ancestor (tMRCA) for each branch (genotypes) 
of the tree were estimated using the Bayesian MCMC approach available in the Bayesian 
evolutionary  analysis  by  sampling  trees  (BEAST)  package  (http://beast.bio.ed.ac.uk/ 
Main_Page,version 1.4.7) (7). HCV sequences recovered from the same epidemic area or 
isolated from nonhuman primates were excluded from the analyses. After removing all 
gaps, the 42 HCV genomes were used for analysis (Table 1). Various parameters such as 
gamma distribution (Γ4), invariant sites (I), specific partition into codon position, i.e., 2 
partitions (codon positions (1+2)) and 3 partitions (codon positions 1,2,3) were applied to 
test the best evolutionary model. Data sets were analysed using a constant population size 
under both strict and relaxed molecular clock (uncorrelated lognormal) models, which do 
not assume a constant rate across lineages for molecular evolution study (24). In each 
case, MCMC chains were run for at least 10 million times to achieve the Effective 
Sample Sites (ESS), and models were compared using Bayes Factor (BF), available in 
TRACER program (version 1.4: http://beast.bio.ed.ac.uk/Tracer). The uncertainty in the 
data is reflected in the 95% highest probability density (HPD). 
 
RESULTS 
Phylogenetic signal of HCV sequences. 
The phylogenetic signal of the complete HCV genome and different genomic 
regions were analysed with the likelihood mapping method. As shown in Table 2, the 
full-length genome has the highest phylogenetic information (98.1%). The lowest signal 
contents were observed in the 5’UTR, p7, and NS4A, ranging from 62.3% to 76.4%. The 
regions that exhibited the highest phylogenetic information were NS5B (95.8%), NS3 
(95.7%) and NS5A (93.3%) respectively.  
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Table 1. Detailed of HCV sequences included in this study.  
 
Name                  Genotype   Accession Year Country  Note 
 
H77 1a AF009606  1997 United States  
PHCV-1/SF9_A 1a AF271632  2000 United States        chimpanzee 
COLONEL 1a AF290978  2000 United States        chimpanzee 
HEC278830* 1a AJ278830  2000 United Kingdom  
HC-J1 1a D10749  1992 Japan  
HCV-1 HCV-PT 1a M62321  1991 United States            chimpanzee 
HCV-H* 1a M67463  1992 United States  
MD1-0 1b AF165045  1999 Japan  
HCV-S1 1b AF356827  2001 Singapore  
HCV-TR1* 1b AF483269  2002 Turkey  
HCV-A 1b AJ000009  1997 Australia  
HC-C2 1b D10934  1993 China  
N589* 1b AY587844  1999 Russian Federation  
J33 1b D14484  1991 Japan  
HCV-JS 1b D85516  1996 Japan 
D89815 1b D89815  1996 Japan 
HCV-J* 1b D90208  1990 Japan 
HEBEI 1b L02836  1992 China 
HPCGENANTI 1b M84754  1992 Taiwan 
HCV-L2 1b U01214  1993 South Korea 
HCU16362 1b U16362  1994 South Korea 
HD-1 1b U45476  1996 Germany 
AY051292 1c AY051292  2001 India 
Khaja1 1c AY651061  2004 India 
HC-G9* 1c D14853  1993 Indonesia 
AJ851228* 1 AJ851228  2004 Equatorial Guinea 
NDM228 2a AF169002  1999 Japan 
G2AK3 2a AF169004  1999 Japan 
NDM59 2a AF169005  1999 Japan 
JFH-1 2a AB047639  2000 Japan 
AY746460* 2a AY746460  2004 Japan 
HC-J6* 2a D00944  1991 Japan 
JPUT971017 2b AB030907  1999 Japan 
MD2b1-1* 2b AY232730  2003 Japan 
HC-J8* 2b D10988  1992 Japan 
BEBE1* 2c D50409  1995 Italy 
VAT96* 2k AB031663  1999 Moldova 
D54* 2i DQ155561  2002 Vietnam 
CB 3a AF046866  1998 Australia 
NZL1* 3a D17763  1993 Japan 
K3A 3a D28917  1994 United States 
HCVCENS1 3a X76918  1995 Germany 
HCV-Tr* 3b D49374  1994 Japan 
JK049* 3k D63821  1995 Indonesia 
01-09 4a DQ418782  2006 Egypt 
F753 4a DQ418787  2006 Egypt 
ED43* 4a Y11604  1997 Egypt 
03-18* 4d DQ418786  2006 Egypt 
24 4d DQ516083  2006 Egypt 
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Table 1. (Continue) 
 
Name                   Genotype Accession       Year Country        Note 
 
24 4d DQ516083  2006 Egypt 
IFBT88* 4f EF589161  2007 France 
SA13* 5a AF064490  1992 South Africa 
EUH1480 5a Y13184  1997 United Kingdom 
6a77 6a DQ480512  2006 Hong Kong 
EUHK2* 6a Y12083  1997 Hong Kong 
D9 6a EU246930  2002 Vietnam 
TH580* 6b D84262  1994 Thailand 
Th846* 6c EF424629  1999 Thailand 
VN235* 6d D84263  1996 Vietnam 
GX004 6e DQ314805  2005 China 
D42*  6e EU246931  2002 Vietnam 
D88 6e EU246932  2002 Vietnam 
C-0044 6f DQ835760  2006 Thailand 
C-0046 6f DQ835764  2006 Thailand 
TH52* 6f EU246936  2002 Thailand 
JK046* 6g D63822  1995 Indonesia 
HK6554 6g DQ314806  2005 Hong Kong 
VN004* 6h D84265  1996 Vietnam 
C-0159 6i DQ835762  2006 Thailand 
Th602* 6i DQ835770  1994 Thailand 
TH24 6i EU246935  2002 Thailand 
C-0667 6j DQ835761  2006 Thailand 
Th553* 6j DQ835769  1999 Thailand 
KM45 6k AY878650  2002 China 
KM41 6k AY878651  2002 China 
VN405* 6k D84264  1996 Vietnam 
537796 6l EF424628  2007 United States 
D33* 6l EU246933  2002 Vietnam 
C-0208 6m DQ835763  2006 Thailand 
C-0185 6m DQ835765  2006 Thailand  
C-0192 6m DQ835766  2006 Thailand  
B4/92* 6m DQ835767  1995 Thailand  
D86/93* 6n DQ835768  1994 Thailand  
KM42 6n AY878652  2002 China  
TH22 6n EU246937  2002 Thailand  
TH31 6n EU246938  2002 Thailand  
QC227 6o EF424627  2005 Canada    Asian immigrant 
D85* 6o EU246934  2002 Vietnam  
QC216* 6p EF424626  2005 Canada  Asian immigrant 
QC99* 6q EF424625  2004 Canada  Asian immigrant 
D49* 6t EU246939  2002 Vietnam  
TV241 6t EF632069  2007 Vietnam  
TV249 6t EF632070  2007 Vietnam  
VT21 6t EF632071  2007 Vietnam  
D83* 6u EU246940  2002 Vietnam  
GZ52557* 6 DQ278892   2004 China  
QC69* 7a EF108306  2003 Canada  Asian immigrant 
* samples collected for evolutionary rate and molecular clock analysis 
 125
Chapter 6 
Table 2.  Likelihood mapping analysis of the 10,000 possible quartets of the full-genome 
HCV genotype 1-6 and only genotype 6.    
 
                Tree-like Phylogeny  Star-like Phylogeny 
Gene region    No. sites   Constant sites      (phylogenetic signal)a (phylogenetic noise)a 
                    (%)           Genotype 1-6   Genotype 1-6       
 
FGa  9357    30.1   98.1   1.9 
5’UTR   237    75.1     62.3              37.7  
CORE    573    44.0    91.5   8.5  
E1   579    21.4    89.8              10.2  
E2              1116    26.6    89.3              10.7   
p7   189    15.9    74.5              25.5  
NS2   651    20.9   89.3              10.7  
NS3              1893    35.6   95.7   4.3  
NS4A   162    30.9   76.4              23.6  
NS4B   783    30.3   90.9   9.1  
NS5A              1434    19.8   93.3   6.7  
NS5B              1737    31.8   95.8   4.2  
 
a FG: Full genome 
 
Best-fit nucleotide substitution model selection and phylogenetic reconstruction. 
In order to determine the best model of evolution, we compared the likelihood 
scores estimated by the ModelTest from either full-length genome or from individual 
genomic regions using the hLRTs and the AIC method. Different data sets resulted in 
different best-fit models of nucleotide substitution (Table 3). The commonly used K80 
model of evolution was only selected for the 5’UTR by the hLTR method. The models of 
nucleotide substitution increased in complexity, i.e becoming more parameter rich, for 
the more diverse regions. All the models incorporated invariant sites (I) and assumed rate 
heterogeneity (Γ) across sites.  
Phylogenetic trees were reconstructed for the full-length HCV genome, NS3, 
NS5A, and NS5B genes using the GTR + Γ substitution model. Phylogenetic analysis of 
the full-length genome suggest that genotypes 1 and 4, genotypes 3 and 5, and genotypes 
2 and 7 respectively, shared a common ancestor (Fig 1A). In contrast genotype 6 formed 
a single clade, which based on the branch length, separated earlier than the other 
genotypes. Furthermore, genotype 2 had a longer evolution time compared to the other 
genotypes, while genotype 7 split after genotype 1, 3, 4 and 5. The tree based on NS3 
(1893 bps, Fig.1B) and NS5A (1434 bps, Fig.1C), had a clustering pattern similar to full-
length genome. Branch lengths of the NS3 tree indicated an evolution rate for genotype 
and subtype similar to the evolution rate of the whole genome. The NS5A tree had 
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shorter branch lengths, indicating a different evolution rate (Fig.1C). In contrast, analysis 
of the NS5B (1737 bps, Fig.1D) tree demonstrated a different phylogenetic relationship 
between the HCV genotypes. The best tree constructed from NS5B sequences shows that 
genotype 2, 5 and 7 split from genotype 1, while genotype 3 and 4 shared a common 
ancestor. Genotype 6 is a separate clade.  
 
Table 3. Likelihood values of different nucleotide substitution models for full-length 
HCV and individual genomic regions. 
 
Regions                 hLRTs        AICs 
                  Best-fit Model   - ln Likehood         Best-fit Model    - ln Likehood 
 
FGa   TrN+I+Γ 311970.5625  GTR+I+Γ  311310.4062 
5’UTR   K80+I+Γ     1076.6461  GTR+I+Γ     1045.5182 
Core   TrN+I+Γ   11152.3809  TVM+I+Γ   11122.0908 
E1  GTR+I+Γ   21913.9805  TVM+I+Γ   21914.0566 
E2  GTR+I+Γ   46293.6641   GTR+I+Γ   46293.6641 
P7  HKY+I+Γ     7700.5259  GTR+I+Γ     7678.0122 
NS2  TrN+I+Γ   26788.3438  GTR+I+Γ   26721.1621 
NS3   TrN+I+Γ   59567.1328  GTR+I+Γ   59458.5625 
NS4a  GTR+I+Γ     5063.7207  GTR+I+Γ     5063.7207 
NS4b  TrN+I+Γ   25488.7715  GTR+I+Γ   25443.5293 
NS5a   TrN+I+Γ   51390.1094  GTR+I+Γ   51226.6211 
NS5b  TrN+I+Γ   51677.6328  GTR+I+Γ   51559.8750 
 
a FG: FG: Full genome 
 
 
Substitution rates, divergence times, and population dynamics 
Since NS3 and NS5A genes were superior representatives of full-length HCV 
genome evolution, they were used as targets for further analyses. Rates of nucleotide 
substitution for NS3 was first analysed from 42 sequences using a Bayesian coalescent 
approach (Table 4). For the NS3 gene, the best-fit population dynamic model for HCV 
evolution was estimated to be a constant population growth. Strict and relaxed 
uncorrelated lognormal models were analysed and BF was used to select the best model. 
The 3-codon partitions (CP3) of rate heterogeneity among sites (GTR+Γ+CP3) showed a 
substantially superior fit to data than the GTR+I+Γ (Table 4), also when compared to the 
CP2 without rate heterogeneity gamma distribution (log BF=847.90, data not shown). 
The substitution rate in NS3 for the CP2 ranged from 6.60 to 13.09 x 10-4 
substitutions/site/year (95% HPD: 0.012-30.09) depending on molecular clock model 
tested (Table 4). 
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Based on the GTR+Γ+CP3 model, the mean rate of nucleotide substitution in 
HCV was then compared for full-length genome, NS3 and NS5A genes. As shown in 
table 5, similar substitution rates were estimated for NS3 and NS5A genes, at between 
14.5 and 18.8 x 10-4 substitutions/site/year and with similar HPD values (Table 5).  The 
mean substitution rate of all genotypes was much smaller across the whole genome (5.71 
x 10-4 substitutions/site/year), with HPD values overlapping NS3 and NS5A. This effect 
is probably due to the presence of high conserved regions such as 5’ and 3’ UTRs in the 
full-length genome. The lower 95% HPD value, which represents the lowest possible 
(most conservative) rates of HCV evolution were 4.4 x 10-6 sub/site/year for full-length 
genome, 1.6 x 10-6 sub/site/year for NS3 and 7.7x10-6 for NS5A gene respectively.  
The estimated age of genetic diversity in the NS3 and NS5A genes was broadly 
similar between the different genotypes (mean estimates of 2639-3893 and 1114-2599 
years respectively). Although the estimated age of genetic diversity for the NS5A gene 
was smaller, the HPD values overlap with those estimated for NS3. In all cases, the strict 
molecular clock was rejected as a valid description of the evolutionary dynamics of HCV 
in favour of a relaxed uncorrelated lognormal molecular clock. It is worth noting that the 
Bayesian Factor (BF) of strict and relaxed clock analysis was less than 20, indicating that 
the difference between both models was small. The approximated age of the entire tree 
calculated based on full length genomes was estimated to be about 4610 years (Table 5). 
Based on the tMRCA estimation for full-length HCV genome, genotype 2 and 7, and 
genotype 3 and 5 evolved in a period of about 4000-4400 years, while genotype 1 and 4 
emerged in the same period as genotype 6, in the range of 2600-3000 years ago. These 
results correlated with the phylogenetic relationships observed from the branch lengths of 
genotype 2 and 7 and of genotype 3 and 5 (Fig. 1A).  
 
 
 
Figure 1. The best unrooted ML trees depicting the phylogenetic relationship among 96 HCV 
strains obtained from HCV database. Trees were constructed for a complete genome (A), a 
complete NS3 codons (B), a complete NS5A codons (C) and a complete NS5B codons (D) 
datasets using Heuristic ML tree search parameter with Branch-swapping Subtree-pruning-
regrafting (SPR) algorithm conducted by PAUP (see Material and methods). Branch lengths are 
drawn to scale. Boldface numbers along the branches indicates the six major lineages of HCV; 
subtypes of the viruses are also given (according the new nomenclature). Genbank accession 
number of all sequences shown in Table 1. 
 130
                                                                                                 Molecular evolution of HCV 
 
Table 4  Sum
m
ary of the likelihood scores, substitutions rates and estim
ated  tim
e of different m
olecular clock m
odel analysis of H
C
V
 N
S3 gene  
(42 taxa, 1893 bps)  
  Substitution M
odel        M
olecular clock m
odel a     
         
-ln Likelihood
b         
   Substitution rate x10
-4 
 
A
ge, yrs (95%
 H
PD
)  d
 
 
 
 
 
 
 
 
 
 
Subs/site/year (95%
H
PD
)  c
 G
TR
 + C
P2 
 
Strict 
 
 
     
40700           
          
 6.60 (0.012-14.99) 
 
3766.06 (277.22-10820) 
G
TR
 + C
P2 
 
R
elaxed U
ncor. log. 
 
40680 (B
F=15.83)  
 9.15 (0.013-19.67) 
 
3018.24 (211.58-5788.79) 
G
TR
 + I + Γ 
 
Strict 
 
 
 
40120 
 
          
 9.47 (0.026-19.32) 
 
2841.09 (233.86-6806.75) 
G
TR
 + I + Γ 
 
R
elaxed U
ncor. log. 
 
40100 (B
F=6.54)  
10.10 (0.015-22.82) 
 
3189.93 (221.64-6803.45) 
G
TR
 + Γ + C
P2 
 
Strict 
 
 
 
38940 
 
              12.00 (0.007-25.39) 
 
6363.28 (408.22-11540) 
G
TR
 + Γ + C
P2 
 
R
elaxed U
ncor. log. 
 
38920 (B
F=5.44)    
13.09 (0.019-30.09) 
 
4765.49 (300.02-12230) 
G
TR
 + Γ + C
P3 
 
Strict 
 
 
 
38750 
 
 
 14.06 (0.483-28.16) 
 
2311.87 (364.58-6902.87) 
G
TR
 + Γ + C
P3 
 
R
elaxed U
ncor. log. 
 
38740 (B
F=4.02)    
14.77 (0.013-30.81) 
 
4783.60 (311.58-10880) 
 
   
 
 
 
 
 
a R
elaxed U
ncorrelated lognorm
al 
b B
ayer Factor , com
parison of strict and relaxed m
olecular clock of each m
odel 
c,d  (low
er 95%
H
PD
 - upper 95%
H
PD
)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 131
Chapter 6 
Additional analysis on dating of HCV has been done using the NS3 and NS5A 
regions. Molecular clock analysis based on NS3 revealed that genotype 2 and 7 and 
genotype 3 and 5 are the oldest groups, separated about 3700-3900 years ago, while 
branches of genotype 1, 4, and 6 separated much later (around 2300-2600 years ago) 
(Table 5). The analysis based on the NS5A gene showed that estimated evolutionary rate 
was about 18.8x10-4 sub/site/yrs, suggesting a faster evolution than entire genomes and 
NS3 gene. The mean tMRCA for all genotypes based on NS3 was similar to the entire 
genome, suggesting that NS3 is a better representative of the whole genome than the 
NS5A gene. 
 
 
Table 5  Substitution Rates and dating of HCV full-length genome (8,922 bps), NS3 
(1,893 bps), and NS5A gene (1,284 bps) under GTR + Γ + CP3 substitution model and 
the relaxed molecular clock analysis 
 
Data sets    Substitution rate x10-4   tMRCAc (95% HPD) 
Subs/site/year (95%HPD) b
 
HCV FGa, for all genotypes  5.71 (0.044-12.6)  4610.42 (493.71-15420) 
Genotype 1 and 4 (n=10)      3168.00 (343.91-10590) 
Genotype 2 and 7 (n=8)      4380.11 (433.90-14730) 
Genotype 3 and 5 (n=4)      3917.41 (457.29-13100) 
Genotype 6 (n=20)       2596.71 (302.45-8715.57) 
 
HCV NS3 gene, for all genotypes   14.50 (0.016-30.4) 4402.99 (311.63-10360) 
Genotype 1 and 4 (n=10)       2639.36 (182.11-6102.68) 
Genotype 2 and 7 (n=8)       3748.69 (248.02-8876.83) 
Genotype genotype 3 and 5 (n=4)      3893.54 (283.06-9245.59) 
Genotype genotype 6 (n=20)      2341.13 (157.90-5568.35) 
 
HCV NS5A gene for all genotypes  18.8 (0.077-37.1)  2599.67 (331.41-6430.00) 
Genotype 1 and 4 (n=10)      1114.57 (154.95-2745.19) 
Genotype 2 and 7 (n=8)      2599.52 (331.41-6430.00) 
Genotype 3 and 5 (n=4)      1355.52 (186.79-3348.76) 
Genotype 6 (n=20)       1142.26 (160.95-2846.22) 
 
a  FG: Full genome 
b  (lower 95%HPD - upper 95%HPD) 
c Mean age in years 
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DISCUSSION 
  
It is known that HCV is a fast-evolving virus with an average evolutionary rate 
similar to human immunodeficiency virus (HIV-1), in the order of 10-3 /site/year (11, 33, 
37). Because of its high mutation rate, HCV has the characteristic sequence heterogeneity 
resulting in quasispecies, subtypes and genotypes. In this study, molecular phylogenetic 
analyses were used to study HCV evolution and divergence times. 
Although phylogenetic analysis has been used to clarify the origin and the 
evolution of HCV (21, 25, 33), some aspects of the evolutionary dynamics of the virus 
still remain unclear. An important aspect in studying molecular evolution of HCV is 
obtaining an accurate rate of nucleotide substitution, from which divergence times can be 
estimated. We have used full-length genome sequences of HCV to evaluate the presence 
of phylogenetic signal. It seems intuitive that a simple model like K-80 may not 
adequately represent the complexity of the nucleotide substitution process in RNA 
viruses such as HIV or HCV (25). We found that full-length genome and the NS5B, NS3 
and NS5A genomic regions contain high phylogenetic signal, indicating their power to 
clarify the relationships between different genotypes and subtypes. This finding is in 
agreement with findings described by Salemi et al. (25). Furthermore, the complex model 
GTR+I+Γ was selected as the best-fit model of nucleotide substitutions for full-length 
genome, NS3, NS5A, and NS5B data sets. The strong rate heterogeneity across sites in 
the different HVC genes (not shown) may be explained by the different selective 
pressures along the genome. It is noteworthy that NS5B, together with CORE and E1 are 
the recommended regions to use for  phylogenetic analysis of HCV strains when the full-
length genome is not available (31). However, comparison of trees based on NS3 and 
NS5A revealed that these genomic regions are more appropriate than NS5B for 
investigating the phylogenetic relationships between subtypes. The low resolution of 
NS5B for revealing accurate phylogenetic relationships may be caused by the use of the 
whole gene sequence. As previously reported, the best region for phylogenetic analysis 
of HCV is located at nucleotides 8283 to 8624 (333 bps) of NS5B (32). This study raises 
the awareness that using NS5B sequences for genotyping should be restricted to that 
specific region, especially for identification of new genotypes or subtypes. 
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 Several groups have estimated the evolutionary rate of HCV (11, 21, 33). In our 
study, the estimated mean rate of nucleotide substitution across sites of all genotypes was 
about 5.71x10-4 sub/site/year, slightly low compare to the approximated rate observed in 
long term chronically infected chimpanzee (1.44 x 10-3 sub/site/year) (21). Next, we 
inferred the tMRCA of HCV genotypes using the Bayesian coalescent approach. In all 
cases the strict molecular clock was rejected, confirming a previous study describing 
rejection of the strict molecular clock even when the third-codon position was analysed 
separately (25). Rejection of the strict molecular clock may be explained by the unequal 
evolutionary rates among different clades of HCV, which is plausible in light of the 
different selective pressures exerted by the immune system. A substitution model 
incorporating the third-codon partitions, and assuming a relaxed uncorrelated lognormal 
molecular clock, proved superior to estimate rates in the NS3 gene. This is in agreement 
with the Hillis and Huelsenbeck (10), which suggested that all three codons are involved 
in HCV evolution. In addition, few sequences are available for genotypes 5 and 7.  
Under the relaxed molecular clock model (uncorrelated lognormal), we estimated 
the tMRCA of the different genotypes, which ranged between 2600 and 4600 years ago, 
a deeper time estimate of evolution than reported previously (34, 18, 23). Such a 
timescale suggests that modern dispersal is responsible for the phylogeographic of HCV. 
Genotype 1a, 1b and 3a have a worldwide distribution with blood transfusion and sharing 
of contaminated needles between infected drug users representing the common modes of 
transmission (23). These strains contain low sequence diversity, as a result of rapid 
spreading of a few original strains. On the other hand, genotype 2 and 6 circulates in 
African and Asian countries and constitute highly divergent strains. This suggests a long 
period of HCV infection in these areas through vertical and horizontal transmission (23, 
36). Based on the genotype distributions, it was suggested that HCV has been endemic in 
sub-Saharan Africa and South-East Asia for a considerable time, and that the occurrence 
of infection in Western and other non-tropical countries represents a relatively recent 
emergence of infection in new risk groups for infection (19, 30). It remains unclear what 
forced the earlier divergence of the six major genotypes of HCV. New genotypes may be 
generated when viruses spread into the new host populations, resulting in mutants able to 
escape host immune responses. Furthermore, many factors such as co-infection of 
HCV/HIV in intravenous drug users or a strong selection pressure as a result of the 
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antiviral therapy may influence HCV evolutionary rates. Further studies on the  
molecular evolution of HCV will require precise data sets combining phylogenetic data 
with epidemiological data. 
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ABSTRACT 
 
CD8+ cytotoxic T lymphocytes (CTLs) play a crucial role in the pathogenesis of hepatitis 
C virus (HCV) infection. Given the fact that HCV displays enormous sequence diversity 
and most studies employed genotype 1 based antigens to analyse epitope specificity of 
CTLs, only limited knowledge exits on genotype cross reactivity of HCV specific CTLs. 
We therefore explored the possibility to use an Epstein Barr virus (EBV) based plasmid 
system that allows rapid generation of diverse sets of HCV expressing vectors. First, 
HLA-A1 restricted HCV specific T cells were obtained from the liver of a chronic HCV 
patient. These CD8+ T cells were shown to specifically recognize recombinant Vaccinia 
virus (rVV) infected BLCL expressing NS3, when analysed for IFN-gamma production 
by ELISA, ELISPOT and FACS. Next we cloned different NS3 fragments into EBV 
based expression plasmids. The efficiency to present HCV antigens by BLCL stably 
transfected with EBV-based plasmid was similar to BLCL infected with rVV-HCV and 
enabled the identification of an HLA-A1 restricted epitope. Thus, EBV based expression 
plasmids can be used as an alternative strategy to detect HCV specific CD8+ CTLs.  
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INTRODUCTION 
 
Cytotoxic T lymphocytes (CTLs) play a major role in the pathogenesis of chronic 
viral infections (5, 15, 20). Through recognition of virus-infected cells, CTLs may lyse 
infected cells, or secrete cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor 
(TNF) that inhibit viral replication and/or recruit other nonspecific inflammatory cells (3, 
4, 21). It is likely that cell-mediated immune responses play an important role in viral 
clearance and/or the clinical outcome of HCV infection. Frequencies of HCV specific 
CD8+ T cells in chronic infected patients, however, are relatively low especially in the 
peripheral blood (1, 11, 12) and are associated with failure to clear HCV (16). 
HCV contains a positive-stranded RNA genome of about 9.4 kilobases, which 
translates into a single uninterrupted open reading frame that encodes a protein of 3010 
amino acids. (2). Sequence diversity from different geographical areas has led to the 
identification and classification of at least six major genotypes, many of which contain a 
number of more closely related, yet distinct subtypes (17). The overall sequence 
similarities of complete genomic sequences is approximately 65-70% between 
genotypes, and about 80-85% between different subtypes (18). The virus also shows a 
high degree of variation during the course of infection, resulting in the generation of a 
number of variants or quasispecies (10).  
Assays to monitor HCV specific T cell response require stimulator or target cells 
presenting viral antigens. Because natural HCV variants cannot infect antigen-presenting 
cells, alternatives have to be developed to characterise the specificity of the CTL 
response. A classical way to generate stimulator cells employs autologous Epstein Barr 
transformed B-cells (BLCLs) infected with recombinant Vaccinia viruses (rVV) 
encoding parts of the HCV genome (6). However, poxvirus vectors are not convenient to 
use because of safety issues and the complexity of generating recombinants (8). In this 
study the use of eukaryotic expression plasmids utilizing CMV or EBV based promotors 
was considered to transfect BLCL (13, 19).  EBV based plasmids may be suitable 
plasmids for this purposes as these are activated through EPNA-1 from EBV, expressed 
in BLCLs. (7, 14). We compared the efficiency of EBV-based plasmid and rVVs in 
expression of HCV-NS3 in BLCLs and evaluated their ability to stimulate HCV specific 
T cells in vitro. 
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MATERIALS AND METHODS 
 
Patients. Needle liver biopsies and heparinized blood were obtained from chronically 
HCV-infected patients at the Erasmus MC, Rotterdam, The Netherlands. All patients 
were infected with HCV genotype 1. Informed consent was written by each patient to 
participate in our study, and the experiment protocol was approved by the local ethics 
committee.  
Liver-derived T cell lines. Liver biopsies were washed extensively in phosphate-buffer 
saline (PBS) to remove contaminating blood. To disrupt the hepatic tissue and to release 
infiltrating lymphomononuclear cells, liver specimens were minced by scalpel and then 
digested with 0.5 mg/ml collagenase/dipase enzymes and 40 KU/ml Dnase I for 30 
minutes at 37oC. The suspension was filtrated through a cell strainer (Becton Dickinson) 
and centrifuged at 1600 rpm for 10 minutes. After discarding the supernatant, the pellet 
was suspended in tissue culture medium (RPMI-1640) containing 2 mmol/L L-
Glutamine, 100 U/ml Penicillin, 100 μg/ml Streptomycin and 10% fetal bovine serum 
(R10F) in the presence of irradiated allogeneic PBMCs, irradiated BLCLs, 1 μg/ml PHA 
and 50 IU/ml IL-2. T cell lines were cultured until they stopped proliferating, analysed 
for CD3, CD56, CD4 and CD8 expression using FACs analysis or frozen for future 
experiments.  
EBV transformed B cells.  PBMCs were collected from heparinized blood using 
Lymphoprep centrifugation at 2,800 rpm for 30 minutes and washed with PBS for 3 
times. BLCLs were established through incubation with Epstein-Barr virus (EBV) 
overnight at 37oC. Transformed B cells were washed with medium and cultured in R10F 
medium. 
Vaccinia virus vectors and peptides. Recombinant vaccinia viruses (rVV) expressing 
HCV genes derived from the HCV-1 strain (genotype 1a) were kindly provided by 
Chiron Corporation (Emeryville, CA).  The vaccinia constructs used in this study include 
the vv-Poly encoding aa 1-966 , vv-NS3 encoding aa 364-1619, vv-NS4 encoding aa 
1590-2053, vv-NS5A encoding aa 2006-2397 and vv-NS5B encoding aa 2396-3011 of 
HCV. Wild type vaccinia virus was used as control.  
Synthetic peptides (ATDALMTGY and CINGVCWTV) corresponding to HLA-
A1 and HLA-A2 restricted epitopes, respectively, were purchased from Eurogentec. The 
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peptides were selected, based on location in NS3-NS4 region of HCV genome (aa 966-
1619) using the SYFPEITHI program (http://syfpeithi.bmi-heidelberg.com). 
Cloning and expression of NS3 gene.  The 1,980 bp fragment located in NS3 gene (aa 
966-1,619) was amplified from vv-NS3 construct using forward primer NNRdF (5’-
CAGTATGGATCTGGCCGTGGCTGT-3’) and reverse primer NNRdR (5’-
AGGGTGGGCTTGAGGCGAAT-3’). The amplified PCR product was ligated into 
pCR2.1 vector (TA cloning ® kit, Invitrogen) and transformed into E.coli INVαF’ 
according to the manufacturer’s protocol. Positive clones were selected by X-gal/IPTG 
and ampicillin resistant. Recombinant plasmid was purified and inserted DNA was 
digested with the restriction enzyme EcoR I followed by a fill-in and dephosphorylation 
steps. DNA was subcloned into a VR1012 Neo+ mammalian expression vector (Vical) at 
the EcoR V site and subcloned again into pNS EBV-based vector at the BamH I site  
(Fig. 1). Positive clones were selected by kanamycin resistance and plasmid DNA were 
extracted and examined by restriction enzyme digestion. Recombinant DNA was purified 
for the transfection experiment using the StrataPrep EF plasmid Midiprep Kit 
(Stratagene) according to the manufacturer’s protocol. To specify the specific region 
recognized by specific T cells, small fragments containing different parts of the NS3 
gene were amplified and subcloned into the pNS vector. Positive clones of construct 4 
(aa. 966-1135), construct 5 (aa. 1126-1344) and construct 6 (aa. 1328-1617) were 
selected and purified as previously described.  
Purified pNS-NS3 and control vectors were transfected into NKNT-3 cells by 
using Lipofectamine 2000 reagent (Life Technologies) or into BLCLs by electroporation 
using a Gene Pulser apparatus (BioRad Laboratories) pulsed at 390 V/500μF. Cells were 
selected for stable transfection by adding 1 mg/ml G418 sulfate in RPMI 1640 medium 
on day 3 after transfection. Transfected NKNT-3 cells were cultured for 24-48 hrs and 
fixed with 5% paraformaldehyde in phosphate-buffered saline (PBS). After washing with 
PBS, cells were incubated with 1.0 M glycine for 10 minutes followed by 0.05% H2O2 in 
70% ethanol.  Non-specific binding was blocked with 1% normal goat serum. The cells 
were incubated with a mouse monoclonal antibody to NS3 (5F-1, Organon) at 4o C for 12 
hrs. After incubating with biotin conjugated goat anti-mouse IgG and streptavidine 
peroxidase reagent, substrate was added (3’-amino-9-ethylcarbazole, AEC) in 50 mM 
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acetate buffer pH5.0 and examined under light microscopy. BLCL were stained similarly 
except that a goat anti-mouse-FITC antibody was used as a second step.  
 
 
 
 
 
                                      
 
NNRd (aa. 966-1619 )          
        pNS 4 (aa. 966-1135) 
        pNS 5 (aa. 1126-1344) 
pNS 6 (aa.1328-1617)  
  
           cloned into pCR2.1 and VR1012 vectors 
   and subcloned into pNS vector 
 
 
 
 
 
 
                                                                       
1
581
1161
1741
2321
2901
3481
4061
4641
5221
 pNS vector 
 5800 bp 
Poly A  
Neo  P
  tk  P 
 
SR∝  P Bgl II 
Hind III 
Bam HI 
Neo ®  
Poly A 
Ori  
Ori P 
 
Sal I 
         
 
 
Figure 1 clone strategy of HCV NS3 genes amplified from rVV construct (genotype 1). Different 
PCR fragments (NNRd, pNS 4-6) were separately cloned into pCR 2.1 and subcloned into 
VR1012 and pNS vectors, respectively.    
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FACS analysis for IFN-γ production. Cells were stimulated for 2 hours with 
autologous BLCLs infected with recombinant vaccinia-HCV, autologous BLCLs stably 
transfected with pNS-HCV and control autologous BLCLs. Golgi-Stop was added at a 
ratio of 4 μl Golgi Stop and 6 ml medium and further incubated for 4 hours. Cells from 
each well were washed and suspended in Cytifix/Cytoperm solution for 20 minutes at 
4oC. The permeabilized cells were washed 2 times with 1x Perm/Wash solution 
(Pharmingen) and stained for intracellular IFN-γ production by using anti- IFN-γ-PE and 
isotype control for 30 minutes in the dark on ice. After this the cells were washed 2 times 
with 1x Perm/Wash solution and resuspended in 250 μl staining buffer before FACS 
analysis. FACS analysis was performed by FACScan flow cytometers and analyzed with 
Cell Quest software (Beckton Dickinson, San Jose,CA) 
 
ELISA and ELISPOT assay for IFN-γ production Nitrocellulose-bottom Silent Screen 
96-well plates (Nalge Nunc International) were coated with 100 μl of the IFN-γ 
monoclonal antibody (Mabtech) at a concentration of 1 μg/ml in 0.1 M carbonate 
bicarbonate buffer pH 9.6 and were incubated overnight at 4oC. Unbound antibodies 
were removed via 3 successive washings with PBS. The coated wells were blocked with 
culture medium (RPMI-1640 and 10% human serum) for 2 hours in 37o C incubator. 
Wells were washed and filled with 100 μl R10F containing 1x105 T cells together with 2 
x 104 irradiated BLCLs infected with VV expressing HCV or transfected with pNS 
vectors. PHA (1μg/ml) or PMA was used as a positive control (these mixtures were 
previously incubated in round bottom 96 well plate in 37oC incubator for 4 hours before 
transferred to ELISPOT plate). The samples were incubated for 24 hours at 37oC 
incubator with 5% CO2. After incubation, cells were removed by washing the plate 6 
times with PBS containing 0.05% Tween 20. The biotin-conjugated anti-IFN-γ (Mabtech 
AB) was added to each well at the concentration of 1 μg/ml and incubated for 3 hours at 
room temperature. The plates were rinsed 3 times by immersion in PBS containing 
0.05% Tween 20 and were exposed to 100 μl of streptavidin-alkaline phosphatase 
(Mabtech AB) for 1 hour. Unbound conjugate was removed by washing with PBS, and 
finally, 100 μl of 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium substrate 
solution (BCIP/NBT, Bio-Rad Laboratories, Richmond, CA) was added, and the sample 
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was incubated for 40 minutes. The color reaction was stopped by extensive washings 3 
times with distilled water, and after dry, the number of spots was scored by using the  
dissection microscope.  IFN gamma in supernatants was determined by ELISA according 
the manufacturer’s guidelines (U-Cytech). 
T cell depletion and HLA restriction analysis.  Depletion and isolation of CD4+ or 
CD8+ T cells was performed using DYNABEADS M-450 (111.05 and 111.07; Dynal, 
Oslo, Norway) according to the manufacturer’s protocol. Depleted CD4+ or CD8+ were 
stimulated with rVV-NS3 and VV wild type. The positive control C1R cell expressing 
HLA-A1 restrict and wild type were kindly provided by Dr. A.C.M. Boon (Virology 
department, Erasmus MC, Rotterdam). Both cells line were infected with rVV-NS3 and 
VV wild type. 
 
RESULTS AND DISCUSSION 
 
Generation of T cell lines from liver biopsies.  
We collected liver biopsies and heparinized blood from fifteen chronically HCV infected 
patients. All patients were infected with HCV genotype 1 and previous non-responder to 
IFN-α and ribavirin therapy. T cell lines from all patients were analyzed by FACS 
analysis to determine the percentage of CD4+ and CD8+ T cells. Most of the CD3+ cells 
expressed the CD8 marker (Fig. 2A and 2B). Next, T cell lines generated from liver 
biopsies were tested for HCV specificity using recombinant VVs expressing different 
fragments of the HCV genome. No specific IFN-gamma producing cells were detected 
with exception from patient 816 (Fig. 2C). This T cell line specifically recognised BLCL 
infected with VV-NS3. Similar results were obtained using T cell lines from the same 
patient obtained at two different time points during subsequent IFN-α and ribavirin 
therapy (not shown). Similarly to our finding, low frequencies of intrahepatic HCV 
specific T-cells have been observed in other studies examining the presence of 
intrahepatic HCV specific T-cells in previous non responders to IFN therapy (9). 
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Figure 2.  Characterization of intra-hepatic T cell lines from chronic hepatitis C patients. T cell 
lines from fifteen HCV infected patients were analysed by FACS for cell surface markers CD3 
and CD56 (A) and CD3+ cells were further characterized for expression of CD4 and CD8 (B). 
HCV specific responses were analysed for IFN gamma secretion using recombinant VV infected 
BLCL in an ELISPOT assay (C). 
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HLA restriction.   
The T cell line of patient 816 was further analysed for HLA restriction using T cell 
depletion and HLA restriction studies. As shown in figure 3A, depletion of CD8+ cells 
from the T-cell line abrogated the specific T cell response whereas no effect was 
observed when applying CD4 depletion. When a panel of HLA typed BLCL was infected 
with recombinant VV expressing NS3, only those expressing HLA-A1 were specifically 
recognized by the T-cells (not shown). To confirm HLA-A1 restriction, C1R cells 
expressing HLA-A1 were infected with VV expressing NS3 (Figure 3B). 
 
                            
Figure 3.  HLA restriction of T cell line 816. Depletion of CD4 and CD8 positive T cells from T 
cell line 816 (A) and restriction through HLA-A1 as determined in CR1 and CR1 HLA-A1 
transfected cells infected with recombinant VV expressing NS3 analysed using IFN-gamma 
ELISA (B). 
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pNS expression plasmids encoding NS3.  
In order to further characterize the epitope recognized by the T cells, we utilized Epstein 
Barr based plasmids. The EBV-based plasmids that we used in the present study (pNS 
vector, Fig.1) carry the oriP region from EBV as cis elements for DNA replication. After 
transfection into BLCLs, EBNA-1 from EBV in BLCLs binds to oriP and facilitates the 
retention and replication of the plasmid DNA, making pNS vector a very efficient 
expression vector (7) 
First, we amplified the HCV NS3 gene (from rVV-NNRd) using primer NNRdF 
and NNRdR. The PCR product was cloned into the TA cloning vector and subcloned into 
VR1012 and pNS vectors as described in materials and methods (Fig.1). The efficiency 
of these vectors to express NS3 protein was first verified in NKNT-3 cells. Plasmids 
carrying the CMV promoter transfected into NKNT-3 cells using Lipofectamine 2000 
were shown to express NS3 but no staining was observed when pNS-NS3 was 
transfected, confirming the promoter specificity (not shown). In contrast, when BLCL 
were electroporated with pNS-NS3 and subsequently selected under Geneticin pressure, 
we observed significant expression of NS3 (Figure 4). In contrast, relatively low levels of 
NS3 were detected in VR-NS3 transfected BLCL (not shown). 
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Figure 4. NS3 antigen expression in pNS transfected cells. BLCL infected with wt VV, 
recombinant VV expressing NS3, or transfected with pNS and pNS-NS3 were stained for NS3 
using a monoclonal antibody and subsequent Facs analysis.  
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Epitope specificity of T cell line 816 
Next we tested the antigen presenting properties of pNS transfected cells using 
three different methods to detect IFN-γ production (ELISPOT, ELISA and intracellular 
FACS staining). As a positive control, T cells were stimulated with PHA or PMA. As 
shown in Fig. 5A, T cells specifically produced IFN-γ when incubated with BLCL 
transfected with pNS-NS3 or BLCL infected with rVV-NS3. The amount of IFN-γ 
produced was not significantly different using both types of stimulator cells. Similar 
results were obtained using ELISPOT or intracellular Facs analysis (not shown).  
To further pinpoint the region that contains the HLA-A1 restricted epitope, three 
overlapping fragments of the NS3 gene were cloned into the pNS vector. Only 
BLCLpNS6.1 that contains aa. 1328-1617 of the NS3 gene was specifically recognized 
(Fig 5B), enabling the identification of the epitope recognized by the IFN-gamma 
producing T cells through bioinformatics analysis of potential HLA-A1 restricted 
epitopes present in the encoded protein. A peptide located in the NS3 coding region of 
plasmid pNS6.1, ATDALMTGY, was specifically recognized when peptide pulsed 
BLCL were used to restimulate the T-cell line 816. No IFN-gamma was produced when 
BLCL were pulsed with HLA-A2 restricted control peptide (also located in NS3). Thus, 
EBV expression vectors encoding parts of the HCV genome are extremely effective in 
activating HCV specific CTL when transfected into BLCL. Although autologous BLCL 
infected with recombinant VVs encoding parts of the HCV genome can be used to 
monitor HCV specific CTL responses they pose several disadvantages such as 
infectivity, cytopathic effect and difficulty to generate recombinant vectors. 
Alternatively, overlapping peptides covering a specific HCV genome may be used to 
pulse antigen-presenting cells, but this technique remains quite costly when multiple 
genomes have to be screened. Therefore, EBV based plasmid expression vectors offer an 
alternative method to monitor HCV specific CTL responses in HCV chronic infected 
patients.  
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Figure 5. Epitope mapping of T cell line 816 using pNS based expression plasmids. BLCL 
infected with wt VV, recombinant VV expressing NS3, or transfected with pNS and pNS-NS3 
were used to determine IFN gamma production (A). Plasmids expressing overlapping NS3 
fragments (pNS6.1, pNS5.2, pNS4.8) were used to further localize the epitope (B), subsequently 
identified by bioinformatic analysis (C).  
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SUMMARIZING DISCUSSION 
 
HCV infection is a major cause of chronic hepatitis, cirrhosis and hepatocellular 
carcinoma. Some 170 million persons, translating into 3% of the world population, are 
chronically infected with HCV, and this number increases annually due to the lack of 
effective treatments and vaccines (60). A major hallmark of HCV is its genetic variation, 
which has hampered among others viral classification, diagnosis and vaccine 
development. In addition, the heterogeneity of HCV plays an important role in the failure 
of the host’s immune response to clear the virus and to protect the host from re-infection 
or super-infection with different HCV strains. In order to understand the epidemiology 
and develop effective therapies and vaccines we need to further characterize HCV 
diversity and the mechanisms that drive the evolution of HCV. 
At the start of this study, HCV was classified into 6 genotypes and numerous 
subtypes. HCV genotypes show different geographical distributions and levels of 
diversity, reflecting their different epidemic histories and routes of transmission. 
Sequences reported in the Los Alamos HCV database show that genotypes 1a/b and 3 
make up for the majority (~85%) of HCV infections worldwide distributed in Europe, 
USA, Japan, and Russia (Fig. 1). Genotype 2a infections have been reported from 
Europe and Japan whereas more divergent genotype 2 subtypes were reported from 
African countries (5, 16, 35, 44, 59). Genotypes 4 and 5 observed in about 4% of the 
HCV-infected population, show a high genetic heterogeneity and are mainly restricted to 
Africa, although cases have been reported from Europe as well (7, 31, 68). To date, 
genotype 6 viruses were shown to circulate in Thailand, Vietnam, Cambodia, Myanmar, 
Indonesia, Hong Kong, Singapore, Taiwan and the southern part of China (HCV Los 
Alamos database). A small number of genotype 6 strains was identified in Europe, 
Canada, USA and Australia, but mostly these were isolated from immigrants originating 
from South East Asia (34). The other 2,000 reported HCV  sequences (5.45%) are highly 
diverse (rare subtypes) and several are unassigned (Fig.1). Although prevalent in only 
2% of HCV-infected persons, genotype 6 viruses are genetically highly diverse and have 
been classified in 19 subtypes (6a-6s). Epidemiological data of subtype 6 viruses in 
South East Asia are limited due to the difficulties related to specimen collection and viral 
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classification. Therefore, the natural history of HCV genotype 6 infections in this area is 
unclear. 
                           
 
Figure 1.  HCV genotype prevalence in the World using sequences deposited in the Los Alamos 
database.  
 
Most studies on HCV diversity and its role in almost any aspect of HCV biology 
have been performed on the highly prevalent genotypes 1, 2, and 3. Relatively little is 
known about whether insights obtained for these genotypes also apply to the less well-
studied genotypes, among which genotype 6. In contrast to genotype 1 HCV strains, 
genotype 6 viruses display more sequence diversity, are basically restricted to a 
geographical location and appear to be relatively rare, characteristic for endemic 
transmission (29). Limited clinical symptoms and a relative good response to standard 
IFN therapy have been reported for genotype 6 viruses (11, 12). In addition, current 
HCV detection systems designed to detect and classify highly prevalent worldwide 
strains may fail to detect or classify diverse genotype 6 strains correctly. We studied 
HCV genotype 6 diversity using serum samples from Thailand and Vietnam (Chapters 2-
5) to obtain insights into HCV epidemiology and molecular evolution. Current 
genotyping/subtyping methods were improved using phylogenetic analysis and a novel 
line probe assay (chapter 2). Evolutionary mechanisms of HCV genotype 6 were 
investigated (chapter 3-4), and new subtypes 6 viruses were identified (chapter 5). 
Bioinformatics tools were applied to study evolution and characterization of HCV 
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(chapter 6) and molecular tools to detect CTL activity of HCV chronic infected patients 
are described (Chapter 7). 
 
Genotyping - a novel line probe assay 
 As a first step towards characterization of the HCV diversity in South East Asia, 
we analysed HCV-positive samples collected from blood donors in Bangkok Thailand 
and Ho Chi Minh City, Vietnam in the period from 2000 to 2002. The prevalence of 
different HCV genotypes was determined using the most practical HCV genotyping test, 
the VERSANT® HCV genotype assay (INNO-LiPA). This assay is based on the 
amplification of the conserved 5’UTR region and hybridization to genotype specific 
probes (53). However, this region contains lower phylogenetic information than other 
parts of the genome, such as the Core and NS5B genes (45). Not surprisingly, the ability 
of the VERSANT® HCV genotype assay (INNO-LiPA) to discriminate between HCV 
genotypes was challenged by the high diversity of HCV variants, especially by the 
genotype 6c-l variants from SEA that show identical 5’UTR sequences to genotype 1 
((47, 49, 53), chapter 2). The new VERSANT HCV genotype 2.0 assay was developed to 
increase the accuracy of HCV genotype/subtype identification by including Core specific 
probes that discriminate between genotype 1a, 1b and 6c-l variants. This assay was used 
to determine the genotype of HCV viruses in our samples and results were compared to 
conventional sequence analysis procedures for genotype determination. 
As reported in chapter 2, HCV samples from Ho Chi Minh City, Vietnam 
contained genotype 1 (38%), 2 (10.3%) and 6 (51.7%) sequences, while genotype 1 
(40.0%), 3 (45.3%) and 6 (14.7%) were found in the Thai population (chapter 2 and 
(55)). Overall a relatively high prevalence of genotype 6 viruses was found in both 
countries. Subtypes characterized from these specimens are 6a, 6d, 6e, 6f, 6i, 6l, 6n and 
several unassigned or new candidate subtypes. Considering previous reports of HCV 
diversity in this area, it was not surprising to find a high variation of subtypes 6 viruses 
since many new subtypes were regularly characterized from Vietnam and Thailand (28, 
29, 56, 57).  
Molecular diagnostics of HCV is a crucial tool for controlling the epidemic and 
following the disease progression of HCV. Moreover, clinical studies have shown that 
the HCV genotype is an important predictor for efficiency of antiviral treatment and 
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progression of hepatitis (63). Therefore, most treatment protocols require preceding 
genotype information for HCV infected patients. HCV genotyping relies on the analyses 
of phylogenetically informative coding regions and comparison to defined genotype 
sequences. However, sequence analysis of amplicons is laborious and is not successful in 
identifying mixed infections. Many efforts have been made to develop HCV qualitative 
and quantitative assays and several commercial tests are available (43). Examination of 
the HCV positive samples from Thailand and Vietnam by using the old and new 
VERSANT HCV genotype tests confirmed that a great improvement in accurate 
genotyping is made with the 5’UTR-Core probe as compared to the 5’UTR probe alone 
(~96% versus 71%). With regard to the heterogeneity of genotype 6 sequences, 5’UTR-
Core line probe assay proved its ability to recognize a broad variety of subtype 6 
variants. Moreover, this test also increases the accuracy of genotype 1a/1b identification 
(4). The new VERSANT® HCV Genotype 2.0 assay may actually be the most suitable 
tool for routine HCV genotyping. This assay may not only be crucial for clinical 
evaluation of patients, but also for future epidemiological, evolutionary and pathogenesis 
studies.  
 
HCV recombination  
To investigate the accuracy of the newly developed VERSANT HCV genotype 
2.0 assay for genotype 6 identification, genotyping of samples was also performed by 
sequencing Core and NS5B fragments. This effort led us to the identification of an HCV 
recombinant strain of genotype 2i and 6p (RF2_2i/6p, chapter 3). The recombination 
break point was identified between nucleotides 3405–3464, which corresponds to the 
cleavage site of the NS2-NS3 protease that is conserved among different HCV 
genotypes. Interestingly, the recombination breakpoint of the first identified inter-
genotypic recombinant strain of HCV genotype 2k/1b from St. Peterberg, Russia is also 
located in the NS2/NS3 region of the genome (18). More recently, the 2k/1b 
recombinant strain was isolated from patients in Ireland (32), Uzbekistan (21) and 
Estonia (54), suggesting it spreads successfully and is able to compete with wildtype 
strains.  
The fact that both recombinant strains have their recombination breakpoint in the 
NS2/NS3 region of the genome may suggest that this region is preferable for creating 
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viable recombinants in vivo. Interestingly, the most efficiently propagating HCV 
chimeras in vitro are also recombinants with the breakpoint located in the NS2/NS3 
region (26, 40). Currently it is thought that this breakpoint represents the separation point 
of the genome into two parts, one from NS3-NS5B, involved in and sufficient for 
replication, whereas the Core-NS2 region encodes structural proteins and proteins 
needed for assembly of the virus. Depending on the strains fused in vitro, viruses with 
different replication/propagation kinetics arise (40). This may suggest that not all 
recombinant HCV strains are viable or have an increase in fitness compared to the non-
recombinant parental strains in vivo.  
  To investigate whether more recombination events occurred during the 
diversification of genotype 6 viruses, we collected full-length genomes of 96 HCV from 
the HCV database, including 35 sequences of genotype 6 viruses. Similarity plot and 
bootscan analysis identified a new intergenotypic recombination strain, one that was 
previously identified as subtype 6d in 1998 (57). Strain VN235 (accession number 
D84263), however, is a recombinant of TH52- (genotype 6f, EU246936) and G2AK3- 
(genotype 2a, AF169004) like ancestors (Fig. 2). The recombination breakpoints are 
located in the E1 and E2 genes (position 1468-2289), as was previously observed for the 
intratypic 1a/1c recombinant (12). These recombination events may have provided the 
progeny recombinant viruses with a selective advantage by the ability to escape the host 
immune system by exchanging the E1/E2 region.  
Recently, more recombinant forms of inter- and intra-genotype HCV 
recombinations were described from Vietnam, The Philippines, France and Peru (Table 
1), proving our hypothesis that we may be underestimating the true frequency of HCV 
recombination and that HCV recombination is an important process in the divergence 
and evolution of HCV (chapter 3). Despite the number of HCV recombinant strains 
reported nowadays, the true frequency of this event may still be considerably 
underestimated especially in high endemic areas where multiple genotypes normally 
coexist in the population. HCV recombinant strains are difficult to detect, especially 
because most studies use single, short genomic regions to genotype viruses, making the 
detection of potential recombinants unlikely. Sequence analysis of whole HCV genomes 
would be an improvement to current genotyping assays and most likely increase the 
detection of natural HCV recombinants.  
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Figure 2. (A) Similarity plots of the intergenotypic recombinant VN235 strain (genotype 6d) and 
HCV genotype 2a (G2AK3), 6f (TH52) and 5a (SA13) based on the entire genome using a 
window size of 800 bp, a step size of 20 bp, and the maximum-likelihood parameter. Gaps were 
ignored, and 1,000 bootstrap replicates were used. (B) Bootscan plots showing the likelihood of 
clustering of the putative intergenotypic recombinant of VN235 sequence with reference strains, 
with 1000 bootstrap replicates and neighbor-joining tree analysis. Crossover junctions locate at 
the nucleotide position 1468-2289. As a reference, the genomic organization of HCV, drawn to 
scale, is depicted at the top. Arrows indicate the recombination breakpoints. The nucleotide 
positions are numbered according to the numbering system for the prototype strain H-77 
(accession number AF009606, Los Alamos HCV Database) 
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Table 1 Inter- and intra-genotypic HCV recombinant strains. 
 
Name   Accession      Recombinant     Recombinant    Year        Origin      References 
                 number             region                 genotype  
  
N687  AY587845 2k/1b     NS2/NS3       2002         Russia          (18) 
PE22  AJ82127          1a/1b                 NS5B             2004        Peru         (8) 
                   AJ582131 
  AJ582134 
SE-03-07-1689  DQ364460 2b/1b           NS3               2006        Philipines     (17) 
D3  DQ155560        2i/6p      NS2/NS3       2006        Vietnam       chapter 3 
HC-J1              D10749* 1a/1c       E1/E2            2006        Japan            (10) 
RF25    AM408911        2/5              NS2/NS3       2007        France          (24) 
VN235              D84263**         6f/2a                 E1/E2             2008       Vietnam       this thesis    
 
*   reported in 1992 as genotype 1a (37) 
** reported in 1998 as genotype 6d  (56) 
 
We conclude that the assumption that HCV diversity is caused only via genetic 
drift is no longer tenable and that the role recombination plays in HCV evolution and 
biology demands serious consideration (Chapter 3). It would be interesting to know if 
virus chimeras develop more frequently in vivo, what type of junction is preferred, and to 
what extent the appearance of chimeras contributes to pathogenesis, efficacy of therapy 
and vaccination. 
 
Deletion mutants  
During the effort to characterize HCV using phylogenetic analysis of different 
genome regions, we stumbled upon a sample that apparently contained a double 
infection of genotype 2i and 6h viruses. Surprisingly, we detected a full-length genome 
of genotype 2i, and a natural HCV mutant genotype 6h that contained a 674 amino acid 
in-frame deletion in the E1 and E2 genes (chapter 4). Further analysis showed the 
presence of deletion mutants in about 10-20% of chronic HCV patients infected with 
genotype 1, 3 or 6. These HCV mutant RNAs always co-existed with full-length 
genomes and contained a large in-frame deletion varying from 1254 to 2022 nucleotides 
in the E1-NS2 region of the genome. The presence of HCV deletion mutants contributes 
to the already prominent genetic diversity of HCV. 
More recently, several HCV deletion mutants have been described in 
immunosilent chronically infected patients and liver transplant recipients with recurrent 
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HCV infection (1, 15, 61). All mutant RNAs forms described thus far show a deletion 
within the E1 and E2 regions (Fig. 3). The deletion genomes contain essential parts for 
autonomous HCV replication (5’UTR, core, and NS2-NS5-3’UTR), similar to what has 
been described for the artificially constructed subgenomic replicons (27, 58), and may 
therefore represent naturally occurring subgenomic replicons. Interestingly, Steinmann et 
al., (2008) developed a trans-packaging system of subgenomic viral RNAs (51) and 
demonstrated that subgenomic JFH1 replicons lacking the entire core to NS2 coding 
region are efficiently encapsidated into infectious virus-like particles by using JFH1 
helper viruses. Their data indicate that two types of particles are generated: on one hand, 
replication-competent infectious HCV particles carrying the complete HCV genome and, 
on the other hand, virus-like particles carrying the subgenomic replicon RNA and thus 
supporting only single-round infection. The trans-complemented HCV particles 
penetrate target cells through the CD81 receptor and produce particles with a buoyant 
density comparable to HCV. It is of note that all HCV natural deletion genomes found in 
our study (Chapter 4) contain complete core coding regions, suggesting that the presence 
of the core sequence or the production of core protein from the deletion mutant genome 
is essential for the survival of deletion mutants in vivo.  
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Figure 3 Schematic drawing of HCV deletion mutants described thus far. Numbering at the 
upper part of the panel refers to the amino acid positions within the HCV genome 
(acknowledgment to Dr.Giacomo Paonessa, IRBM) 
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These facts allow us to hypothesize about the generation of deletion mutants 
during a natural infection with HCV. We suggest that deletion mutant genomes are 
generated from wild-type HCV within infected cells through errors of the polymerase. In 
theory, many deletion forms can be generated in the liver (61), however, in-frame 
deletions which may be favored because of retaining the coding capacity for viral 
replication, will be selected and circulate. Both the dominant deletion mutant and the 
wildtype genome supposedly replicate independently. The deletion mutants hijack the 
structural proteins produced by full-length genomes and produce virus-like particles. At 
the same time wildtype virus particles are produced as well (Fig. 4a). The ratio of 
produced wildtype and virus-like particles that is released from infected cells is 
unknown. It is possible that deletion mutant genomes, due to their reduced genome size, 
have a replication advantage over full-length genomes, resulting in a higher production of 
deletion mutant particles than wildtype particles (Fig. 4b). It is also unclear whether 
coinfection of deletion mutant and wildtype viruses can occur. Deletion mutants can 
infect target cells and replicate in the absence of full-length HCV RNA (51). Whether 
core particles are released from these cells is unknown (Fig. 4c). Several studies showed 
that HCV populations in serum of infected patient are very heterogeneous in size and can 
be successfully separated by ultracentrifugation (14, 39, 41). Nonenveloped 
nucleocapsids of HCV were fractioned by CsCl gradient at 1.32 to 1.34 g/ml and showed 
the ability to bind to immunoglobulin and anti-Core antibodies (30). These observations 
suggest that deletion mutant genomes may enhance core particle rise into the blood 
circulation. Infectivity of core particles is unlikely due to the lack of E1/E2 proteins for 
specific binding protein to the receptor CD81. We cannot exclude, however, that when 
produced, core particles may spread through other mechanisms, such as cell-to-cell 
infection, or target other cell types by using a different receptor. 
 The role of HCV deletion mutants in the life cycle of HCV is unclear. They may 
play a role in the establishment and maintenance of chronic infection as described for 
defective interfering RNAs of MVE and JE viruses and their role in persistene in vitro 
(22, 62). Increased levels of HCV Core protein, resulting from increased 
replication/translation of deletion mutants, may play a role in host    immunosuppression, 
prolonged viremia (23), or disease progression (33). On the other hand, deletion of 
E1/E2 may have a great impact on the viability of cells either directly through  effects on 
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Figure 4.  Proposed model of HCV deletion mutant propagation and particle generation.   
 
the ER induced stress response or indirectly by modulating the immune response. 
Deletion mutants may interfere with the host immune response against HCV, since 
E1/E2 act as a target molecule for neutralizing antibodies that block the binding of viral 
particles to host cell receptors (2). Whether and how HCV deletion genomes play a role 
in HCV infection remains to be delineated. To unravel the role of HCV deletion mutants 
in HCV biology, methods to discriminate between deletion mutant and wildtype virus 
need to be developed. This is of particular importance in antiviral therapy studies, where 
response/non-response is defined by measurements of viral load that are determined 
based on amplification of the 5’UTR (36), which is the sum of deletion mutant and 
wildtype virus. 
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New HCV subtypes 6  
Because of the high diversity of HCV genomes, international standardization and 
coordination of the nomenclature of variants of hepatitis C virus (HCV) is increasingly 
needed.  Recently, a standardized procedure for HCV nomenclature of currently 
described variants of HCV was proposed and phylogenetic analysis of entire viral 
genome sequences was set as a golden standard (46). However, genome sequencing of 
highly diverse strains, such as subtypes of genotype 6, is not always successful due to 
mismatching of the primers during RT-PCR. We have developed a procedure to amplify 
large fragments of HCV by RT-PCR from only 100 μl of plasma, using degenerate 
primers (chapter 3). Based on this new technique, entire genomes of subtype 6a, 6e, 6f, 
6i, 6l, 6n and 6o were obtained. Moreover, two new genome sequences both isolated 
from Vietnamese blood donors were characterized as new subtypes 6t and 6u (chapter 5). 
Other strains of subtypes 6t and 6u were characterized from Asian immigrants in Canada 
(34) demonstrating that HCV genotype 6 infection is not restricted to South-East Asia, 
but spreads throughout the world.  
As mentioned before, HCV genotypes show different geographic distributions, 
with genotypes 1-3 being prevalent worldwide, whereas genotypes 4-6 that show more 
sequence diversity, are more restricted to African and Asian countries (51). Population 
genetic models suggest that there are differences in the epidemic history between HCV 
strains. Growth rates of genotype 1 viruses are higher than those of genotype 4 and 6 
viruses, suggesting a recent rapid spread of genotype 1 viruses, in contrast to a long 
period of localized endemic infections for genotypes 4 and 6. These observations are 
thought to reflect different modes of transmission. Genotype 1 viruses concurred the 
world recently through injecting drug use and contaminated blood products, whereas 
genotype 4 and 6 viruses are thought to spread via undefined social and domestic routes 
(46). Whereas some genotype 6 viruses, such as subtype 6a, occur throughout South-East 
Asia, some subtypes are very rare among which 6b, 6c, 6o, 6p, and 6q. Clusters of 
specific subtypes were found in restricted areas, such as subtype 6c, 6f, 6i and 6j that 
only circulate in Thailand, subtype 6d, 6h and 6l are found in Vietnam while genotype 
6m and 6n are present in Thailand and Myanmar (Fig. 5). Although there may be some 
sampling bias and information about subtype distribution is lacking from some countries 
 171
Chapter 8 
such as Laos, Cambodia and Myanmar, these results suggest that the spread of HCV 
genotype 6 is indeed limited to closed populations. 
          
Figure. 5   Deposited HCV genotype 6 sequences from Asian countries. 
 
Molecular evolution of HCV   
HCV evolution is believed to be mediated by several processes such as genetic 
drift caused by lack of proof-reading activity in the viral RNA-dependent RNA-
polymerase during replication (52), immune pressure (3) and recombination (18). 
Despite the >30% sequence diversity that is observed among HCV genotypes, they all 
retain a similar replication cycle in human hosts. Moreover, the ability to establish 
persistent infection with high circulating viral loads and to produce a slowly progressive 
and largely asymptomatic infection are similar between different genotypes. Thus, HCV 
evolution might be affected by neutral evolution with little or no effect of nucleotide 
changes on organism fitness, resulting in chance fixation of variants in the population 
(20). ‘Neutral’ sequence drift undoubtedly accounts for much of the genetic diversity 
that is observed between geographically or epidemiologically separated populations of 
HCV.  
Very little is known about the divergence of the six genotypes of HCV and the 
origins of this infection in humans.  In Africa and Asia, where high divergence strains 
emerged, human and ape population ranges overlap. The most closely related viruses to 
HCV, hepatitis GB viruses B (HGV-B), were found to naturally infect tamarins and 
other new world primates (48). There is, however, no evidence to support cross-species 
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transmission of HCV from animal to humans, which has hampered dating the origin of 
the HCV. In chapter 6, we inferred phylogenetic relationships and estimated the times of 
divergence of the six main clades and also the times of splitting of HCV genotypes, 
using a relaxed molecular clock model, assuming a nucleotide substitution rate over 
time. We concluded that the phylogenetic signal of the NS3 region is closest to that of 
the full-length genome and therefore best to investigate HCV phylogeny for viral 
identification (both genotyping and subtyping), epidemiology and evolution studies. The 
estimated rate of nucleotide changing across sites among all genotypes revealed an 
average high rate of evolutionary change up to 5.71x10-4 (full-length genome) to 
1.45x10-3 (NS3 gene) nucleotide substitutions per site per year, similar to the 
approximate rate calculated from long term chronic HCV infection in chimpanzees (38). 
This rate suggested that the age of the entire tree, based on the whole genome sequences, 
was about 4600 years, more ancient than determined in other studies (50). The most 
recent common ancestors of genotype 2 and 7, and 3 and 5 would have originated ~4400 
and ~4000 years ago, respectively. Surprisingly, we found that genotype 1 and 4 were 
generated in the same era as genotype 6 in the range of 2600-3000 years ago.  
Our data suggest that modern dispersal is responsible for the phylogeographic 
distribution of HCV (Fig. 6). For example, genotype 1 that is prevalent worldwide, and 
genotype 4, mainly restricted to Africa, share a common ancestor. Moreover, relatively 
rare subtypes 1d, 1e, 1g, 1h, 1l and 1m have been isolated from African countries as 
well, suggesting that genotype 1 may have originated from Africa. A few “founder” 
strains may have been transmitted rapidly through blood transfusion and sharing of 
contaminated needles. These strains contain low sequence diversity, resulting from the 
rapid spreading of a few original strains. Genotype 2 and 6 strains, on the other hand, 
show high sequence diversity and are basically restricted locally, suggesting a long 
period of endemic HCV infection in these areas through vertical and horizontal 
transmission (42, 52). These conclusions are similar to the ones drawn before (46), even 
though the estimated dates of origin of HCV genotypes were dissimilar. 
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Figure 6. The best unrooted ML tree depicting the phylogenetic relationship among 96 
HCV strains obtained from HCV database. Prevalence areas of genotypes are indicated. 
 
Detection of HCV specific CD8+ T cells  
Viral escape typically occurs in the presence of a CTL response that is focused on 
a single viral epitope. This type of T cell response, however, is unusual during acute 
HCV infection and accordingly, the loss of a single epitope would probably not be 
sufficient for the survival of viral escape mutants. It is also important to emphasize that 
selection of escape variants occurrs in the presence of an HCV-specific T cell response 
that is significantly weaker compared to animals that are able to clear the virus (9, 13). 
Thus, the different outcomes of infection, clearance versus persistence, may not be 
explained primarily by the occurrence of viral escape mutations but by initially weak 
virus-specific T cell responses that make viral escape possible. According to this notion, 
escape may be the result rather than the cause of viral persistence. Interestingly, escape 
mutations detected in chronically infected patients did not diversify further during 
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several years of follow-up (6). Consequently, it was suggested that T cell escape occurs 
early during infection. This hypothesis has been subsequently confirmed by an analysis 
of the early T cell–virus interactions in acutely infected chimpanzees (13). Indeed, three 
animals that developed viral persistence acquired mutations in multiple epitopes that 
impaired MHC class I binding and/or cytotoxic T lymphocyte (CTL) recognition within 
the first 16 weeks of infection. As expected from the human studies, these mutations 
remained fixed for years without further diversification and CD8+ T cell responses 
against variant epitopes were not observed. The failure to generate variant specific CD8+ 
T cell responses can be explained by the lack of sufficient priming or suppression by 
regulatory T-cells. In this thesis, we have developed an efficient method to detect HCV 
specific CTL using plasmids encoding NS3 of HCV. These plasmids can be manipulated 
easily and transfected in BLCL to be used as antigen presenting cells (chapter 7).   
 
Main conclusions 
 Viral escape mutations are crucial for the development of HCV persistence. The 
precise mechanisms by which these evolve, however, are unclear. We identified new 
subtypes 6t and 6u (chapter 5) that probably originated from genetic drift through a long 
term presence in human hosts. Evidence for genetic shift was obtained by the 
identification of two recombinant HCV strains, 2i/6p (chapter 3) and 6f/2a (chapter 8). 
Moreover, the formation of spontaneous deletion mutants, circulating in chronically 
infected patients, may contribute to the already considerable genetic diversity of HCV 
(chapter 4). Based on our observations, we would recommend that HCV characterization 
is best done based on full-length sequences, enabling detection of recombinant strains 
and deletion mutants. This may be of significant importance as HCV genotype is an 
important predictor for efficiency of antiviral treatment and progression of hepatitis (62) 
and deletion mutants may potentially play a role in treatment efficacy as well (15). 
However, full-length genome sequencing is often not an option for routine HCV 
genotyping in the clinical setting. Currently, the new VERSANT HCV Genotype 2.0 
assay may be the most suitable tool (chapter 2) to discriminate between most subtypes. 
In addition, mixed infections can be detected using this test. However, one should keep 
in mind that it cannot detect recombinants. Considering the complexity of HCV genome 
sequences, the application of phylogenetic analysis tools for characterization and 
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evolution studies should be considered. Using these tools, we demonstrated that the NS3 
region of the genome contains the strongest phylogenetic signal to study the evolution of 
HCV (chapter 6). Viral escape mutants as described in this thesis may have an important 
impact on the pathogenesis of HCV. Methods to detect these variants and to analyse the 
immune response against them (chapter 7) can be used to improve our understanding of 
the biology of HCV, and the development of antiviral therapies and effective vaccines.  
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HCV infectie is een belangrijke oorzaak van chronische hepatitis, cirrhose en 
levercarcinoom. Zo’n 170 miljoen mensen zijn chronisch geïnfecteerd met HCV en dit 
aantal neemt jaarlijks toe door het ontbreken van effectieve behandelingen en vaccins. 
Een bekend fenomeen van HCV is de grote genetische variatie van het virus dat 
problematisch is voor onder andere virus classificatie, diagnose en vaccin ontwikkeling. 
Daarbij speelt de heterogeniteit van HCV een belangrijke rol in het falen van de immuun 
respons van de gastheer om het virus op te ruimen en om de gastheer te beschermen voor 
re- of superinfectie met verschillende HCV varianten. Om de epidemiologie van HCV 
beter te begrijpen en om effectieve behandelingsmethodes en vaccins te ontwikkelen, is 
het noodzakelijk om de genetische diversiteit van HCV en de mechanismen die 
betrokken zijn bij evolutie van HCV verder te karakteriseren. 
Bij de start van deze studie was HCV geclassificeerd in 6 genotypen en een groot 
aantal subtypen. HCV genotypen hebben een verschillende geografische distributie en 
mate van diversiteit.veroorzaakt door een verschillende epidemiologische geschiedenis 
en transmissie route. De meeste HCV infecties wereldwijd (~85%) zijn infecties met 
genotypen 1a/b en 3, voorkomend in Europa, USA, Japan en Rusland. Genotype 2a 
infecties zijn gerapporteerd in Europa en Japan, terwijl de meer gedivergeerde genotype 
2 subtypen in Afrika voorkomen. Genotypen 4 en 5 komen voor in ~4% van de HCV 
geïnfecteerde populatie, hebben een hoge genetische diversiteit en worden voornamelijk 
gezien in Afrika, alhoewel verschillende gevallen bekend zijn in Europa. Genotype 6 
virussen, prevalent in ongeveer 2% van de HCV geïnfecteerde populatie, zijn genetisch 
zeer divers en zijn geclassificeerd in 19 subtypen (6a-6s). Epidemiologische data van 
subtype 6 virussen uit Zuid-Oost Azië zijn gelimiteerd door moeilijkheden rondom 
collectie van monsters en virale classificatie. Daarom is de natuurlijke historie van 
genotype 6 virussen in deze regio onduidelijk. In tegenstelling tot genotype 1 virussen, 
hebben genotype 6 virussen veel meer sequentie heterogeniteit, een beperkte 
geografische spreiding en lijken relatief zeldzaam. Dit is karakteristiek voor endemische 
transmissie. Daarbij zijn de huidige HCV detectie systemen ontwikkeld voor het 
detecteren en classificeren van hoog prevalente, wereldwijd voorkomende varianten en 
zijn mogelijk niet in staat om genotype 6 virussen correct te classificeren. Wij hebben de 
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HCV genotype 6 diversiteit bestudeerd met behulp van serum monsters uit Thailand en 
Vietnam om inzicht te verkrijgen in HCV epidemiologie en moleculaire evolutie 
(Hoofdstukken 2-5). De huidige genoytyperings- en subtyperingsmethoden zijn verbeterd 
door gebruik te maken van phylogenetische analyses en een nieuwe “line probe” techniek 
(Hoofdstuk 2). Evolutionaire mechanismen van HCV genotype 6 zijn bestudeerd 
(Hoofdstuk 3-4) en nieuwe subtype 6 virussen geïdentificeerd (Hoofdstuk 5). 
Bioinformatica analyses zijn toegepast om de evolutie van HCV te bestuderen 
(Hoofdstuk 6) en moleculaire technieken voor het detecteren van CTL activiteit in 
chronisch HCV geïnfecteerde patiënten (Hoofdstuk 7). 
Als eerste stap in de richting van het karakteriseren van HCV diversiteit in Zuid-
Oost Azië, hebben we HCV positieve monsters van bloeddonoren uit Bangkok, Thailand 
en Ho Chi Minh City, Vietnam uit de periode 2000-2002 geanalyseerd. De prevalentie 
van verschillende HCV genotypen is bepaald met behulp van de nieuwe VERSANT 
HCV genotype 2.0 assay. Deze test is ontwikkeld om de accuraatheid van HCV 
genotype/subtype identificatie te verhogen door het toevoegen van Core-specifieke 
sequenties die verschil kunnen maken tussen genotype 1a, 1b en 6c-l varianten 
(Hoofdstuk 2). HCV positieve monsters uit Ho Chi Minh City bevatten genotype 1 
(38%), 2 (10.3%), en 6 (51.7%) sequenties, terwijl genotype 1(40%), 3 (45.3%) en 6 
(14.7%) werden gevonden in de Thaise populatie (Hoofdstuk 2, 55). Subtypen van deze 
monsters waren 6a, 6d, 6e, 6f, 6i, 6l, 6n en verschillende ongeclassificeerde of nieuwe 
subtypen. 
Tijdens ons onderzoek met de VERSANT HCV genotype 2.0 assay, werd 
genotypering van monsters ook gedaan door sequencen van Core en NS5B fragmenten. 
Dit leidde tot de identificatie van een HCV recombinant van genotype 2i en 6p 
(RF2_2i/6p; Hoofdstuk 3). Het recombinatiebreekpunt ligt tussen nucleotiden 3405-
3464. Dit correspondeert met de geconserveerde klievingspositie van het NS2-NS3 
protease. Het recombinatiebreekpunt van de als eerst gekarakteriseerde intergenotypische 
recombinant 2k/1b uit St. Petersburg, Rusland, lag ook in de NS2/NS3 regio van het 
genoom. Recent is de 2k/1b recombinant geïsoleerd uit patiënten in Ierland, Oezbekistan 
en Estland. Dit suggereert dat deze recombinant succesvol is in verspreiding en kan 
competeren met wildtype HCV varianten. 
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Om te bestuderen of meer recombinatie is opgetreden tijdens de diversificatie van 
genotype 6 virussen, hebben we 96 HCV genomen uit de HCV database, waaronder 35 
sequenties van genotype 6 virussen, verzameld. Met behulp van similarity plot en 
bootscan analyse hebben we een nieuwe intergenotypische HCV recombinant gevonden. 
Deze was eerder geclassificeerd als subtype 6d in 1998. Isolaat VN235 (accession 
nummer D84263) is echter een recombinant virus met sequenties van TH52- (genotype 
6f, EU246936) en G2AK3-achtige (genotype 2a, AF169004) voorouders. De 
recombinatiebreekpunten liggen in de E1 en E2 genen (positie 1468-2289), net als in de 
eerder gevonden intra-genotypische 1a/1c recombinant. Deze recombinatie 
gebeurtenissen hebben de ontstane recombinant virussen mogelijk een selectief voordeel 
gegeven in de mogelijkheid om te ontsnappen aan de gastheer immuun respons door het 
uitwisselen van de E1/E2 regio. 
Tijdens het karakteriseren van HCV met phylogenetische analyses van 
verschillende genoom regio’s, zijn we gestoten op een monster dat blijkbaar zowel 
genotype 2i als 6h virussen bevatte. In dit monster detecteerden wij een geheel genoom 
van genotype 2i en een natuurlijk mutant genotype 6h dat een 674 aminozuur in-frame 
deletie bevatte in de E1 en E2 genen (Hoofdstuk 4). Verdere analyse suggereerde dat 
deletie mutanten voorkomen in 10-20% van de chronisch geïnfecteerde HCV patiënten 
met genotypen 1, 3, of 6. De HCV mutant RNAs werden altijd gevonden in combinatie 
met wildtype genomen en bevatten deleties variërend in grootte van 1254-2022 
nucleotiden in de E1-NS2 regio van het genoom. HCV deletie mutanten vergroten de 
toch al prominente genetische diversiteit van HCV. 
Om de sterke diversiteit van HCV genomen in kaart te brengen is een standaard 
procedure voor genotypering/subtypering van HCV varianten gepostuleerd. Hierbij is de 
phylogenetische analyse van volledige genomen de gouden standaard. Echter, genoom 
sequentiebepaling van sterk gedivergeerde varianten, zoals subtypen van genotype 6 
virussen, is niet altijd succesvol door “mismatching” van oligonucleotiden in de PCR 
procedure. Wij hebben een methode ontwikkeld om grote fragmenten van HCV te 
amplificeren met behulp van RT-PCR uit 100 μl plasma, gebruikmakende van 
gedegenereerde oligo’s (Hoofdstuk 3). Met behulp van deze techniek zijn volledige 
genomen van subtypen 6a, 6e, 6f, 6i, 6l, 6n en 6o verkregen. Bovendien hebben we twee 
nieuwe genoomsequenties bemachtigd, subtypen 6t en 6u, uit Vietnamese bloeddonoren 
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(Hoofdstuk 5). Andere subtype 6t en 6u varianten zijn gevonden in Aziatische 
immigranten in Canada. Dit suggereert dat genotype 6 infectie niet langer 
plaatsgebonden is, maar wereldwijd aan het verspreiden is. 
De evolutie van HCV lijkt gemedieerd te worden door verschillende processen, 
waaronder “genetic drift” veroorzaakt door een gemis in “proof-reading”activiteit van het 
virale polymerase, druk van het immuunsysteem en recombinatie. Er is weinig bekend 
van de divergentie van de zes HCV genotypen en de oorsprong van infectie in de humane 
populatie. In hoofdstuk 6 hebben we phylogenetische verwantschappen bepaald, de tijd 
van divergentie en de tijd van afsplitsen van de zes genotypen geschat met behulp van 
een relaxed molecular clock model en een constante nucleotide substitutie snelheid in de 
tijd aannemende. Wij concludeerden dat het phylogenetische signaal van NS3 het dichtst 
in de buurt komt van het volledige genoom en daardoor de beste regio is voor het 
bestuderen van HCV phylogenie voor genotypering/subtypering, epidemiologie en 
evolutie. De geschatte snelheid van nucleotide verandering van alle genotypen liet een 
hoge gemiddelde snelheid van evolutionaire verandering zien met tot 5.71 x 10-4 
(volledige genoom) en 1.45 x 10-3 (NS3 gene) nucleotide veranderingen per positie per 
jaar. Deze waarden komen overeen met de snelheid bepaald voor HCV in chronische 
infectie in chimpansees. Bovendien suggereerde deze snelheid dat de leeftijd van de 
gehele phylogenetische boom ongeveer 4600 jaar is, ouder dan bepaald in andere studies. 
De meest recente zelfde voorouder van genotype 2 en 7, en 3 en 5 zouden respectievelijk 
4400 en 4000 jaar geleden ontstaan zijn. Genotype 1 en 4 zijn ontstaan in dezelfde tijd 
als genotype 6, ongeveer 2600-3000 jaar geleden. 
Onze data suggereren dat moderne spreiding verantwoordelijk is voor de 
phylogeografische distributie van HCV. Genotype 1 met een wereldwijde prevalentie en 
genotype 4 dat voorkomt in Afrika delen dezelfde voorouder, bijvoorbeeld. Relatief 
zeldzame subtypen 1d, 1e, 1g, 1h, 1l en 1m zijn geïsoleerd in Afrika. Dit suggereert dat 
genotype 1 zich mogelijk vanuit Afrika heeft verspreid. Een aantal “founder” varianten 
hebben zich mogelijk snel verspreid via bloedtransfusies en het delen van besmette 
naalden. Deze varianten bevatten weinig sequentie diversiteit, door de snelle spreiding 
van een paar originele varianten. Genotype 2 en 6 isolaten, daarentegen, hebben hoge 
sequentie diversiteit en vertonen een lokale distributie in de wereld. Dit suggereert een 
lange periode van endemische infectie door verticale en horizontale transmissie. Deze 
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conclusies komen overeen met die van anderen, ook al zijn de geschatte tijden van 
ontstaan van HCV genotypen verschillend. 
Het ontsnappen van virussen aan het immuunsysteem gebeurt voornamelijk in 
aanwezigheid van een CTL respons die zich richt op een enkel virale epitoop. Dit type T-
cel respons is niet gangbaar tijdens acute HCV infectie en daarom zou het verlies van dit 
epitoop niet voldoende zijn voor het ontsnappen van het virus. Het is van belang te 
benadrukken dat selectie van “escape” varianten gebeurt in de aanwezigheid van een 
virus-specifieke T-cel respons die significant zwakker is dan in individuen die het virus 
opruimen (9,13). Dus de verschillende uitkomsten van infectie, opruiming versus 
persistentie, kunnen mogelijk primair niet verklaard worden door het ontstaan van escape 
mutaties, maar door een initieel zwakke virus-specifieke T-cel respons die virale 
“escape” mogelijk maakt. Naar aanleiding van deze aanname zou escape  eerder het 
gevolg dan de oorzaak zijn van virale persistentie. Escape mutaties in HCV van 
chronisch geïnfecteerde individuen stapelden zich niet op in de jaren van infectie. Dus 
werd er geconcludeerd dat T-cel escape plaatsvindt vroeg in infectie. Deze hypothese 
werd later onderbouwd door een analyse van de vroege T-cel interacties in acuut 
geïnfecteerde chimpansees. Drie dieren, die een virale persistentie ontwikkelden, hadden 
mutaties in meerdere epitopen, betrokken bij MHC class I binding en/of CTL 
herkenning, in de eerste 16 weken na infectie. Deze mutaties bleven gefixeerd voor jaren 
zonder verdere diversificatie en CD8+ T-cel responsen tegen gevarieerde epitopen 
werden niet gezien. Het falen in de productie van variant-specifieke CD8+ T-cell 
responsen kan verklaard worden door een gebrek in “priming”of suppressie door 
regulerende T-cellen. In dit proefschrift hebben we een efficiënte methode ontwikkeld 
voor het detecteren van HCV-specifieke CTL door gebruik te maken van vectoren die 
NS3 van HCV coderen. Deze vectoren zijn makkelijk te manipuleren en te transfecteren 
in B-lymphocyten die als antigeen presenterende cellen gebruikt kunnen worden 
(Hoofdstuk 7).  
Virale escape mutaties zijn cruciaal voor het ontwikkelen van HCV persistentie, 
de precieze mechanismen die hierbij betrokken zijn blijven echter onduidelijk. Wij 
hebben nieuwe subtypes 6t en 6u geïdentificeerd die waarschijnlijk door genetische drift 
ontstaan zijn veroorzaakt door lange tijd van persistentie in de gastheer (hoofdstuk 5). 
Bewijs voor genetische shift is verkregen door het identificeren van twee recombinant 
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hepatitis C virussen, 2i/6p (hoofdstuk 3) and 6f/2a (hoofdstuk 8). Het genereren van 
deletiemutanten zoals beschreven in hoofdstuk 4 draagt verder bij tot de gigantische 
genetische variabiliteit van HCV. Gebaseerd op onze waarnemingen bevelen we aan om 
volledige genoom analyse te doen voor HCV karakterisatie waardoor deletiemutanten en 
recombinanten kunnen worden gedetecteerd. Deze verdere karakterisatie kan van belang 
zijn daar is aangetoond dat HCV genetische variatie en met name de genotype 1 en 4 
varianten (62) maar ook het aanwezig zijn van deletiemutanten (15) van voorspellende 
waarde is voor het succesvol verlopen van antivirale therapie en progressie van hepatitis. 
Het bepalen van de gehele genoomsequentie van HCV is echter geen optie binnen de 
klinische setting. De nieuwe VERSANT HCV Genotype 2.0 assay is op dit moment de 
meest geschikte test om de meest voorkomende HCV genotype en subtypes te bepalen 
(hoofdstuk 2). Dubbel infecties met HCV kunnen met deze test ook worden aangetoond 
maar recombinant HCV echter niet. Doordat de HCV genomen zo divers zijn is het 
noodzakelijk de juiste phylogenetische analyse methoden toe te passen. Wij hebben 
aangetoond dat de NS3 regio uitermate geschikt is om de evolutie van HCV nader te 
analyseren (hoofdstuk 6). Virale escape mutanten zoals beschreven in deze studie hebben 
mogelijk een belangrijke rol in de pathogenese van HCV. Methodes om deze varianten 
en de immuun respons hier tegen te detecteren (hoofdstuk 7) kunnen worden gebruikt om 
onze kennis betreffende de biologie van HCV en het ontwikkelen van antivirale middelen 
en vaccins te verbeteren. 
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